



(86) Date de dépôt PCT/PCT Filing Date: 2013/05/10
(87) Date publication PCT/PCT Publication Date: 2013/11/28
(85) Entrée phase nationale/National Entry: 2014/11/07
(86) N° demande PCT/PCT Application No.: US 2013/040627
(87) N° publication PCT/PCT Publication No.: 2013/176909
(30) Priorités/Priorities: 2012/05/11 (US61/645,832);
2013/03/15 (US61/787,480)

(51) Cl.Int./Int.Cl. *C12N 9/04* (2006.01)
(71) Demandeur/Applicant:
BUTAMAX ADVANCED BIOFUELS LLC, US
(72) Inventeurs/Inventors:
GOVINDARAJAN, SRIDHAR, US;
LI, YUGEN, US;
LIAO, DER-ING, US;
O'KEEFE, DANIEL P., US;
MINSHULL, JEREMY STEPHEN, US;
ROTHMAN, STEVEN CARY, US;
TOBIAS, ALEXANDER VINCENT, US
(74) Agent: TORYS LLP

(54) Titre : ENZYMES CETOL ACIDE REDUCTOISOMERASES ET LEURS PROCEDES D'UTILISATION
(54) Title: KETOL-ACID REDUCTOISOMERASE ENZYMES AND METHODS OF USE

(57) **Abrégé/Abstract:**

Provided herein are polypeptides having ketol-acid reductoisomerase activity as well as microbial host cells comprising such polypeptides. Polypeptides provided herein may be used in biosynthetic pathways, including, but not limited to, isobutanol biosynthetic pathways.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



WIPO | PCT



(10) International Publication Number

WO 2013/176909 A3

(43) International Publication Date
28 November 2013 (28.11.2013)

(51) International Patent Classification:

C12N 9/04 (2006.01)

(21) International Application Number:

PCT/US2013/040627

(22) International Filing Date:

10 May 2013 (10.05.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/645,832	11 May 2012 (11.05.2012)	US
61/787,480	15 March 2013 (15.03.2013)	US

(71) Applicant: BUTAMAX ADVANCED BIOFUELS LLC
[US/US]; Route 141 & Henry Clay, DuPont Experimental
Station, Bldg. 356, Wilmington, Delaware 19880-0356
(US).

(72) Inventors: GOVINDARAJAN, Sridhar; 973 Campbell
Avenue, Los Altos, California 94024 (US). LI, Yougen; 4
Kentsdale Drive, Pennington, New Jersey 08534 (US).
LIAO, Der-Ing; 2612 Maclary Drive, Wilmington,
Delaware 19808-2260 (US). O'KEEFE, Daniel P.; 328
Shaw Road, Ridley Park, Pennsylvania 19078-2731 (US).
MINSHULL, Jeremy Stephen; 679 Los Ninos Way, Los
Altos, California 94022 (US). ROTHMAN, Steven Cary;
2621 Longwood Drive, Wilmington, Delaware 19810
(US). TOBIAS, Alexander Vincent; 278 Chippenham
Lane, Hockessin, Delaware 19707 (US).

(74) Agent: STERLING, Deborah A.; Patent Records
Center/DuPont Legal, Barley Mills Plaza 25, P.O. Box
80025, Wilmington, Delaware 19805 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:

13 February 2014

(54) Title: KETOL-ACID REDUCTOISOMERASE ENZYMES AND METHODS OF USE

(57) Abstract: Provided herein are polypeptides having ketol-acid reductoisomerase activity as well as microbial host cells comprising such polypeptides. Polypeptides provided herein may be used in biosynthetic pathways, including, but not limited to, isobutanol biosynthetic pathways.



WO 2013/176909 A3

TITLEKETOL-ACID REDUCTOISOMERASE ENZYMES AND METHODS OF
USE5 GOVERNMENT LICENSE RIGHTS

This invention was made with Government support under Agreement DE-AR0000006 awarded by the United States Department of Energy. The Government has certain rights in this invention.

10 FIELD OF THE INVENTION

The invention relates to polypeptides comprising ketol-acid reductoisomerase activity, polynucleotides encoding such polypeptides, host cells comprising such polynucleotides and polypeptides, and methods of using such compositions.

15 CROSS-REFERENCE TO RELATED APPLICATIONS

This application is related to and claims the benefit of priority to U.S. Provisional Patent Application No. 61/645,832 filed on May 11, 2012 and United States Patent Application No. 61/787,480 filed on March 15, 20
2013, both of which are herein incorporated by reference in their entireties.

REFERENCE TO SEQUENCE LISTING SUBMITTEDELECTRONICALLY VIA EFS-WEB

The content of the Sequence Listing submitted electronically
25 herewith (Name: 20130510_CL5631WOPCT_SEQLIST.txt; Size :
1,319,613 bytes; Date of Creation: May 10, 2013) is herein incorporated
by reference in its entirety.

BACKGROUND OF THE INVENTION

30 Ketol-acid reductoisomerase (KARI) enzymes are involved in the
biological production of valine and isoleucine. KARI enzymes have also
been shown to be useful for pathways for the production of isobutanol
using engineered microorganisms (US Patents 7,851,188 and 7,993,

889). Such microorganisms can be used to produce isobutanol from plant-derived substrates.

While methods for the chemical synthesis of isobutanol are known (oxo synthesis, catalytic hydrogenation of carbon monoxide (Ullmann's Encyclopedia of Industrial Chemistry, 6th edition, 2003, Wiley-VCH Verlag GmbH and Co., Weinheim, Germany, Vol. 5, pp. 716-719) and Guerbet condensation of methanol with n-propanol (Carlini et al., J. Molec. Catal. A. Chem. 220:215-220, 2004)), these processes use starting materials derived from petrochemicals and are generally expensive. Furthermore, chemical synthesis of isobutanol does not have the potential for environmental advantages such as minimization of green house gas emissions. Production of isobutanol from plant-derived raw materials would represent an advance in the art.

A KARI enzyme that can utilize reduced nicotinamide adenine dinucleotide (NADH) can capitalize on the NADH produced by the existing glycolytic pathway and other metabolic pathways in commonly used microbial cells and may result in improved isobutanol production. U.S. Patent 8,129,162 and US Appl. Pub. No. 2010/0197519A1 describe the generation of KARI enzymes with varying abilities to utilize the cofactor (NADH). However, there remains a need in the art for alternative polypeptides that have KARI activity suitable for production pathways such as isobutanol biosynthetic pathways.

SUMMARY OF THE INVENTION

Provided herein is a polypeptide having ketol-acid reductoisomerase activity, wherein the amino acid at the position corresponding to 52 of SEQ ID NO: 2 is D or E, and wherein the polypeptide comprises at least one substitution in one of the following regions: in at least one of the inter-molecular dimer interface region, inter-domain interface region, N-domain surface helix region, hydrophobic bridge region, or the C-terminal tail region, wherein the at least one substitution is at the position corresponding to I13, V53, A68, A69, A71, G72, V76, S86, L88, K99, Y113, N114, V117, I127, I152, S157, V171, M238, Y239, E264, N267, A268, Q272, R275, A277, R280, Y286, I291,

S292, A295, M301, R306, S322, A329, K335, or A336 of SEQ ID NO: 2. In embodiments, the polypeptide further comprises a substitution at at least one of position L33, P47, F50, F61, I80, or V156. In embodiments, the polypeptide comprises at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99% identity to SEQ ID NO: 2

Provided herein are polypeptide variants comprising at least about 80% identity, at least about 85%, at least about 90%, at least about 95%, or at least about 99% identity to SEQ ID NO: 1 or SEQ ID NO: 2 and a substitution at at least one of the following positions: Y286, I152, S322, S292, I291, I13, P47, F50, V53, A268, V76, A336, L88, A71, G72, M301, Y239, Y113, N114, A329, A69, A295, E264, R280, S157, M238, Q272, K335, K99, R275, or R306. In embodiments, the polypeptides have ketol-acid reductoisomerase activity.

Accordingly, provided herein are polypeptides comprising (a) the amino acid sequence of SEQ ID NO: 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 20, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 116, 118, 119, 120, 121, 123, 124, 128, 129, 131, 132, 133, 134, 136, 137, 138, 139, 140, 141, 142, 143, 144, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 157, 159, 160, 161, 346, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, or 382; (b) at least about 95% or at least about 99% identity to SEQ ID NO: 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 20, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 116, 118, 119, 120, 121, 123, 124, 128, 129, 131, 132, 133, 134, 136, 137, 138, 139, 140,

141, 142, 143, 144, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155,
 157, 159, 160, 161, 346, 350, 351, 352, 353, 354, 355, 356, 357, 358,
 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372,
 373, 374, 375, 376, 377, 378, 379, 380, 381, or 382; or (c) an active
 5 fragment of (a) or (b). In some embodiments, microbial host cells
 comprise such polypeptides. In some embodiments, such microbial host
 cells produce isobutanol.

Polypeptides provided herein include polypeptides having ketol-acid
 reductoisomerase activity and comprising at least about 85%, at least
 10 about 95%, or at least about 99% identity to SEQ ID NO: 2 and at least
 one of the following substitutions: Y286F, A336R, I152V, S322A, S292A,
 I291V, or a combination thereof; or an active fragment of such
 polypeptide. In embodiments, the polypeptides further comprise at least
 one of the following substitutions: I13L, P47Y, F50A, V53A, A268E, V76I,
 15 A336G, L88V, or a combination thereof. In embodiments, polypeptides
 comprise 95% or at least about 99% identity to SEQ ID NO: 3, 4, 5, 6, 7, 8,
 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 20, 22, 23, 24, 25, 26, 27, 28, or 29.

Polypeptides provided herein include polypeptides having ketol-acid
 reductoisomerase activity and comprising at least about 85%, at least
 20 about 95%, or at least about 99% identity to SEQ ID NO: 2 and at least
 one of the following substitutions: Y286F, A71K, G72W, A336R, I152V,
 A268T, A329E, or a combination thereof; or an active fragment of such
 polypeptide. In embodiments, polypeptides comprise at least about 95%
 or at least about 99% identity to SEQ ID NO: 33, 34, 35, 36, 37, 38, 39,
 25 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58,
 59, 60, 61, 62, 63, or 64.

Polypeptides provided herein include polypeptides having ketol-acid
 reductoisomerase activity and comprising at least about 85%, at least
 about 95%, or at least about 99% identity to SEQ ID NO: 41; and at least
 30 one of the following substitutions: M301I, Y239H, Y113F, S322A, A71K,
 N114G, A329R, A69T, N114S, G72W, A295V, E264K, R280D, A329E,
 S157T, M238I, Q272T, K335M, R280H, or a combination thereof; or an
 active fragment of such polypeptide. In embodiments, polypeptides
 comprise at least about 95% or at least about 99% identity to SEQ ID NO:

99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 116, 118, 119, 120, 121, 123, 124, 128, 129, 131, 132, 133, 134, 136, 137, 138, 139, 140, 141, 142, 143, 144, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 157, 159, 160, or 161. In embodiments, the
 5 polypeptide having ketol-acid reductoisomerase activity comprises the amino acid sequence of SEQ ID NO: 365, 366, 157, 159, 154, 377, 367, 123, 42, or 41.

Polypeptides provided herein include polypeptides having ketol-acid reductoisomerase activity and comprising at least about 85%, at least
 10 about 95%, or at least about 99% identity to SEQ ID NO: 346 and at least one of the following substitutions: A68E, I152V, Y286F, and A336R.

The polypeptides provided here also may increase biosynthetic pathway productivity as compared to SEQ ID NO:2 or wild type ketol-acid reductoisomerase enzymes. The increase in productivity may include an
 15 increase in performance of a step of the pathway such as rate of the reaction catalyzed by the ketol-acid reductoisomerase and/or reduced susceptibility to inhibition or substrate competition. The increase in productivity may also manifest in an increase in product yield such as increased isobutanol production as compared to polypeptides without the
 20 modifications described herein such as SEQ ID NO: 2. The productivity increase may be on the order of at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50% to about 100%.

In embodiments, in polypeptides provided herein, the amino acid at
 25 the position corresponding to position 52 of SEQ ID NO: 2 is D or E. In embodiments, the amino acid at the position corresponding to position 24 of SEQ ID NO: 2 is F; the amino acid at the position corresponding to position 33 of SEQ ID NO: 2 is L; the amino acid at the position corresponding to position 47 of SEQ ID NO: 2 is P; the amino acid at the
 30 position corresponding to position 50 of SEQ ID NO: 2 is F; the amino acid at the position corresponding to position 61 of SEQ ID NO: 2 is F; the amino acid at the position corresponding to position 80 of SEQ ID NO: 2 is I; and the amino acid at the position corresponding to position 156 of SEQ ID NO: 2 is V.

Also provided herein are polynucleotides encoding such polypeptides. Also provided are recombinant microbial host cell comprising such polynucleotides. Also provided herein are recombinant microbial host cells comprising such polypeptides.

5 Provided herein are polynucleotides comprising the sequence of 394, 396, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 410, 412, 413, 414, 415, 416, 417, 418, 419, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 10 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 506, 508, 510, 511, 513, 514, 518, 519, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 15 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 547, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 579, 580, 581, 582, or 583. In embodiments, polynucleotides provided herein comprise the sequence of SEQ ID NO: 393, 394, 395, 396, 397, 398, 399, 20 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 25 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 30 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, or 584. In embodiments, polynucleotides provided herein comprise the sequence of SEQ ID NO: 567, 568, 549, 544, 579, 569, 513,

432, or 431. Also provided are recombinant host cells comprising polynucleotides provided herein.

In some embodiments, microbial host cells further comprise reduced or eliminated acetolactate reductase activity. In embodiments, host cells further comprises at least one deletion, mutation, and/or substitution in *fra2*. In embodiments, host cells further comprise the substrate to product conversions: pyruvate to acetolactate; acetolactate to 2,3-dihydroxyisovalerate; 2,3-dihydroxyisovalerate to α -ketoisovalerate; α -ketoisovalerate to isobutyraldehyde; and isobutyraldehyde to isobutanol. In embodiments, the polypeptide having ketol-acid reductoisomerase activity is selected from the group consisting of SEQ ID Nos: 11, 41, and 42. In embodiments, the polypeptide having ketol-acid reductoisomerase activity comprises the amino acid sequence of SEQ ID NO: 365, 366, 157, 159, 154, 377, 367, 123, 42, or 41. In embodiments, the host cell is a yeast host cell. In embodiments, the host cell is *Saccharomyces cerevisiae*.

Also provided herein are methods for converting acetolactate to dihydroxyisovalerate comprising the polypeptides provided. Also provided are methods for converting acetolactate to dihydroxyisovalerate comprising providing a microbial host cell comprising a polypeptide provided; and contacting the polypeptide with acetolactate wherein dihydroxyisovalerate is produced. Also provided are methods of producing a product selected from the group consisting of isobutanol, pantothenate, valine, leucine, isoleucine, 3, 3-dimethylmalate, and 2-methyl-1-butanol comprising: providing a recombinant host cell provided herein wherein the recombinant host cell comprises a product biosynthetic pathway; and contacting the microbial host cell with a carbon substrate under conditions whereby the product is produced. In embodiments, at least a portion of the contacting occurs under anaerobic conditions.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGURE 1- Shows four different isobutanol biosynthetic pathways. The steps labeled "a", "b", "c", "d", "e", "f", "g", "h", "i", "j" and "k" represent the substrate to product conversions described below.

5 FIGURE 2 depicts an alignment of the amino acid sequences of the KARI from *Pseudomonas fluorescens* ("PF5"; SEQ ID NO: 1) and a variant thereof ("JEA1"; SEQ ID NO: 2; described in U.S. Appn. Pub. No. 2010/0197519 which is incorporated herein by reference).

10 FIGURE 3 is a plasmid map of pLH556 (pHR81-Pilv5-Pf5.KARI) (SEQ ID NO: 162). Plasmid pLH556 contains a 2-micron origin of replication for yeast, a pBR322 origin for *E. coli*, Leu2 and Ura3 auxotrophic marker genes for maintenance in yeast, an ampicillin resistance marker gene for maintenance in *E. coli*, and a KARI open reading frame cloned between PmeI and SfiI restriction sites. The KARI
15 promoter is ilv5p and the KARI terminator is ilv5t.

20 FIGURE 4 is a plasmid map of pBP915 (SEQ ID NO: 163). Plasmid pBP915 contains a 2-micron origin of replication for yeast, a pMB1 origin for *E. coli*, and an F1 origin for phage F1. It contains a His3 auxotrophic marker gene for maintenance in yeast, and an ampicillin resistance marker gene for maintenance in *E. coli*. The IlvD (DHAD) gene from *S. mutans* strain UA159 is cloned between AflII and NotI restriction sites. The ilvD promoter is FBAP and the ilvD terminator is FBAt. The horse alcohol dehydrogenase gene is also present, with a GPMp promoter and ADHt terminator.

25 FIGURE 5 is a plasmid map of pBP2090 (pHR81-Pilv5p.K9D3.TEF1(M4)p.ilvD) vector (SEQ ID NO: 164). Plasmid pBP2090 contains a 2-micron origin of replication for yeast, a pBR322 origin for *E. coli*, Leu2 and Ura3 auxotrophic marker genes for maintenance in yeast, an ampicillin resistance marker gene for maintenance in *E. coli*, and a KARI ORF cloned between PmeI and SfiI
30 restriction sites. The KARI promoter is ilv5p and the KARI terminator is ilv5t. The plasmid also contains the IlvD (DHAD) gene from *S. mutans* strain UA159 cloned between AflII and NotI restriction sites. The ilvD promoter is a modified TEF1 promoter (TEF1(M4)p) and the ilvD

terminator is FBAt.

FIGURE 6 shows an isobutanol biosynthetic pathway. Step "a" represents the conversion of pyruvate to acetolactate. Step "b" represents the conversion of acetolactate to DHIV. Step "c" represents the conversion of dihydroxyisovalerate (DHIV) to ketoisovalerate (KIV). Step "d" represents the conversion of KIV to isobutyraldehyde. Step "e" represents the conversion of isobutyraldehyde to isobutanol. Step "f" represents the conversion of acetolactate to 2,3-dihydroxy-2-methylbutyrate (DHMB).

FIGURE 7 is a plasmid map of an example of the vector (SEQ ID NO: 347; containing the coding sequence for KARI variant 65139) used in combination with the plasmid given as SEQ ID NO: 163 in the Examples where indicated. This plasmid is similar to the plasmid depicted in Figure 3, but the Ura3 gene has been modified with a silent mutation to eliminate the BsmBI site within.

FIGURE 8 is a plasmid map of an example of the vector (SEQ ID NO: 349; containing the coding sequence for KARI variant 76437 "R9E8") used in the Examples where indicated. This plasmid is similar to the plasmid depicted in Figure 5, but the Ura3 gene has been modified with a silent mutation to eliminate the BsmBI site within.

FIGURE 9 shows the homology model of Pf5 KARI dimer. Positions I13, I152 and S157 are indicated (arrows) in one of the monomers.

FIGURE 10 shows the homology model of Pf5 KARI, monomer A only. The N-domain (residues 1-181) and the C-domain (residues 182-327) are shown. In FIGURE 10A, the location of positions M238, Y239, E264, N267, A268, Q272, A277, R280, Y286, I291, S292, M301, S322, in the inter-molecular dimer interface is shown. In FIGURE 10B, the location of positions Y113, N114, N114, I291, S292, and A295, in the inter-domain interface region are shown.

FIGURE 11A shows the positions of P47, P50, V53, T80, and L88, part of the modeled nucleotide binding region. FIGURE 11B shows positions 68, 69, 71 and 72 on an alpha helix of two short turns (positions 64-73) on the surface of the N-domain. Residue 76 in the model interacts

with the side chain of residue 70 through hydrophobic interaction. The N-terminal portion of this short helix is packed against the main chain of residue 47 part of the modeled nucleotide binding region.

FIGURE 12 shows the positions C33, L61, I127, I152, and V171 in
5 the N-domain hydrophobic bridge region.

DETAILED DESCRIPTION

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of
10 ordinary skill in the art to which this invention belongs. In case of conflict, the present application including the definitions will control. Also, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. All publications, patents and other references mentioned herein are incorporated by reference in their
15 entireties for all purposes as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference, unless only specific sections of patents or patent publications are indicated to be incorporated by reference.

Although methods and materials similar or equivalent to those
20 disclosed herein can be used in practice or testing of the present invention, suitable methods and materials are disclosed below. The materials, methods and examples are illustrative only and are not intended to be limiting. Other features and advantages of the invention will be apparent from the detailed description and from the claims.

25 In order to further define this invention, the following terms, abbreviations and definitions are provided.

It will be understood that "derived from" with reference to polypeptides disclosed herein encompasses sequences synthesized based on the amino acid sequences of the KARIs present in the indicated
30 organisms as well as those cloned directly from the organism's genetic material.

As used herein, the terms "comprises," "comprising," "includes," "including," "has," "having," "contains" or "containing," or any other variation thereof, will be understood to imply the inclusion of a stated

integer or group of integers but not the exclusion of any other integer or group of integers and are intended to be non-exclusive or open-ended. For example, a composition, a mixture, a process, a method, an article, or an apparatus that comprises a list of elements is not necessarily limited to
5 only those elements but can include other elements not expressly listed or inherent to such composition, mixture, process, method, article, or apparatus. Further, unless expressly stated to the contrary, "or" refers to an inclusive or and not to an exclusive or. For example, a condition A or B is satisfied by any one of the following: A is true (or present) and B is false
10 (or not present), A is false (or not present) and B is true (or present), and both A and B are true (or present).

As used herein, the term "consists of," or variations such as "consist of" or "consisting of," as used throughout the specification and claims, indicate the inclusion of any recited integer or group of integers,
15 but that no additional integer or group of integers can be added to the specified method, structure, or composition.

As used herein, the term "consists essentially of," or variations such as "consist essentially of" or "consisting essentially of," as used throughout the specification and claims, indicate the inclusion of any recited integer or
20 group of integers, and the optional inclusion of any recited integer or group of integers that do not materially change the basic or novel properties of the specified method, structure or composition. See M.P.E.P. § 2111.03.

Also, the indefinite articles "a" and "an" preceding an element or component of the invention are intended to be nonrestrictive regarding the
25 number of instances, i.e., occurrences of the element or component. Therefore "a" or "an" should be read to include one or at least one, and the singular word form of the element or component also includes the plural unless the number is obviously meant to be singular.

The term "invention" or "present invention" as used herein is a non-
30 limiting term and is not intended to refer to any single embodiment of the particular invention but encompasses all possible embodiments as described in the claims as presented or as later amended and supplemented, or in the specification.

As used herein, the term "about" modifying the quantity of an

ingredient or reactant of the invention employed refers to variation in the numerical quantity that can occur, for example, through typical measuring and liquid handling procedures used for making concentrates or solutions in the real world; through inadvertent error in these procedures; through
5 differences in the manufacture, source, or purity of the ingredients employed to make the compositions or to carry out the methods; and the like. The term "about" also encompasses amounts that differ due to different equilibrium conditions for a composition resulting from a particular initial mixture. Whether or not modified by the term "about", the claims
10 include equivalents to the quantities. In one embodiment, the term "about" means within 10% of the reported numerical value, or within 5% of the reported numerical value.

The term "isobutanol biosynthetic pathway" refers to the enzymatic pathway to produce isobutanol. For example, certain isobutanol
15 biosynthetic pathways are disclosed in U.S. Patent 7,851,188, which is incorporated by reference in its entirety herein. Certain isobutanol biosynthetic pathways are illustrated in Figure 1 and described herein. From time to time "isobutanol biosynthetic pathway" is used synonymously with "isobutanol production pathway".

20 The term "butanol" as used herein refers to 2-butanol, 1-butanol, isobutanol or mixtures thereof. Isobutanol is also known as 2-methyl-1-propanol.

A recombinant host cell comprising an "engineered alcohol production pathway" (such as an engineered butanol or isobutanol
25 production pathway) refers to a host cell containing a modified pathway that produces alcohol in a manner different than that normally present in the host cell. Such differences include production of an alcohol not typically produced by the host cell, or increased or more efficient production.

30 The term "heterologous biosynthetic pathway" as used herein refers to an enzyme pathway to produce a product in which at least one of the enzymes is not endogenous to the host cell containing the biosynthetic pathway.

The term "extractant" as used herein refers to one or more solvents

which can be used to extract butanol from a fermentation broth.

The term "effective titer" as used herein, refers to the total amount of a particular alcohol (e.g. butanol) produced by fermentation per liter of fermentation medium. The total amount of butanol includes: (i) the
5 amount of butanol in the fermentation medium; (ii) the amount of butanol recovered from the organic extractant; and (iii) the amount of butanol recovered from the gas phase, if gas stripping is used.

The term "effective rate" as used herein, refers to the total amount of butanol produced by fermentation per liter of fermentation medium per
10 hour of fermentation.

The term "effective yield" as used herein, refers to the amount of butanol produced per unit of fermentable carbon substrate consumed by the biocatalyst.

The term "separation" as used herein is synonymous with
15 "recovery" and refers to removing a chemical compound from an initial mixture to obtain the compound in greater purity or at a higher concentration than the purity or concentration of the compound in the initial mixture.

The term "aqueous phase," as used herein, refers to the aqueous
20 phase of a biphasic mixture obtained by contacting a fermentation broth with a water-immiscible organic extractant. In an embodiment of a process described herein that includes fermentative extraction, the term "fermentation broth" then specifically refers to the aqueous phase in biphasic fermentative extraction.

25 The term "organic phase," as used herein, refers to the non-aqueous phase of a biphasic mixture obtained by contacting a fermentation broth with a water-immiscible organic extractant.

The terms "PDC-," "PDC knockout," or "PDC-KO" as used herein refer to a cell that has a genetic modification to inactivate or reduce
30 expression of a gene encoding pyruvate decarboxylase (PDC) so that the cell substantially or completely lacks pyruvate decarboxylase enzyme activity. If the cell has more than one expressed (active) PDC gene, then each of the active PDC genes can be inactivated or have minimal expression thereby producing a PDC- cell.

The term "polynucleotide" is intended to encompass a singular nucleic acid as well as plural nucleic acids, and refers to a nucleic acid molecule or construct, e.g., messenger RNA (mRNA) or plasmid DNA (pDNA). A polynucleotide can contain the nucleotide sequence of the full-length cDNA sequence, or a fragment thereof, including the untranslated 5' and 3' sequences and the coding sequences. The polynucleotide can be composed of any polyribonucleotide or polydeoxyribonucleotide, which can be unmodified RNA or DNA or modified RNA or DNA. For example, polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that can be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. "Polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

A polynucleotide sequence can be referred to as "isolated," in which it has been removed from its native environment. For example, a heterologous polynucleotide encoding a polypeptide or polypeptide fragment having dihydroxy-acid dehydratase activity contained in a vector is considered isolated for the purposes of the present invention. Further examples of an isolated polynucleotide include recombinant polynucleotides maintained in heterologous host cells or purified (partially or substantially) polynucleotides in solution. Isolated polynucleotides or nucleic acids according to the present invention further include such molecules produced synthetically. An isolated polynucleotide fragment in the form of a polymer of DNA can be comprised of one or more segments of cDNA, genomic DNA or synthetic DNA.

The term "NAD(P)H consumption assay" refers to an enzyme assay for the determination of the specific activity of the KARI enzyme, involving measuring the disappearance of the KARI cofactor, NAD(P)H, from the enzyme reaction. Such assays are described in Aulabaugh and Schloss, Biochemistry 29: 2824-2830, 1990, which is herein incorporated by reference in its entirety.

The term "NAD(P)H" refers to either NADH or NADPH.

"KARI" is the abbreviation for the enzyme ketol-acid reductoisomerase.

The term "close proximity" when referring to the position of various amino acid residues of a KARI enzyme with respect to the adenosyl 2'-phosphate of NADPH means amino acids in the three-dimensional model for the structure of the enzyme that are within about 4.5 Å of the phosphorus atom of the adenosyl 2'-phosphate of NADPH bound to the enzyme.

The term "ketol-acid reductoisomerase" (abbreviated "KARI"), and "acetohydroxy acid isomeroreductase" will be used interchangeably and refer to enzymes capable of catalyzing the reaction of (S)-acetolactate to 2,3-dihydroxyisovalerate, classified as EC number EC 1.1.1.86 (Enzyme Nomenclature 1992, Academic Press, San Diego). KARI is found in a variety of organisms and amino acid sequence comparisons across species have revealed that there are 2 types of this enzyme: a short form (class I) found in fungi and most bacteria, and a long form (class II) typical of plants. Class I KARIs typically have between 330-340 amino acid residues. The long form KARI enzymes have about 490 amino acid residues. However, some bacteria such as *Escherichia coli* possess a long form, where the amino acid sequence differs appreciably from that found in plants. KARI is encoded by the *ilvC* gene and is an essential enzyme for growth of *E. coli* and other bacteria in a minimal medium. Class II KARIs generally consist of a 225-residue N-terminal domain and a 287-residue C-terminal domain. The N-terminal domain, which contains the cofactor-binding site, has an $\alpha\beta$ structure and resembles domains found in other pyridine nucleotide-dependent oxidoreductases. The C-terminal domain consists almost entirely of α -helices.

KARI enzymes are described for example, in U.S. Patent Nos. 7,910,342 and 8,129,162 and U.S. Pub. App. No.2010/0197519, all of which are herein incorporated by reference in their entireties.

Ketol-acid reductoisomerase (KARI) enzymes are useful in pathways for the production of isobutanol using engineered microorganisms (US Patents 7,851,188 and 7,993,889, incorporated by reference in their entireties herein).

A KARI that can utilize NADH can capitalize on the NADH produced by the existing glycolytic and other metabolic pathways in most commonly used microbial cells and can result in improved isobutanol production. Rane et al. (Arch. Biochem. Biophys., 338: 83-89, 1997) discusses cofactor switching of a ketol acid reductoisomerase isolated from *E. coli*.
5 US Appl. Pub. Nos. 2009/0163376 and 2010/0197519 (each of which is herein incorporated by reference in its entirety) describe variants of KARI enzymes which can use NADH. US Appl. Pub. No. 2010/0143997 (which is herein incorporated by reference in its entirety) describes *E. coli* variants
10 with improved K_M values for NADH.

The terms "ketol-acid reductoisomerase activity" and "KARI activity" refer to the ability to catalyze the substrate to product conversion (S)-acetolactate to 2,3-dihydroxyisovalerate.

The term "acetolactate synthase" refers to an enzyme that
15 catalyzes the conversion of pyruvate to acetolactate and CO_2 . Acetolactate has two stereoisomers ((R) and (S)); the enzyme prefers the (S)- isomer, which is made by biological systems. Certain acetolactate synthases are known by the EC number 2.2.1.6 (Enzyme Nomenclature 1992, Academic Press, San Diego). These enzymes are available from a
20 number of sources, including, but not limited to, *Bacillus subtilis* (SEQ ID NO: 165), *Klebsiella pneumoniae* (SEQ ID NO: 166) and *Lactococcus lactis*.

The term "acetohydroxy acid dehydratase" refers to an enzyme that catalyzes the conversion of 2,3-dihydroxyisovalerate to α -ketoisovalerate.
25 valerate. Certain acetohydroxy acid dehydratases are known by the EC number 4.2.1.9. These enzymes are available from a vast array of microorganisms, including, but not limited to, *E. coli*, *S. cerevisiae*, *M. maripaludis*, *B. subtilis*, *Lactococcus lactis* (SEQ ID NO:167), and *Streptococcus mutans* (SEQ ID NO: 168).

30 The term "branched-chain α -keto acid decarboxylase" refers to an enzyme that catalyzes the conversion of α -ketoisovalerate to isobutyraldehyde and CO_2 . Certain branched-chain α -keto acid decarboxylases are known by the EC number 4.1.1.72 and are available

from a number of sources, including, but not limited to, *Lactococcus lactis* (SEQ ID NO: 169), *Salmonella typhimurium*, *Clostridium acetobutylicum*, *Macrococcus caseolyticus* (SEQ ID NO: 171), and *Listeria grayi* (SEQ ID NO: 170).

5 The term "branched-chain alcohol dehydrogenase" refers to an enzyme that catalyzes the conversion of isobutyraldehyde to isobutanol. Certain branched-chain alcohol dehydrogenases are known by the EC number 1.1.1.265, but can also be classified under other alcohol dehydrogenases (specifically, EC 1.1.1.1 or 1.1.1.2). These enzymes
10 utilize NADH (reduced nicotinamide adenine dinucleotide) and/or NADPH as electron donor and are available from a number of sources, including, but not limited to, *S. cerevisiae*, *E. coli*, *C. acetobutylicum*, *B. indica* (SEQ ID NO: 173), *A. xylosoxidans* (SEQ ID NO: 172).

As used herein, "DHMB" refers to 2,3-dihydroxy-2-methyl butyrate.
15 DHMB includes "fast DHMB," which has the 2S, 3S configuration, and "slow DHMB," which has the 2S, 3R configurate. See Kaneko et al., *Phytochemistry* 39: 115-120 (1995), which is herein incorporated by reference in its entirety and refers to fast DHMB as angliceric acid and slow DHMB as tigliceric acid.

20 As used herein, "reduced activity" refers to any measurable decrease in a known biological activity of a polypeptide when compared to the same biological activity of the polypeptide prior to the change resulting in the reduced activity. Such a change can include a modification of a polypeptide or a polynucleotide encoding a polypeptide as described
25 herein. A reduced activity of a polypeptide disclosed herein can be determined by methods well known in the art and/or disclosed herein.

As used herein, "eliminated activity" refers to the complete abolishment of a known biological activity of a polypeptide when compared to the same biological activity of the polypeptide prior to the change
30 resulting in the eliminated activity. Such a change can include a modification of a polypeptide or a polynucleotide encoding a polypeptide as described herein. An eliminated activity includes a biological activity of a polypeptide that is not measurable when compared to the same biological activity of the polypeptide prior to the change resulting in the

eliminated activity. An eliminated activity of a polypeptide disclosed herein can be determined by methods well known in the art and/or disclosed herein.

The term "carbon substrate" or "fermentable carbon substrate" refers to a carbon source capable of being metabolized by host organisms of the present invention and particularly carbon sources selected from the group consisting of monosaccharides, oligosaccharides, polysaccharides, and one-carbon substrates or mixtures thereof. Non-limiting examples of carbon substrates are provided herein and include, but are not limited to, monosaccharides, oligosaccharides, polysaccharides, ethanol, lactate, succinate, glycerol, carbon dioxide, methanol, glucose, fructose, sucrose, xylose, arabinose, dextrose, or mixtures thereof. Other carbon substrates can include ethanol, lactate, succinate, or glycerol.

"Fermentation broth" as used herein means the mixture of water, sugars (fermentable carbon sources), dissolved solids (if present), microorganisms producing alcohol, product alcohol and all other constituents of the material held in the fermentation vessel in which product alcohol is being made by the reaction of sugars to alcohol, water and carbon dioxide (CO₂) by the microorganisms present. From time to time, as used herein the term "fermentation medium" and "fermented mixture" can be used synonymously with "fermentation broth".

"Biomass" as used herein refers to a natural product containing a hydrolysable starch that provides a fermentable sugar, including any cellulosic or lignocellulosic material and materials comprising cellulose, and optionally further comprising hemicellulose, lignin, starch, oligosaccharides, disaccharides, and/or monosaccharides. Biomass can also comprise additional components, such as protein and/or lipids. Biomass can be derived from a single source, or biomass can comprise a mixture derived from more than one source. For example, biomass can comprise a mixture of corn cobs and corn stover, or a mixture of grass and leaves. Biomass includes, but is not limited to, bioenergy crops, agricultural residues, municipal solid waste, industrial solid waste, sludge from paper manufacture, yard waste, wood, and forestry waste. Examples of biomass include, but are not limited to, corn grain, corn cobs, crop

residues such as corn husks, corn stover, grasses, wheat, rye, wheat straw, barley, barley straw, hay, rice straw, switchgrass, waste paper, sugar cane bagasse, sorghum, soy, components obtained from milling of grains, trees, branches, roots, leaves, wood chips, sawdust, shrubs and bushes, vegetables, fruits, flowers, animal manure, and mixtures thereof.

"Feedstock" as used herein means a product containing a fermentable carbon source. Suitable feedstock include, but are not limited to, rye, wheat, corn, sugar cane, and mixtures thereof.

The term "aerobic conditions" as used herein means growth conditions in the presence of oxygen. Typically, oxygen is replaced by agitation of the medium such that gas exchange with the atmosphere occurs.

The term "microaerobic conditions" as used herein means growth conditions with low levels of oxygen (i.e., below normal atmospheric oxygen levels). "Microaerobic conditions" include conditions wherein the medium is not necessarily oxygen free when inoculated with a microorganism, but, the oxygen present in the medium is consumed and its replacement by gas exchange is limited, for example, by limiting agitation and/or sealing the vessel from the atmosphere.

The term "anaerobic conditions" as used herein means growth conditions in the absence of oxygen.

The term "isolated nucleic acid molecule", "isolated nucleic acid fragment" and "genetic construct" will be used interchangeably and will mean a polymer of RNA or DNA that is single- or double-stranded, optionally containing synthetic, non-natural or altered nucleotide bases. An isolated nucleic acid fragment in the form of a polymer of DNA can be comprised of one or more segments of cDNA, genomic DNA or synthetic DNA.

The term "amino acid" refers to the basic chemical structural unit of a protein or polypeptide. The following abbreviations are used herein to identify specific amino acids:

Amino Acid	Three-Letter Abbreviation	One-Letter Abbreviation
------------	------------------------------	----------------------------

<u>Amino Acid</u>	<u>Three-Letter Abbreviation</u>	<u>One-Letter Abbreviation</u>
Alanine	Ala	A
Arginine	Arg	R
Asparagine	Asn	N
Aspartic acid	Asp	D
Cysteine	Cys	C
Glutamine	Gln	Q
Glutamic acid	Glu	E
Glycine	Gly	G
Histidine	His	H
Isoleucine	Ile	I
Leucine	Leu	L
Lysine	Lys	K
Methionine	Met	M
Phenylalanine	Phe	F
Proline	Pro	P
Serine	Ser	S
Threonine	Thr	T
Tryptophan	Trp	W
Tyrosine	Tyr	Y
Valine	Val	V

The term "gene" refers to a nucleic acid fragment that is capable of being expressed as a specific protein, optionally including regulatory sequences preceding (5' non-coding sequences) and following (3' non-coding sequences) the coding sequence. "Native gene" refers to a gene as found in nature with its own regulatory sequences. "Chimeric gene" refers to any gene that is not a native gene, comprising regulatory and coding sequences that are not found together in nature. Accordingly, a chimeric gene can comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source, but arranged in a manner different than that found in nature. "Endogenous gene" refers to a native gene in its natural location in the genome of a microorganism. A "foreign" gene refers to a gene not normally found in the host

microorganism, but that is introduced into the host microorganism by gene transfer. Foreign genes can comprise native genes inserted into a non-native microorganism, or chimeric genes. A "transgene" is a gene that has been introduced into the genome by a transformation procedure.

5 As used herein, "native" refers to the form of a polynucleotide, gene, or polypeptide as found in nature with its own regulatory sequences, if present.

As used herein the term "coding sequence" or "coding region" refers to a DNA sequence that encodes for a specific amino acid sequence. "Suitable regulatory sequences" refer to nucleotide sequences
10 located upstream (5' non-coding sequences), within, or downstream (3' non-coding sequences) of a coding sequence, and which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences can include promoters, translation leader sequences, introns, polyadenylation recognition
15 sequences, RNA processing sites, effector binding sites and stem-loop structures.

As used herein, "endogenous" refers to the native form of a polynucleotide, gene or polypeptide in its natural location in the organism or in the genome of an organism. "Endogenous polynucleotide" includes a
20 native polynucleotide in its natural location in the genome of an organism. "Endogenous gene" includes a native gene in its natural location in the genome of an organism. "Endogenous polypeptide" includes a native polypeptide in its natural location in the organism transcribed and
25 translated from a native polynucleotide or gene in its natural location in the genome of an organism.

The term "heterologous" when used in reference to a polynucleotide, a gene, or a polypeptide refers to a polynucleotide, gene, or polypeptide not normally found in the host organism. "Heterologous"
30 also includes a native coding region, or portion thereof, that is reintroduced into the source organism in a form that is different from the corresponding native gene, e.g., not in its natural location in the organism's genome. The heterologous polynucleotide or gene can be introduced into the host organism by, e.g., gene transfer. A heterologous

gene can include a native coding region with non-native regulatory regions that is reintroduced into the native host. For example, a heterologous gene can include a native coding region that is a portion of a chimeric gene including non-native regulatory regions that is reintroduced into the native host. "Heterologous polypeptide" includes a native polypeptide that is reintroduced into the source organism in a form that is different from the corresponding native polypeptide.

A "transgene" is a gene that has been introduced into the genome by a transformation procedure.

As used herein, the term "modification" refers to a change in a polynucleotide disclosed herein that results in reduced or eliminated activity of a polypeptide encoded by the polynucleotide, as well as a change in a polypeptide disclosed herein that results in reduced or eliminated activity of the polypeptide. Such changes can be made by methods well known in the art, including, but not limited to, deleting, mutating (e.g., spontaneous mutagenesis, random mutagenesis, mutagenesis caused by mutator genes, or transposon mutagenesis), substituting, inserting, down-regulating, altering the cellular location, altering the state of the polynucleotide or polypeptide (e.g., methylation, phosphorylation or ubiquitination), removing a cofactor, introduction of an antisense RNA/DNA, introduction of an interfering RNA/DNA, chemical modification, covalent modification, irradiation with UV or X-rays, homologous recombination, mitotic recombination, promoter replacement methods, and/or combinations thereof. Guidance in determining which nucleotides or amino acid residues can be modified, can be found by comparing the sequence of the particular polynucleotide or polypeptide with that of homologous polynucleotides or polypeptides, e.g., yeast or bacterial, and maximizing the number of modifications made in regions of high homology (conserved regions) or consensus sequences.

"Regulatory sequences" refers to nucleotide sequences located upstream (5' non-coding sequences), within, or downstream (3' non-coding sequences) of a coding sequence, and which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences can include promoters,

enhancers, operators, repressors, transcription termination signals, translation leader sequences, introns, polyadenylation recognition sequences, RNA processing site, effector binding site and stem-loop structure.

5 The term "promoter" refers to a nucleic acid sequence capable of controlling the expression of a coding sequence or functional RNA. In general, a coding sequence is located 3' to a promoter sequence. Promoters can be derived in their entirety from a native gene, or be composed of different elements derived from different promoters found in
10 nature, or even comprise synthetic nucleic acid segments. It is understood by those skilled in the art that different promoters can direct the expression of a gene in different tissues or cell types, or at different stages of development, or in response to different environmental or physiological conditions. Promoters which cause a gene to be expressed
15 in most cell types at most times are commonly referred to as "constitutive promoters". "Inducible promoters," on the other hand, cause a gene to be expressed when the promoter is induced or turned on by a promoter-specific signal or molecule. It is further recognized that since in most cases the exact boundaries of regulatory sequences have not been
20 completely defined, DNA fragments of different lengths can have identical promoter activity. For example, it will be understood that "FBA1 promoter" can be used to refer to a fragment derived from the promoter region of the FBA1 gene.

 The term "terminator" as used herein refers to DNA sequences
25 located downstream of a coding sequence. This includes polyadenylation recognition sequences and other sequences encoding regulatory signals capable of affecting mRNA processing or gene expression. The polyadenylation signal is usually characterized by affecting the addition of polyadenylic acid tracts to the 3' end of the mRNA precursor. The 3'
30 region can influence the transcription, RNA processing or stability, or translation of the associated coding sequence. It is recognized that since in most cases the exact boundaries of regulatory sequences have not been completely defined, DNA fragments of different lengths can have identical terminator activity. For example, it will be understood that "CYC1

terminator" can be used to refer to a fragment derived from the terminator region of the CYC1 gene.

The term "operably linked" refers to the association of nucleic acid sequences on a single nucleic acid fragment so that the function of one is affected by the other. For example, a promoter is operably linked with a coding sequence when it is capable of effecting the expression of that coding sequence (i.e., that the coding sequence is under the transcriptional control of the promoter). Coding sequences can be operably linked to regulatory sequences in sense or antisense orientation.

The term "expression", as used herein, refers to the transcription and stable accumulation of sense (mRNA) or antisense RNA derived from the nucleic acid fragment of the invention. Expression can also refer to translation of mRNA into a polypeptide.

The term "overexpression," as used herein, refers to expression that is higher than endogenous expression of the same or related gene. A heterologous gene is overexpressed if its expression is higher than that of a comparable endogenous gene. The term overexpression refers to an increase in the level of nucleic acid or protein in a host cell. Thus, overexpression can result from increasing the level of transcription or translation of an endogenous sequence in a host cell or can result from the introduction of a heterologous sequence into a host cell. Overexpression can also result from increasing the stability of a nucleic acid or protein sequence.

As used herein the term "transformation" refers to the transfer of a nucleic acid fragment into the genome of a host microorganism, resulting in genetically stable inheritance. Host microorganisms containing the transformed nucleic acid fragments are referred to as "transgenic" or "recombinant" or "transformed" microorganisms.

The terms "plasmid", "vector" and "cassette" refer to an extra chromosomal element often carrying genes which are not part of the central metabolism of the cell, and usually in the form of circular double-stranded DNA fragments. Such elements can be autonomously replicating sequences, genome integrating sequences, phage or nucleotide sequences, linear or circular, of a single- or double-stranded

DNA or RNA, derived from any source, in which a number of nucleotide sequences have been joined or recombined into a unique construction which is capable of introducing a promoter fragment and DNA sequence for a selected gene product along with appropriate 3' untranslated sequence into a cell. "Transformation cassette" refers to a specific vector containing a foreign gene and having elements in addition to the foreign gene that facilitates transformation of a particular host cell. "Expression cassette" refers to a specific vector containing a foreign gene and having elements in addition to the foreign gene that allow for enhanced expression of that gene in a foreign host.

As used herein the term "codon degeneracy" refers to the nature in the genetic code permitting variation of the nucleotide sequence without affecting the amino acid sequence of an encoded polypeptide. The skilled artisan is well aware of the "codon-bias" exhibited by a specific host cell in usage of nucleotide codons to specify a given amino acid. Therefore, when synthesizing a gene for improved expression in a host cell, it is desirable to design the gene such that its frequency of codon usage approaches the frequency of preferred codon usage of the host cell.

The term "codon-optimized" as it refers to genes or coding regions of nucleic acid molecules for transformation of various hosts, refers to the alteration of codons in the gene or coding regions of the nucleic acid molecules to reflect the typical codon usage of the host organism without altering the polypeptide encoded by the DNA. Such optimization includes replacing at least one, or more than one, or a significant number, of codons with one or more codons that are more frequently used in the genes of that organism.

Deviations in the nucleotide sequence that comprise the codons encoding the amino acids of any polypeptide chain allow for variations in the sequence coding for the gene. Since each codon consists of three nucleotides, and the nucleotides comprising DNA are restricted to four specific bases, there are 64 possible combinations of nucleotides, 61 of which encode amino acids (the remaining three codons encode signals ending translation). The "genetic code" which shows which codons encode which amino acids is reproduced herein as Table 1. As a result,

many amino acids are designated by more than one codon. For example, the amino acids alanine and proline are coded for by four triplets, serine and arginine by six, whereas tryptophan and methionine are coded by just one triplet. This degeneracy allows for DNA base composition to vary
 5 over a wide range without altering the amino acid sequence of the proteins encoded by the DNA.

Table 1. The Standard Genetic Code

	T	C	A	G
T	TTT Phe (F) TTC " TTA Leu (L) TTG "	TTT Ser (S) TTC " TCA " TCG "	TAT Tyr (Y) TAC " TAA Stop TAG Stop	TGT Cys (C) TGC " TGA Stop TGG Trp (W)
C	CTT Leu (L) CTC " CTA " CTG "	CTT Pro (P) CCC " CCA " CCG "	CAT His (H) CAC " CAA Gln (Q) CAG "	CGT Arg (R) CGC " CGA " CGG "
A	ATT Ile (I) ATC " ATA " ATG Met (M)	ACT Thr (T) ACC " ACA " ACG "	AAT Asn (N) AAC " AAA Lys (K) AAG "	AGT Ser (S) AGC " AGA Arg (R) AGG "
G	GTT Val (V) GTC " GTA " GTG "	GCT Ala (A) GCC " GCA " GCG "	GAT Asp (D) GAC " GAA Glu (E) GAG "	GGT Gly (G) GGC " GGA " GGG "

Many organisms display a bias for use of particular codons to code
 10 for insertion of a particular amino acid in a growing peptide chain. Codon preference, or codon bias, differences in codon usage between organisms, is afforded by degeneracy of the genetic code, and is well documented among many organisms. Codon bias often correlates with the efficiency of translation of messenger RNA (mRNA), which is in turn
 15 believed to be dependent on, inter alia, the properties of the codons being translated and the availability of particular transfer RNA (tRNA) molecules. The predominance of selected tRNAs in a cell is generally a reflection of the codons used most frequently in peptide synthesis. Accordingly, genes can be tailored for optimal gene expression in a given organism based on
 20 codon optimization.

Given the large number of gene sequences available for a wide variety of animal, plant and microbial species, it is possible to calculate the relative frequencies of codon usage. Codon usage tables are readily available, for example, at the "Codon Usage Database" available at
 5 www.kazusa.or.jp/codon/ (visited March 20, 2008), and these tables can be adapted in a number of ways. See Nakamura, Y., et al. Nucl. Acids Res. 28:292 (2000). Codon usage tables for yeast, calculated from GenBank Release 128.0 [15 February 2002], are reproduced below as Table 2B. This table uses mRNA nomenclature, and so instead of
 10 thymine (T) which is found in DNA, the tables use uracil (U) which is found in RNA. Table 2 has been adapted so that frequencies are calculated for each amino acid, rather than for all 64 codons.

Table 2. Codon Usage Table for *Saccharomyces cerevisiae*

Amino Acid	Codon	Number	Frequency per thousand
Phe	UUU	170666	26.1
Phe	UUC	120510	18.4
Leu	UUA	170884	26.2
Leu	UUG	177573	27.2
Leu	CUU	80076	12.3
Leu	CUC	35545	5.4
Leu	CUA	87619	13.4
Leu	CUG	68494	10.5
Ile	AUU	196893	30.1
Ile	AUC	112176	17.2
Ile	AUA	116254	17.8
Met	AUG	136805	20.9
Val	GUU	144243	22.1
Val	GUC	76947	11.8
Val	GUA	76927	11.8
Val	GUG	70337	10.8
Ser	UCU	153557	23.5
Ser	UCC	92923	14.2
Ser	UCA	122028	18.7
Ser	UCG	55951	8.6
Ser	AGU	92466	14.2
Ser	AGC	63726	9.8
Pro	CCU	88263	13.5
Pro	CCC	44309	6.8
Pro	CCA	119641	18.3
Pro	CCG	34597	5.3

Amino Acid	Codon	Number	Frequency per thousand
Thr	ACU	132522	20.3
Thr	ACC	83207	12.7
Thr	ACA	116084	17.8
Thr	ACG	52045	8.0
Ala	GCU	138358	21.2
Ala	GCC	82357	12.6
Ala	GCA	105910	16.2
Ala	GCG	40358	6.2
Tyr	UAU	122728	18.8
Tyr	UAC	96596	14.8
His	CAU	89007	13.6
His	CAC	50785	7.8
Gln	CAA	178251	27.3
Gln	CAG	79121	12.1
Asn	AAU	233124	35.7
Asn	AAC	162199	24.8
Lys	AAA	273618	41.9
Lys	AAG	201361	30.8
Asp	GAU	245641	37.6
Asp	GAC	132048	20.2
Glu	GAA	297944	45.6
Glu	GAG	125717	19.2
Cys	UGU	52903	8.1
Cys	UGC	31095	4.8
Trp	UGG	67789	10.4
Arg	CGU	41791	6.4
Arg	CGC	16993	2.6
Arg	CGA	19562	3.0
Arg	CGG	11351	1.7
Arg	AGA	139081	21.3
Arg	AGG	60289	9.2
Gly	GGU	156109	23.9
Gly	GGC	63903	9.8
Gly	GGA	71216	10.9
Gly	GGG	39359	6.0
Stop	UAA	6913	1.1
Stop	UAG	3312	0.5
Stop	UGA	4447	0.7

By utilizing this or similar tables, one of ordinary skill in the art can apply the frequencies to any given polypeptide sequence, and produce a nucleic acid fragment of a codon-optimized coding region which encodes the polypeptide, but which uses codons optimal for a given species.

- 5 Randomly assigning codons at an optimized frequency to encode a given polypeptide sequence, can be done manually by calculating codon frequencies for each amino acid, and then assigning the codons to the polypeptide sequence randomly. Additionally, various algorithms and computer software programs are readily available to those of ordinary skill
- 10 in the art. For example, the "EditSeq" function in the Lasergene Package, available from DNASTar, Inc., Madison, WI, the backtranslation function in the VectorNTI Suite, available from InforMax, Inc., Bethesda, MD, and the "backtranslate" function in the GCG-Wisconsin Package, available from Accelrys, Inc., San Diego, CA. In addition, various resources are publicly
- 15 available to codon-optimize coding region sequences, e.g., the "backtranslation" function at www.entelechon.com/bioinformatics/backtranslation.php?lang=eng (visited April 15, 2008) and the "backtranseq" function available at <http://bioinfo.pbi.nrc.ca:8090/EMBOSS/index.html> (visited July 9, 2002).
- 20 Constructing a rudimentary algorithm to assign codons based on a given frequency can also easily be accomplished with basic mathematical functions by one of ordinary skill in the art.

- Codon-optimized coding regions can be designed by various methods known to those skilled in the art including software packages
- 25 such as "synthetic gene designer" (userpages.umbc.edu/~wug1/codon/sgd/, visited March 19, 2012).

- A polynucleotide or nucleic acid fragment is "hybridizable" to another nucleic acid fragment, such as a cDNA, genomic DNA, or RNA molecule, when a single-stranded form of the nucleic acid fragment can
- 30 anneal to the other nucleic acid fragment under the appropriate conditions of temperature and solution ionic strength. Hybridization and washing conditions are well known and exemplified in Sambrook, J., Fritsch, E. F. and Maniatis, T. Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory: Cold Spring Harbor, NY (1989), particularly

Chapter 11 and Table 11.1 therein (entirely incorporated herein by reference). The conditions of temperature and ionic strength determine the "stringency" of the hybridization. Stringency conditions can be adjusted to screen for moderately similar fragments (such as homologous sequences from distantly related organisms), to highly similar fragments (such as genes that duplicate functional enzymes from closely related organisms). Post hybridization washes determine stringency conditions. One set of conditions uses a series of washes starting with 6X SSC, 0.5% SDS at room temperature for 15 min, then repeated with 2X SSC, 0.5% SDS at 45 °C for 30 min, and then repeated twice with 0.2X SSC, 0.5% SDS at 50 °C for 30 min. Another set of stringent conditions uses higher temperatures in which the washes are identical to those above except for the temperature of the final two 30 min washes in 0.2X SSC, 0.5% SDS was increased to 60 °C. Another set of highly stringent conditions uses two final washes in 0.1X SSC, 0.1% SDS at 65 °C. An additional set of stringent conditions include hybridization at 0.1X SSC, 0.1% SDS, 65 °C and washes with 2X SSC, 0.1% SDS followed by 0.1X SSC, 0.1% SDS, for example.

Hybridization requires that the two nucleic acids contain complementary sequences, although depending on the stringency of the hybridization, mismatches between bases are possible. The appropriate stringency for hybridizing nucleic acids depends on the length of the nucleic acids and the degree of complementation, variables well known in the art. The greater the degree of similarity or homology between two nucleotide sequences, the greater the value of T_m for hybrids of nucleic acids having those sequences. The relative stability (corresponding to higher T_m) of nucleic acid hybridizations decreases in the following order: RNA:RNA, DNA:RNA, DNA:DNA. For hybrids of greater than 100 nucleotides in length, equations for calculating T_m have been derived (see Sambrook et al., supra, 9.50 9.51). For hybridizations with shorter nucleic acids, i.e., oligonucleotides, the position of mismatches becomes more important, and the length of the oligonucleotide determines its specificity (see Sambrook et al., supra, 11.7 11.8). In one embodiment the length for a hybridizable nucleic acid is at least about 10 nucleotides. In one

embodiment, a minimum length for a hybridizable nucleic acid is at least about 15 nucleotides; at least about 20 nucleotides; or the length is at least about 30 nucleotides. Furthermore, the skilled artisan will recognize that the temperature and wash solution salt concentration can be adjusted
5 as necessary according to factors such as length of the probe.

As used herein, the term "polypeptide" is intended to encompass a singular "polypeptide" as well as plural "polypeptides," and refers to a molecule composed of monomers (amino acids) linearly linked by amide bonds (also known as peptide bonds). The term "polypeptide" refers to
10 any chain or chains of two or more amino acids, and does not refer to a specific length of the product. Thus, peptides, dipeptides, tripeptides, oligopeptides, "protein," "amino acid chain," or any other term used to refer to a chain or chains of two or more amino acids, are included within the definition of "polypeptide," and the term "polypeptide" can be used
15 instead of, or interchangeably with any of these terms. A polypeptide can be derived from a natural biological source or produced by recombinant technology, but is not necessarily translated from a designated nucleic acid sequence. It can be generated in any manner, including by chemical synthesis. Suitable methods for polypeptide synthesis are known in the
20 art.

By an "isolated" polypeptide or a fragment, variant, or derivative thereof is intended a polypeptide that is not in its natural milieu. No particular level of purification is required. For example, an isolated polypeptide can be removed from its native or natural environment.
25 Recombinantly produced polypeptides and proteins expressed in host cells are considered isolated for purposes of the invention, as are native or recombinant polypeptides which have been separated, fractionated, or partially or substantially purified by any suitable technique.

As used herein, the terms "variant" and "mutant" are synonymous
30 and refer to a polypeptide differing from a specifically recited polypeptide by one or more amino acid insertions, deletions, mutations, and substitutions, created using, e.g., recombinant DNA techniques, such as mutagenesis. Guidance in determining which amino acid residues can be replaced, added, or deleted without abolishing activities of interest, can be

found by comparing the sequence of the particular polypeptide with that of homologous polypeptides, e.g., yeast or bacterial, and minimizing the number of amino acid sequence changes made in regions of high homology (conserved regions) or by replacing amino acids with consensus sequences.

"Engineered polypeptide" as used herein refers to a polypeptide that is synthetic, i.e., differing in some manner from a polypeptide found in nature.

Alternatively, recombinant polynucleotide variants encoding these same or similar polypeptides can be synthesized or selected by making use of the "redundancy" in the genetic code. Various codon substitutions, such as silent changes which produce various restriction sites, can be introduced to optimize cloning into a plasmid or viral vector for expression. Mutations in the polynucleotide sequence can be reflected in the polypeptide or domains of other peptides added to the polypeptide to modify the properties of any part of the polypeptide. For example, mutations can be used to reduce or eliminate expression of a target protein and include, but are not limited to, deletion of the entire gene or a portion of the gene, inserting a DNA fragment into the gene (in either the promoter or coding region) so that the protein is not expressed or expressed at lower levels, introducing a mutation into the coding region which adds a stop codon or frame shift such that a functional protein is not expressed, and introducing one or more mutations into the coding region to alter amino acids so that a non-functional or a less enzymatically active protein is expressed.

Amino acid "substitutions" can be the result of replacing one amino acid with another amino acid having similar structural and/or chemical properties, i.e., conservative amino acid replacements, or they can be the result of replacing one amino acid with an amino acid having different structural and/or chemical properties, i.e., non-conservative amino acid replacements. "Conservative" amino acid substitutions can be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, or the amphipathic nature of the residues involved. For example, nonpolar (hydrophobic) amino acids include alanine, leucine,

isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; positively charged (basic) amino acids include arginine, lysine, and histidine; and negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Alternatively, "non-conservative" amino acid substitutions can be made by selecting the differences in polarity, charge, solubility, hydrophobicity, hydrophilicity, or the amphipathic nature of any of these amino acids. "Insertions" or "deletions" can be within the range of variation as structurally or functionally tolerated by the recombinant proteins. The variation allowed can be experimentally determined by systematically making insertions, deletions, or substitutions of amino acids in a polypeptide molecule using recombinant DNA techniques and assaying the resulting recombinant variants for activity.

A "substantial portion" of an amino acid or nucleotide sequence is that portion comprising enough of the amino acid sequence of a polypeptide or the nucleotide sequence of a gene to putatively identify that polypeptide or gene, either by manual evaluation of the sequence by one skilled in the art, or by computer-automated sequence comparison and identification using algorithms such as BLAST (Altschul, S. F., et al., J. Mol. Biol., 215:403-410 (1993)). In general, a sequence of ten or more contiguous amino acids or thirty or more nucleotides is necessary in order to putatively identify a polypeptide or nucleic acid sequence as homologous to a known protein or gene. Moreover, with respect to nucleotide sequences, gene specific oligonucleotide probes comprising 20-30 contiguous nucleotides can be used in sequence-dependent methods of gene identification (e.g., Southern hybridization) and isolation (e.g., in situ hybridization of bacterial colonies or bacteriophage plaques). In addition, short oligonucleotides of 12-15 bases can be used as amplification primers in PCR in order to obtain a particular nucleic acid fragment comprising the primers. Accordingly, a "substantial portion" of a nucleotide sequence comprises enough of the sequence to specifically identify and/or isolate a nucleic acid fragment comprising the sequence. The instant specification teaches the complete amino acid and nucleotide

sequence encoding particular proteins. The skilled artisan, having the benefit of the sequences as reported herein, can now use all or a substantial portion of the disclosed sequences for purposes known to those skilled in this art. Accordingly, the instant invention comprises the
5 complete sequences as reported in the accompanying Sequence Listing, as well as substantial portions of those sequences as defined above.

The term "complementary" is used to describe the relationship between nucleotide bases that are capable of hybridizing to one another. For example, with respect to DNA, adenine is complementary to thymine
10 and cytosine is complementary to guanine, and with respect to RNA, adenine is complementary to uracil and cytosine is complementary to guanine.

The term "percent identity", as known in the art, is a relationship between two or more polypeptide sequences or two or more
15 polynucleotide sequences, as determined by comparing the sequences. In the art, "identity" also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences. "Identity" and "similarity" can be readily calculated by known methods, including but
20 not limited to those described in: 1.) Computational Molecular Biology (Lesk, A. M., Ed.) Oxford University: NY (1988); 2.) Biocomputing: Informatics and Genome Projects (Smith, D. W., Ed.) Academic: NY (1993); 3.) Computer Analysis of Sequence Data, Part I (Griffin, A. M., and Griffin, H. G., Eds.) Humana: NJ (1994); 4.) Sequence Analysis in
25 Molecular Biology (von Heinje, G., Ed.) Academic (1987); and 5.) Sequence Analysis Primer (Gribskov, M. and Devereux, J., Eds.) Stockton: NY (1991).

Methods to determine identity are designed to give the best match between the sequences tested. Methods to determine identity and
30 similarity are codified in publicly available computer programs. Sequence alignments and percent identity calculations can be performed using the MegAlign™ program of the LASERGENE bioinformatics computing suite (DNASTAR Inc., Madison, WI). Multiple alignments of the sequences are

performed using the "Clustal method of alignment" which encompasses several varieties of the algorithm including the "Clustal V method of alignment" corresponding to the alignment method labeled Clustal V (described by Higgins and Sharp, CABIOS. 5:151-153 (1989); Higgins, D.G. et al., Comput. Appl. Biosci., 8:189-191 (1992)) and found in the MegAlign™ program of the LASERGENE bioinformatics computing suite (DNASTAR Inc.). For multiple alignments, the default values correspond to GAP PENALTY=10 and GAP LENGTH PENALTY=10. Default parameters for pairwise alignments and calculation of percent identity of protein sequences using the Clustal method are KTUPLE=1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5. For nucleic acids these parameters are KTUPLE=2, GAP PENALTY=5, WINDOW=4 and DIAGONALS SAVED=4. After alignment of the sequences using the Clustal V program, it is possible to obtain a "percent identity" by viewing the "sequence distances" table in the same program. Additionally the "Clustal W method of alignment" is available and corresponds to the alignment method labeled Clustal W (described by Higgins and Sharp, CABIOS. 5:151-153 (1989); Higgins, D.G. et al., Comput. Appl. Biosci. 8:189-191(1992)) and found in the MegAlign™ v6.1 program of the LASERGENE bioinformatics computing suite (DNASTAR Inc.). Default parameters for multiple alignment (GAP PENALTY=10, GAP LENGTH PENALTY=0.2, Delay Divergen Seqs(%)=30, DNA Transition Weight=0.5, Protein Weight Matrix=Gonnet Series, DNA Weight Matrix=IUB). After alignment of the sequences using the Clustal W program, it is possible to obtain a "percent identity" by viewing the "sequence distances" table in the same program.

It is well understood by one skilled in the art that many levels of sequence identity are useful in identifying polypeptides wherein such polypeptides have the same or similar function or activity, or in describing the corresponding polynucleotides. Useful examples of percent identities include, but are not limited to: 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%, or any integer percentage from 55% to 100% can be useful in describing the present invention, such as 55%, 56%, 57%, 58%, 59%,

60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%,
 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%,
 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%
 or 99%. Suitable polynucleotide fragments not only have the above
 5 homologies but typically comprise a polynucleotide having at least 50
 nucleotides, at least 100 nucleotides, at least 150 nucleotides, at least 200
 nucleotides, or at least 250 nucleotides. Further, suitable polynucleotide
 fragments having the above homologies encode a polypeptide having at
 least 50 amino acids, at least 100 amino acids, at least 150 amino acids,
 10 at least 200 amino acids, or at least 250 amino acids. Polynucleotides can
 be cloned or synthesized using methods known in the art.

The term "sequence analysis software" refers to any computer
 algorithm or software program that is useful for the analysis of nucleotide
 or amino acid sequences. "Sequence analysis software" can be
 15 commercially available or independently developed. Typical sequence
 analysis software will include, but is not limited to: 1.) the GCG suite of
 programs (Wisconsin Package Version 9.0, Genetics Computer Group
 (GCG), Madison, WI); 2.) BLASTP, BLASTN, BLASTX (Altschul et al., J.
 Mol. Biol., 215:403-410 (1990)); 3.) DNASTAR (DNASTAR, Inc. Madison,
 20 WI); 4.) Sequencher (Gene Codes Corporation, Ann Arbor, MI); and 5.)
 the FASTA program incorporating the Smith-Waterman algorithm (W. R.
 Pearson, Comput. Methods Genome Res., [Proc. Int. Symp.] (1994),
 Meeting Date 1992, 111-20. Editor(s): Suhai, Sandor. Plenum: New York,
 NY). Within the context of this application it will be understood that where
 25 sequence analysis software is used for analysis, that the results of the
 analysis will be based on the "default values" of the program referenced,
 unless otherwise specified. As used herein "default values" will mean any
 set of values or parameters that originally load with the software when first
 initialized.

30 Standard recombinant DNA and molecular cloning techniques are
 well known in the art and are described by Sambrook, J., Fritsch, E. F. and
 Maniatis, T., Molecular Cloning: A Laboratory Manual, Second Edition,
 Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989)
 (hereinafter "Maniatis"); and by Silhavy, T. J., Bennis, M. L. and Enquist,

L. W., Experiments with Gene Fusions, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1984); and by Ausubel, F. M. et al., Current Protocols in Molecular Biology, published by Greene Publishing Assoc. and Wiley-Interscience (1987). Additional methods used here are

5 in Methods in Enzymology, Volume 194, Guide to Yeast Genetics and Molecular and Cell Biology (Part A, 2004, Christine Guthrie and Gerald R. Fink (Eds.), Elsevier Academic Press, San Diego, CA). Other molecular tools and techniques are known in the art and include splicing by overlapping extension polymerase chain reaction (PCR) (Yu, et al. (2004)

10 Fungal Genet. Biol. 41:973-981), positive selection for mutations at the URA3 locus of *Saccharomyces cerevisiae* (Boeke, J.D. et al. (1984) Mol. Gen. Genet. 197, 345-346; M A Romanos, et al. Nucleic Acids Res. 1991 January 11; 19(1): 187), the cre-lox site-specific recombination system as well as mutant lox sites and FLP substrate mutations (Sauer, B. (1987)

15 Mol Cell Biol 7: 2087-2096; Senecoff, et al. (1988) Journal of Molecular Biology, Volume 201, Issue 2, Pages 405-421; Albert, et al. (1995) The Plant Journal. Volume 7, Issue 4, pages 649-659), "seamless" gene deletion (Akada, et al. (2006) Yeast, 23(5):399-405), and gap repair methodology (Ma et al., Genetics 58:201-216; 1981).

20 The genetic manipulations of a recombinant host cell disclosed herein can be performed using standard genetic techniques and screening and can be made in any host cell that is suitable to genetic manipulation (Methods in Yeast Genetics, 2005, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 201-202).

25 In embodiments, a recombinant host cell disclosed herein can be any yeast or fungi host useful for genetic modification and recombinant gene expression including those yeast mentioned elsewhere herein. In other embodiments, a recombinant host cell can be a member of the genera *Issatchenkia*, *Zygosaccharomyces*, *Saccharomyces*,

30 *Schizosaccharomyces*, *Dekkera*, *Torulopsis*, *Brettanomyces*, *Torulaspora*, *Hanseniaspora*, *Kluveromyces*, *Yarrowia*, and some species of *Candida*.

Polypeptides with KARI Activity Suited for Biosynthetic Pathways

US Appl. Pub. No. 2010/0197519A1 describes variants of the

Pseudomonas fluorescens KARI enzyme suitable for isobutanol production, including a variant "JEA1" (SEQ ID NO: 2) which was demonstrated to have a lower K_M for the cofactor NADH than the wild-type enzyme.

5 As demonstrated in the Examples herein, variants of JEA1 have been provided which are believed to be particularly suitable for use in recombinant microbial host cells comprising an isobutanol biosynthetic pathway, including yeast cells such as *S. cerevisiae* and in methods utilizing such host cells under anaerobic conditions. As such, the
10 variants provided herein may also be useful in other biosynthetic pathways comprising a substrate to product conversion catalyzed by KARI activity.

Based on the results given in the Examples, substitutions at one or more, two or more, three or more, four or more, five or more, six or more, seven or more, or eight or more of the following positions of SEQ ID NO: 2
15 give rise to polypeptides suited for use in recombinant host cells comprising an isobutanol biosynthetic pathway: Y286, I152, S322, S292, I291, I13, P47, F50, V53, A268, V76, A336, L88, A71, G72, M301, Y239, Y113, N114, A329, A69, A295, E264, R280, S157, M238, Q272, K335, K99, R275, R306.

20 In embodiments, substitutions at these positions include, but are not limited to, those demonstrated in the Examples: Y286F, A336R, I152V, S322A, S292A, I291V, I13L, P47Y, F50A, V53A, A268E, V76I, A336G, L88V, A71K, G72W, I152V, A268T, A329E, M301I, Y239H, Y113F, S322A, N114G, A329R, A69T, N114S, A295V, E264K, R280D, S157T,
25 M238I, Q272T, K335M, R280H, K99N, R275K, R306K or a combination thereof.

Combinations of substitutions may include, but are not limited to, those demonstrated in Examples 1-5, Tables 9, 11, 13, 15, and 17. As demonstrated, certain of the combinations of substitutions are suitable for
30 use in recombinant microbial host cells comprising an isobutanol biosynthetic pathway.

For example, as shown in Example 2, a suitable combination is Y286, A336, and I152. Example variants with substitutions in these positions are demonstrated in the Examples. In embodiments, the

substitutions at these positions are Y286F, A336R, and I152V. Another suitable combination is A68, I152, Y286 and A336. In embodiments, the substitutions at these positions are A68E, I152V, Y286F, and A336R. An example variant containing those substitutions is given as SEQ ID NO:

5 346 ("R8-SOG1_y2").

Other combinations comprise substitutions at one or more of the following sites: A69, A71, Y113, M238, Y239, M301, A322, or A329. Examples of such combinations are shown in Example 5.

In embodiments, for variants provided herein, including variants
10 comprising substitutions at I152, Y286 and A336 and optionally A68 substitutions may be selected from those indicated with an "X" in Table 3 for the indicated positions:

Table 3: Substitutions for KARI variants

Amino Acid	Position 152	Position 286	Position 336
A, Ala	X	X	X
C, Cys	X	X	X
D, Asp	X	-	X
E, Glu	X	-	X
F, Phe	X	X	X
G, Gly	X	-	X
H, His	X	X	X
I, Ile	X	X	X
K, Lys	X	-	X
L, Leu	X	-	X
M, Met	X	X	X
N, Asn	X	-	X
P, Pro	X	-	X
Q, Gln	X	-	X
R, Arg	X	-	X
S, Ser	X	-	X
T, Thr	X	-	X
V, Val	X	-	X
W, Trp	X	X	X
Y, Tyr	X	X	X

15 Equipped with this disclosure, one of skill in the art can readily make and use additional substitutions at any of the indicated sites (Y286, I152, S322, S292, I291, I13, P47, F50, V53, A268, V76, A336, L88, A71, G72, M301, Y239, Y113, N114, A329, A69, A295, E264, R280, S157, M238, Q272, K335, K99, R275, and R306.) to produce additional variants.
20 Methods of generating such variants are demonstrated herein (see Example 6) and/or are known in the art as described below. In one

embodiment, conservative substitutions are made based on the sequences exemplified herein. In another embodiment, all or a subset of amino acids are substituted at a given site and screened for activity.

In embodiments, in polypeptides provided herein: the amino acid at the position corresponding to position 24 of SEQ ID NO: 2 is F; the amino acid at the position corresponding to position 33 of SEQ ID NO: 2 is L; the amino acid at the position corresponding to position 47 of SEQ ID NO: 2 is P; the amino acid at the position corresponding to position 50 of SEQ ID NO: 2 is F; the amino acid at the position corresponding to position 61 of SEQ ID NO: 2 is F; the amino acid at the position corresponding to position 80 of SEQ ID NO: 2 is I; and the amino acid at the position corresponding to position 156 of SEQ ID NO: 2 is V.

It will be appreciated that using a combination of structural and sequence information available in the art, polypeptides comprising KARI activity and less than 100% identity to the exemplified sequences can be constructed for use in isobutanol or other biosynthetic pathways. For example, crystal structures of the *E. coli* KARI enzyme at 2.6 Å resolution have been solved (Tyagi, et al., Protein Sci., 14: 3089-3100, 2005) as has the structure of the *P. aeruginosa* KARI (Ahn, et al., J. Mol. Biol., 328: 505-515, 2003) and the KARI enzyme from spinach (Biou V., et al. The EMBO Journal, 16: 3405-3415, 1997). Furthermore, a KARI Profile HMM prepared using amino acid sequences of 25 KARI proteins with experimentally verified function is described in U.S. Patent 8,129,162. The KARIs were from *Pseudomonas fluorescens* Pf-5, *Sulfolobus solfataricus* P2, *Pyrobaculum aerophilum* str. IM2, *Natronomonas pharaonis* DSM 2160, *Bacillus subtilis* subsp. subtilis str. 168, *Corynebacterium glutamicum* ATCC 13032, *Phaeosporillum molischianum*, *Ralstonia solanacearum* GMI1000, *Zymomonas mobilis* subsp. mobilis ZM4, *Alkalilimnicola ehrlichei* MLHE-, *Campylobacter lari* RM2100, *Marinobacter aquaeolei* VT8, *Psychrobacter arcticus* 273-4, *Hahella chejuensis* KCTC 2396, *Thiobacillus denitrificans* ATCC 25259, *Azotobacter vinelandii* AvOP, *Pseudomonas syringae* pv. *syringae* B728a, *Pseudomonas syringae* pv. *tomato* str. DC3000, *Pseudomonas putida*

KT2440, *Pseudomonas entomophila* L48, *Pseudomonas mendocina* ymp, *Pseudomonas aeruginosa* PAO1, *Bacillus cereus* ATCC 10987, *Bacillus cereus* ATCC 10987, and *Spinacia oleracea*. Any protein that matches the KARI Profile HMM (described in U.S. Patent 8,129,162 and
 5 incorporated by reference in its entirety herein) with an E value of $<10^{-3}$ using hmmsearch program in the HMMER package is expected to be a functional KARI.

As shown in Figures 9-12, substitution positions disclosed herein can be grouped according to their structural location using homology
 10 modeling of PF5 KARI as disclosed in U.S. Patent 8,129,162. As disclosed therein, the structure of PF5-KARI with bound NADPH, acetolactate and magnesium ions was built based on the crystal structure of *P. aeruginosa* PAO1-KARI (PDB ID 1NP3, Ahn H. J. et al, J. Mol. Biol., 328, 505-515, 2003) which has 92% amino acid sequence identity to PF5
 15 KARI. PAO1-KARI structure is a homo-dodecamer and each dodecamer consists of six homo-dimers with extensive dimer interface. The active site of KARI is located in this dimer interface. The biological assembly is formed by six homo-dimers positioned on the edges of a tetrahedron resulting in a highly symmetrical dodecamer of 23 point group symmetry.
 20 For simplicity, only the dimeric unit (monomer A and monomer B) was built for the homology model of PF5-KARI because the active site is in the homo-dimer interface.

The model of PF5-KARI dimer was built based on the coordinates of monomer A and monomer B of PAO1-KARI and sequence of PF5-KARI
 25 using DeepView/Swiss PDB viewer (Guex, N. and Peitsch, M.C. Electrophoresis 18: 2714-2723, 1997). This model was then imported to program O (Jones, T.A. et al, Acta Crystallogr. A 47, 110-119, 1991) on a Silicon Graphics system for further modification.

The structure of PAO1-KARI has no cofactor, substrate or inhibitor
 30 or magnesium in the active site. Therefore, the spinach KARI structure (PDB ID 1yve, Biou V. et al. The EMBO Journal, 16: 3405-3415, 1997.), which has magnesium ions, NADPH and inhibitor (N-Hydroxy-N-isopropylloxamate) in the acetolactate binding site, was used to model these molecules in the active site. The plant KARI has very little sequence

identity to either PF5- or PAO1 KARI (<20% amino acid identity), however the structures in the active site region of these two KARI enzymes are very similar. To overlay the active site of these two KARI structures, commands LSQ_ext, LSQ_improve, LSQ_mol in the program O were used to line up the active site of monomer A of spinach KARI to the monomer A of PF5 KARI model. The coordinates of NADPH, two magnesium ions and the inhibitor bound in the active site of spinach KARI were extracted and incorporated to molecule A of PF5 KARI. A set of the coordinates of these molecules was generated for monomer B of PF5 KARI by applying the transformation operator from monomer A to monomer B calculated by the program.

Because there is no cofactor in the active site of PAO1 KARI crystal structure, the structures of the phosphate binding loop region in the cofactor binding site (residues 44-45 in PAO1 KARI, 157-170 in spinach KARI) are very different between the two. To model the cofactor-bound form, the model of the PF5-KARI phosphate binding loop (44-55) was replaced by that of 1yve (157-170). Any discrepancy of side chains between these two was converted to those in the PF5-KARI sequence using the mutate_replace command in program O, and the conformations of the replaced side-chains were manually adjusted. The entire NADPH/Mg/ inhibitor bound dimeric PF5-KARI model went through one round of energy minimization using program CNX (ACCELRYS San Diego CA, Burnger, A.T. and Warren, G.L., Acta Crystallogr., D 54, 905-921, 1998) after which the inhibitor was replaced by the substrate, acetolactate (AL), in the model. The conformation of AL was manually adjusted to favor hydride transfer between C4 of the nicotinamide of NADPH and the substrate. No further energy minimization was performed on this model.

The C-terminal tail (328-338) is not seen in the model and is disordered in the crystal structure PDB code 1np3 that was used to build the homology model of Pf5-KARI. The C-terminal tail has been shown to be important for the binding of cofactor and substrate during catalysis (JMB (2009)389, 167-182 Leung & Guddat). The following positions are in the C-terminal tail region: A329, K335, A336.

As shown in Figure 10, positions M238, Y239, E264, N267, A268

Q272, A277, R280, Y286, I291, S292, M301, S322, are associated with the inter-molecular dimer interface region, and positions Y113, N114, I291, S292, and A295 are associated with the inter-domain interface region.

Positions of P47, P50, V53, T80, and L88 are part of the modeled nucleotide binding region (Figure 11A). Positions 68, 69, 71 and 72 are associated with N-domain surface helix (positions 64-73; Figure 11B).

Positions C33, L61, I127, I152, and V171 are in the N-domain hydrophobic bridge region, shown in Figure 12.

Accordingly, provided herein are variants comprising substitutions in at least one of the inter-molecular dimer interface region, inter-domain interface region, nucleotide binding region, N-domain surface helix region, hydrophobic bridge region, and the C-terminal tail region. In embodiments, variants provided herein comprise substitutions in the nucleotide binding region and substitutions in at least one of, at least two of, or at least three of the following regions: the inter-molecular dimer interface region, inter-domain interface region, N-domain surface helix region, hydrophobic bridge region, or the C-terminal tail region.

The sequences of other polynucleotides, genes and/or polypeptides can be identified in the literature and in bioinformatics databases well known to the skilled person using sequences disclosed herein and available in the art. For example, such sequences can be identified through BLAST searching of publicly available databases with polynucleotide or polypeptide sequences provided herein. In such a method, identities can be based on the Clustal W method of alignment using the default parameters of GAP PENALTY=10, GAP LENGTH PENALTY=0.1, and Gonnet 250 series of protein weight matrix.

Additionally, polynucleotide or polypeptide sequences disclosed herein can be used to identify other KARI homologs in nature. For example, each of the KARI encoding nucleic acid fragments disclosed herein can be used to isolate genes encoding homologous proteins. Isolation of homologous genes using sequence-dependent protocols is well known in the art. Examples of sequence-dependent protocols include, but are not limited to (1) methods of nucleic acid hybridization; (2) methods of DNA and RNA amplification, as exemplified by various

uses of nucleic acid amplification technologies [e.g., polymerase chain reaction (PCR), Mullis et al., U.S. Patent No. 4,683,202; ligase chain reaction (LCR), Tabor et al., Proc. Acad. Sci. USA 82:1074 (1985); or strand displacement amplification (SDA), Walker et al., Proc. Natl. Acad. Sci. U.S.A., 89:392 (1992)]; and (3) methods of library construction and screening by complementation.

It will be appreciated that one of ordinary skill in the art, equipped with this disclosure as well as sequence and structural information available herein and/or in the art, can also generate active fragments of polypeptides provided herein, for example, by truncating polypeptides provided herein at the N-terminus or C-terminus and confirming KARI activity.

Accordingly, provided herein are polypeptides having at least about 90% identity to, at least about 95% identity to, at least about 99% identity to, or having the amino acid sequence of SEQ ID NO: 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 20, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 116, 118, 119, 120, 121, 123, 124, 128, 129, 131, 132, 133, 134, 136, 137, 138, 139, 140, 141, 142, 143, 144, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 157, 159, 160, 161, or 346 or an active fragment thereof.

Generation of variants

Variants described herein may be generated by any method known in the art. Methods known in the art for site-directed mutagenesis include, for example, QuikChange® (Agilent, Santa Clara, CA) and Change-IT® (Affymetrix/USB, Santa Clara, CA). Methods known in the art for random point mutagenesis include, for example, error-prone PCR (e.g., Bloom et al., BMC Biol. 2007, 5:29, doi:10.1186/1741-7007-5-29.) or GeneMorph® (Agilent, Santa Clara, CA), exposure to chemical mutagens (e.g., ethyl methanesulfonate) or ultraviolet light, use of modified nucleotides in PCR (e.g., Wong et al., Nucleic Acids Res. 2004, 32:3, e26.), and use of special

mutator strains. Methods known in the art for DNA recombination or "shuffling" include, for example, random fragmentation and reassembly (e.g. Stemmer 1994 Proc. Natl. Acad. Sci. USA 91:22, 10747-10751.), heteroduplex repair (e.g., Volkov et al., Nucleic Acids Res. 1999 27:18, e18.), staggered extension (e.g., Zhao et al., Nat. Biotechnol. 1998, 16:3, 258-261.), unpaired-primer shuffling (e.g., Milano et al., US Patent # 7,879,582), site-directed recombination (e.g., Hiraga et al., J. Mol. Biol. 2003, 330:2, 287-296.), and synthetic shuffling (e.g., Ness et al., Nat. Biotechnol. 2002, 20, 1251-1255.). Other methods for protein variant library construction include, for example, circular permutation (e.g., Guntas et al., PLoS One. 2012, 7(4):e35998), and chemical DNA synthesis.

Equipped with this disclosure, one of skill in the art can readily make and use the variants provided herein as well as variants with less than 100% identity (as described above) thereto.

KARI activity

Polypeptides described herein include those with KARI activity. KARI activity can be confirmed by assaying for the enzymatic conversion of acetolactate to 2,3-dihydroxyisovalerate using methods described in the art (for example in U.S. Patent 8,129,162, incorporated herein by reference). For example, the conversion may be followed by measuring the disappearance of the cofactor, NADPH or NADH, from the reaction at 340 nm using a plate reader (such as from Molecular Device, Sunnyvale, Calif.).

KARI activity may also be confirmed by expressing a given KARI in a host cell comprising polynucleotides encoding polypeptides that catalyze the substrate to product conversions given in Figure 1, steps a, c, d, and e and measuring the production of isobutanol, as described and demonstrated herein (see Examples). Alternatively, KARI activity may be confirmed by measuring the production of intermediate products in the biosynthetic pathway downstream of the substrate to product conversion catalyzed by KARI. Likewise, host cells comprising the substrate to product conversions for other biosynthetic pathways can also be used to

confirm KARI activity using a like strategy and confirming the production of the biosynthetic pathway product or intermediate products downstream of the substrate to product conversion catalyzed by KARI.

5 Confirmation of Isobutanol Production

The presence and/or concentration of isobutanol in the culture medium can be determined by a number of methods known in the art (see, for example, U.S. Patent 7,851,188, incorporated by reference in its entirety). For example, a specific high performance liquid chromatography (HPLC) method utilizes a Shodex SH-1011 column with a Shodex SHG guard column, both may be purchased from Waters Corporation (Milford, Mass.), with refractive index (RI) detection. Chromatographic separation is achieved using 0.01 M H₂SO₄ as the mobile phase with a flow rate of 0.5 mL/min and a column temperature of 50 °C. Isobutanol has a retention
10 time of 46.6 min under the conditions used.

Alternatively, gas chromatography (GC) methods are available. For example, a specific GC method utilizes an HP-INNOWax column (30 m X 0.53 mm id, 1 µm film thickness, Agilent Technologies, Wilmington, DE), with a flame ionization detector (FID). The carrier gas is helium at a flow
20 rate of 4.5 mL/min, measured at 150 °C with constant head pressure; injector split is 1:25 at 200 °C; oven temperature is 45 °C for 1 min, 45 to 220 °C at 10 °C/min, and 220 °C for 5 min; and FID detection is employed at 240 °C with 26 mL/min helium makeup gas. The retention time of isobutanol is 4.5 min.

25

Reduction of DHMB

The production of DHMB in a host cell comprising an isobutanol biosynthetic pathway indicates that not all of the pathway substrates are
30 being converted to the desired product. Thus, yield is lowered. In addition, DHMB can have inhibitory effects on product production. For example, DHMB can decrease the activity of enzymes in the biosynthetic pathway or have other inhibitory effects on yeast growth and/or productivity during fermentation. Thus, the methods described herein

provide ways of reducing DHMB during fermentation. The methods include both methods of decreasing the production of DHMB and methods of removing DHMB from fermenting compositions.

5 Decreasing DHMB Production

In some embodiments described herein, a recombinant host cell can comprise reduced or eliminated ability to convert acetolactate to DHMB. The ability of a host cell to convert acetolactate to DHMB can be reduced or eliminated, for example, by a modification or disruption of a
10 polynucleotide or gene encoding a polypeptide having acetolactate reductase activity or a modification or disruption of a polypeptide having acetolactate reductase activity. In other embodiments, the recombinant host cell can comprise a deletion, mutation, and/or substitution in an endogenous polynucleotide or gene encoding a polypeptide having
15 acetolactate reductase activity or in an endogenous polypeptide having acetolactate reductase. Such modifications, disruptions, deletions, mutations, and/or substitutions can result in acetolactate reductase activity that is reduced, substantially eliminated, or eliminated. In some embodiments of the invention, the product of the biosynthetic pathway is
20 produced at a greater yield or amount compared to the production of the same product in a recombinant host cell that does not comprise reduced or eliminated ability to convert acetolactate to DHMB.

Thus, the product can be a composition comprising isobutanol that is substantially free of, or free of DHMB. In some embodiments, the
25 composition comprising butanol contains no more than about 5 mM, about 4 mM, about 3 mM, about 2 mM, about 1 mM, about 0.5 mM, about 0.4 mM, about 0.3 mM DHMB, or about 0.2 mM DHMB.

Any product of a biosynthetic pathway that involves the conversion of acetolactate to a substrate other than DHMB can be produced with
30 greater effectiveness in a recombinant host cell disclosed herein having the described modification of acetolactate reductase activity. Such products include, but are not limited to, butanol, e.g., isobutanol, 2-butanol, and BDO, and branched chain amino acids.

In some embodiments, the host cell comprises at least one

deletion, mutation, and/or substitution in at least one endogenous polynucleotide encoding a polypeptide having acetolactate reductase activity. In some embodiments, the host cell comprises at least one deletion, mutation, and/or substitution in each of at least two endogenous polynucleotides encoding polypeptides having acetolactate reductase activity.

In some embodiments, a polypeptide having acetolactate reductase activity can catalyze the conversion of acetolactate to DHMB. In some embodiments, a polypeptide having acetolactate reductase activity is capable of catalyzing the reduction of acetolactate to 2S,3S-DHMB (fast DHMB) and/or 2S,3R-DHMB (slow DHMB).

Table 4: Polypeptides and polynucleotides having acetolactate reductase activity in *Saccharomyces cerevisiae*

Gene	SEQ ID NO: (nucleic acid, amino acid)
YMR226C	174, 175
YIL074C (Chr 9)	176, 177
YIR036C (Chr 9)	178, 179
YPL061W (ALD6)(Chr 16)	180, 181
YPL088W(Chr 16)	182, 183
YCR105W (ADH7)(Chr 3)	184, 185
YDR541C(Chr 4)	186, 187
YER081 (SER3)(Chr 5)	188, 189
YPL275W (FDH2)(Chr 16)	190, 191
YBR006W (UGA5)(Chr2)	192, 193
YOL059W (Chr 15)	194, 195
YER081W (Chr 5)	196, 197
YOR375C (Chr 15)	198, 199

In some embodiments, the conversion of acetolactate to DHMB in a recombinant host cell is reduced, substantially eliminated, or eliminated. In some embodiments, the polypeptide having acetolactate reductase activity is selected from the group consisting of: YMR226C, YER081W, YIL074C, YBR006W, YPL275W, YOL059W, YIR036C, YPL061W, YPL088W, YCR105W, YOR375C, and YDR541C. In some embodiments, the polypeptide having acetolactate reductase activity is a polypeptide

comprising a sequence listed in Table 4 or a sequence that is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 99% identical to a polypeptide sequence listed in Table 4. In some embodiments, the polypeptide having acetolactate reductase activity is a polypeptide encoded by a polynucleotide sequence listed in Table 4 or a sequence that is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 99% identical to a polynucleotide sequence listed in Table 4.

Table 5: Example YMR226C Yeast Homologs

Species	Accession #	SEQ ID NO: (nucleic acid, amino acid)
<i>Saccharomyces paradoxus</i>	AABY01000127	200, 201
<i>Saccharomyces bayanus</i>	AACA01000631	202, 203
		MSQGRKAAERLANKTVLITGAS AGIGKATALEYLEASNGNMKLIL AARRLEKLEELKKTIDEEFPNAK VHVGQLDITQAEKIKPFIEINLPEA FKDIDILINNAGKALGSERVGEIA TQDIQDVFDTNVTALINVTQAVL PIFQAKNSGDIVNLGLGGRQRRIP HRLHLLCFQVCRRCVH*QFEKGT DQHEDQSYLDRAGAG*DRVLTG QIQR**GTS*KRLQGHYAVDGRR RG*LNRIHFHQKAEHRGCRHPDL PHQPSLALPHLSRL* (SEQ ID NO:701) The sequence came from a comparative genomics study using "draft" genome sequences with 7-fold coverage (Kellis et al, Nature 423:241-254 (2003)).
<i>Saccharomyces castellii</i>	AACF01000116	204, 205
<i>Saccharomyces mikatae</i>	AACH01000019	206, 207
<i>Ashbya gossypii</i>	AE016819	208, 209
<i>Candida glabrata</i>	CR380959	210, 211
<i>Debaryomyces hansenii</i>	CR382139	212, 213
<i>Scheffersomyces stipitis</i> (formerly <i>Pichia stipitis</i>)	XM_001387479	214, 215
<i>Meyerozyma guilliermondii</i> (formerly <i>Pichia guilliermondii</i>)	XM_001482184	216, 217
<i>Vanderwaltozyma polyspora</i> (formerly <i>Kluyveromyces</i>)	XM_001645671	218, 219

Species	Accession #	SEQ ID NO: (nucleic acid, amino acid)
<i>polysporus</i>		
<i>Candida dubliniensis</i>	XM_002419771	220, 221
<i>Zygosaccharomyces rouxii</i>	XM_002494574	222, 223
<i>Lachancea thermotolerans</i> (formerly <i>Kluyveromyces thermotolerans</i>)	XM_002553230	224, 225
<i>Kluyveromyces lactis</i>	XM_451902	226, 227
<i>Saccharomyces kluyveri</i>	SAKL0H04730	228, 229
<i>Yarrowia lipolytica</i>	XM_501554	230, 231
<i>Schizosaccharomyces pombe</i>	NM_001018495	232, 233

In some embodiments, a polypeptide having acetolactate reductase activity is YMR226C or a homolog of YMR226C. Thus, in some embodiments, the polypeptide having acetolactate reductase activity is a polypeptide comprising a sequence listed in Table 5 or a sequence that is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 99% identical to a polypeptide sequence listed in Table 5. In some embodiments, the polypeptide having acetolactate reductase activity is a polypeptide encoded by a polynucleotide sequence listed in Table 5 or a sequence that is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 99% identical to a polynucleotide sequence listed in Table 5.

Acetolactate reductases capable of converting acetolactate to DHMB can be identified, for example, by screening genetically altered yeast for changes in acetolactate consumption, changes in DHMB production, changes in DHIV production, or changes in other downstream product (e.g., butanol) production.

One way of identifying a gene involved in DHMB production comprises measuring the amount of DHMB produced by individual yeast strains in a yeast knock-out library. Knock-out libraries are available, for example, from Open Biosystems® (a division of Thermo Fisher Scientific, Waltham, MA). In this method, a decrease in DHMB production indicates that the gene that has been knocked-out functions to increase DHMB

production, and an increase in DHMB production indicates that the gene that has been knocked-out functions to decrease DHMB production.

Two ways that a knockout ("KO") library can be used to identify candidate genes for involvement in DHMB synthesis include: (1) DHMB and DHIV accumulated in the culture during growth from endogenous substrates (acetolactate and NADPH or NADH) can be analyzed in samples from cultures. These samples can be placed in a hot (80-100 °C) water bath for 10-20 min, or diluted into a solution such as 2% formic acid that will kill and permeabilize the cells. After either treatment, small molecules will be found in the supernatant after centrifugation (5 min, 1100 x g). The DHMB/DHIV ratio of a control strain (e.g., BY4743) can be compared to that of the different KO derivatives, and the gene(s) missing from any strain(s) with exceptionally low DHMB/DHIV ratios can encode acetolactate reductase (ALR). (2) DHMB and/or DHIV formation rates in vitro from exogenous substrates (acetolactate and NADH and/or NADPH) can be measured in timed samples taken from a suspension of permeabilized cells, and inactivated in either of the ways described above. Since the substrates for DHMB and DHIV synthesis are the same, this allows one to measure the relative levels of ALR and KARI activity in the sample.

Another way of identifying a gene involved in DHMB production comprises measuring the amount of DHMB produced by individual yeast strains in a yeast overexpression library. Overexpression libraries are available, for example, from Open Biosystems® (a division of Thermo Fisher Scientific, Waltham, MA). In this method, a decrease in DHMB production indicates that the overexpressed gene functions to decrease DHMB production, and an increase in DHMB production indicates that the overexpressed gene functions to increase DHMB production.

Another way of identifying a gene involved in DHMB production is to biochemically analyze a DHMB-producing yeast strain. For example, DHMB-producing cells can be disrupted. This disruption can be performed at low pH and cold temperatures. The cell lysates can be separated into fractions, e.g., by adding ammonium sulfate or other techniques known to those of skill in the art, and the resulting fractions

can be assayed for enzymatic activity. For example, the fractions can be assayed for the ability to convert acetolactate to DHMB. Fractions with enzymatic activity can be treated by methods known in the art to purify and concentrate the enzyme (e.g., dialysis and chromatographic separation). When a sufficient purity and concentration is achieved, the enzyme can be sequenced, and the corresponding gene encoding the acetolactate reductase capable of converting acetolactate to DHMB can be identified.

Furthermore, since the reduction of acetolactate to DHMB occurs in yeast, but does not occur to the same extent in *E. coli*, acetolactate reductases that are expressed in yeast, but not expressed in *E. coli*, can be selected for screening. Selected enzymes can be expressed in yeast or other protein expression systems and screened for the capability to convert acetolactate to DHMB.

Enzymes capable of catalyzing the conversion of acetolactate to DHMB can be screened by assaying for acetolactate levels, by assaying for DHMB levels, by assaying for DHIV levels, or by assaying for any of the downstream products in the conversion of DHIV to butanol, including isobutanol.

DHMB can be measured using any technique known to those of skill in the art. For example, DHMB can be separated and quantified by methods known to those of skill in the art and techniques described in the Examples provided herein. For example, DHMB can be separated and quantified using liquid chromatography-mass spectrometry, liquid chromatography-nuclear magnetic resonance (NMR), thin-layer chromatography, and/or HPLC with UV/Vis detection.

In embodiments, selected acetolactate reductase polynucleotides, genes and/or polypeptides disclosed herein can be modified or disrupted. Many suitable methods are known to those of ordinary skill in the art and include those described for aldehyde dehydrogenase (above).

The modification of acetolactate reductase in a recombinant host cell disclosed herein to reduce or eliminate acetolactate reductase activity can be confirmed using methods known in the art. For example, the presence or absence of an acetolactate reductase-encoding

polynucleotide sequence can be determined using PCR screening. A decrease in acetolactate reductase activity can also be determined based on a reduction in conversion of acetolactate to DHMB. A decrease in acetolactate reductase activity can also be determined based on a reduction in DHMB production. A decrease in acetolactate reductase activity can also be determined based on an increase in butanol production.

Thus, in some embodiments, a yeast that is capable of producing butanol produces no more than about 5 mM, about 4 mM, about 3 mM, about 2 mM, about 1 mM, about 0.9 mM, about 0.8 mM., about 0.7 mM, about 0.6 mM, about 0.5 mM, about 0.4 mM or about 0.3 mM DHMB. In some embodiments, a yeast producing butanol produces no more than about about 5 mM, about 4 mM, about 3 mM, about 2 mM, about 1 mM, about 0.9 mM, about 0.8 mM., about 0.7 mM, about 0.6 mM, about 0.5 mM, about 0.4 mM or about 0.3 mM DHMB. In some embodiments, a yeast producing butanol produces no more than about 0.2 mM or 0.2 mM DHMB.

In some embodiments, a yeast capable of producing butanol produces no more than about about 10 mM DHMB when cultured under fermentation conditions for at least about 50 hours. In some embodiments, a yeast capable of producing butanol produces no more than about about 5 mM DHMB when cultured under fermentation conditions for at least about 20 hours, at least about 25 hours, at least about 30 hours, at least about 35 hours, at least about 40 hours, at least about 45 hours, or at least about 50 hours. In some embodiments, a yeast capable of producing butanol produced no more than about 3 mM DHMB when cultured under fermentation conditions for at least about 5 hours, at least about 10 hours, at least about 15 hours, at least about 20 hours, at least about 25 hours, at least about 30 hours, at least about 35 hours, at least about 40 hours, at least about 45 hours, or at least about 50 hours. In some embodiments, a yeast capable of producing butanol produced no more than about 1 mM DHMB when cultured under fermentation conditions for at least about 1 hour, at least about 5 hours, at least about 10 hours, at least about 15 hours, at least about 20 hours, at least about

25 hours, at least about 30 hours, at least about 35 hours, at least about 40 hours, at least about 45 hours, or at least about 50 hours. In some embodiments, a yeast capable of producing butanol produced no more than about 0.5 mM DHMB when cultured under fermentation conditions for
 5 at least about 1 hour, at least about 5 hours, at least about 10 hours, at least about 15 hours, at least about 20 hours, at least about 25 hours, at least about 30 hours, at least about 35 hours, at least about 40 hours, at least about 45 hours, or at least about 50 hours.

In some embodiments, a yeast comprising at least one deletion, mutation, and/or substitution in an endogenous polynucleotide encoding an acetolactate reductase produces no more than about 0.5 times, about 0.4 times, about 0.3 times, about 0.2 times, about 0.1 times, about 0.05 times the amount of DHMB produced by a yeast containing the endogenous polynucleotide encoding an acetolactate reductase when
 10 cultured under fermentation conditions for the same amount of time.

In some embodiments, a yeast that is capable of producing butanol produces an amount of DHIV that is at least about 5 mM, at least about 6 mM, at least about 7 mM, at least about 8 mM, at least about 9 mM, or at least about 10 mM.

20 In some embodiments, a yeast that is capable of producing butanol produces an amount of DHIV that is at least about the amount of DHMB produced. In some embodiments, a yeast that is capable of producing butanol produces an amount of DHIV that is at least about twice, about three times, about five times, about ten times, about 15 times, about 20 times, about 25 times, about 30 times, about 35 times, about 40 times,
 25 about 45 times, or about 50 times the amount of DHMB produced.

In some embodiments, a yeast that is capable of producing butanol produces DHIV at a rate that is at least about equal to the rate of DHMB production. In some embodiments, a yeast that is capable of producing butanol produces DHIV at a rate that is at least about twice, about three times, about five times, about ten times, about 15 times, about 20 times,
 30 about 25 times, about 30 times, about 35 times, about 40 times, about 45 times, or about 50 times the rate of DHMB production.

In some embodiments, a yeast that is capable of producing butanol

produces less than 0.010 moles of DHMB per mole of glucose consumed. In some embodiments, a yeast produces less than about 0.009, less than about 0.008, less than about 0.007, less than about 0.006, or less than about 0.005 moles of DHMB per mole of glucose consumed. In some
5 embodiments, a yeast produces less than about 0.004, less than about 0.003, less than about 0.002, or less than about 0.001 moles of DHMB per mole of glucose consumed.

In some embodiments, acetolactate reductase activity is inhibited by chemical means. For example, acetolactate reductase could be
10 inhibited using other known substrates such as those listed in Fujisawa et al. including L-serine, D-serine, 2-methyl-DL-serine, D-threonine, L-allo-threonine, L-3-hydroxyisobutyrate, D-3-hydroxyisobutyrate, 3-hydroxypropionate, L-3-hydroxybutyrate, and D-3-hydroxybutyrate (Biochimica et Biophysica Acta 1645:89-94 (2003), which is herein
15 incorporated by reference in its entirety).

DHMB Removal

In other embodiments described herein, a reduction in DHMB can be achieved by removing DHMB from a fermentation. Thus, fermentations
20 with reduced DHMB concentrations are also described herein. Removal of DHMB can result, for example, in a product of greater purity, or a product requiring less processing to achieve a desired purity. Therefore, compositions comprising products of biosynthetic pathways such as ethanol or butanol with increased purity are also provided.

25 DHMB can be removed during or after a fermentation process and can be removed by any means known in the art. DHMB can be removed, for example, by extraction into an organic phase or reactive extraction.

In some embodiments, the fermentation broth comprises less than about 0.5 mM DHMB. In some embodiments, the fermentation broth
30 comprises less than about 1.0 mM DHMB after about 5 hours, about 10 hours, about 15 hours, about 20 hours, about 25 hours, about 30 hours, about 35 hours, about 40 hours, about 45 hours, or about 50 hours of fermentation. In some embodiments, the fermentation broth comprises less than about 5.0 mM DHMB after about 20 hours, about 25 hours,

about 30 hours, about 35 hours, about 40 hours, about 45 hours, or about 50 hours of fermentation.

Biosynthetic Pathways

5 While the KARI variants presented herein are believed to be suitable for production of isobutanol, it is envisioned that KARIs disclosed herein may be useful in any biosynthetic pathway which employs a substrate to product conversion catalyzed by KARI activity such as
10 2,3-dihydroxy-3-methylpentanoate. Such pathways include, but are not limited to, pathways for producing pantothenic acid, valine, leucine, isoleucine or 3,3-dimethylmalate.

Certain suitable isobutanol biosynthetic pathways are disclosed in U.S. Patents 7,851,188 and 7,993,889, each of which is incorporated by
15 reference in their entireties herein. A diagram of the disclosed isobutanol biosynthetic pathways is provided in Figure 1. As described in U.S. Patent 7,851,188, steps in an example isobutanol biosynthetic pathway include conversion of:

- pyruvate to acetolactate (see Fig. 1, pathway step a therein), as
20 catalyzed for example by acetolactate synthase (ALS),
- acetolactate to 2,3-dihydroxyisovalerate (see Fig. 1, pathway step b therein) as catalyzed for example by acetohydroxy acid isomeroreductase (KARI);
- 2,3-dihydroxyisovalerate to 2-ketoisovalerate (see Fig. 1, pathway step c
25 therein) as catalyzed for example by acetohydroxy acid dehydratase, also called dihydroxy-acid dehydratase (DHAD);
- 2-ketoisovalerate to isobutyraldehyde (see Fig. 1, pathway step d therein) as catalyzed for example by branched-chain 2-keto acid decarboxylase; and
- 30 - isobutyraldehyde to isobutanol (see Fig. 1, pathway step e therein) as catalyzed for example by branched-chain alcohol dehydrogenase.

In another embodiment, the isobutanol biosynthetic pathway comprises the following substrate to product conversions:

- pyruvate to acetolactate, which may be catalyzed, for example, by

acetolactate synthase;

- acetolactate to 2,3-dihydroxyisovalerate, which may be catalyzed, for example, by ketol-acid reductoisomerase (KARI);
- 2,3-dihydroxyisovalerate to α -ketoisovalerate, which may be catalyzed, for example, by dihydroxyacid dehydratase;
- α -ketoisovalerate to valine, which may be catalyzed, for example, by transaminase or valine dehydrogenase;
- valine to isobutylamine, which may be catalyzed, for example, by valine decarboxylase;
- isobutylamine to isobutyraldehyde, which may be catalyzed by, for example, omega transaminase; and,
- isobutyraldehyde to isobutanol, which may be catalyzed, for example, by a branched-chain alcohol dehydrogenase.

In another embodiment, the isobutanol biosynthetic pathway comprises the following substrate to product conversions:

- pyruvate to acetolactate, which may be catalyzed, for example, by acetolactate synthase;
- acetolactate to 2,3-dihydroxyisovalerate, which may be catalyzed, for example, by acetohydroxy acid reductoisomerase;
- 2,3-dihydroxyisovalerate to α -ketoisovalerate, which may be catalyzed, for example, by acetohydroxy acid dehydratase;
- α -ketoisovalerate to isobutyryl-CoA, which may be catalyzed, for example, by branched-chain keto acid dehydrogenase;
- isobutyryl-CoA to isobutyraldehyde, which may be catalyzed, for example, by acylating aldehyde dehydrogenase; and,
- isobutyraldehyde to isobutanol, which may be catalyzed, for example, by a branched-chain alcohol dehydrogenase.

In another embodiment, the isobutanol biosynthetic pathway comprises the substrate to product conversions shown as steps k, g, and e in Figure 1.

In another embodiment, the pathway comprising the substrate to product conversion catalyzed by KARI is a pantothenic acid biosynthetic pathway comprising the following substrate to product conversions:

- pyruvate to acetolactate, which may be catalyzed, for example, by acetolactate synthase;
- acetolactate to 2,3-dihydroxyisovalerate, which may be catalyzed, for example, by ketol-acid reductoisomerase (KARI);
- 5 – 2,3-dihydroxyisovalerate to α -ketoisovalerate, which may be catalyzed, for example, by dihydroxyacid dehydratase (DHAD);
- α -ketoisovalerate to 2-dehydropantoate, which may be catalyzed, for example, by 3-methyl-2-oxobutanoate hydroxymethyltransferase (panB; which may be classified as EC 2.1.2.11);
- 10 –2-dehydropantoate to(R)-pantoate, which may be catalyzed, for example by 2-dehydropantoate 2-reductase (panE; which may be classified as EC 1.1.1.169)
- (R)-pantoate to (R)-pantothenate, which may be catalyzed, for example, by pantoate-beta-alanine ligase (panC; which may be classified as EC
- 15 6.3.2.1).

In another embodiment, the pathway comprising a substrate to product conversion catalyzed by KARI is a valine biosynthetic pathway comprising the following substrate to product conversions:

- pyruvate to acetolactate, which may be catalyzed, for example, by
- 20 acetolactate synthase;
- acetolactate to 2,3-dihydroxyisovalerate, which may be catalyzed, for example, by ketol-acid reductoisomerase (KARI);
- 2,3-dihydroxyisovalerate to α -ketoisovalerate, which may be catalyzed, for example, by dihydroxyacid dehydratase (DHAD);
- 25 – α -ketoisovalerate to valine, which may be catalyzed, for example, by branched chain aminotransferase (ilvE (BAT); which may be classified as EC 2.6.1.42).

In another embodiment, the pathway comprising a substrate to product conversion catalyzed by KARI is an isoleucine biosynthetic

- 30 pathway comprising the following substrate to product conversions:
- pyruvate and α -ketobutyrate to 2-aceto-2-hydroxybutanoate, which may be catalyzed for example, by acetolactate synthase;
- 2-aceto-2-hydroxybutanoate to 2,3-dihydroxy-3-methylpentanoate, which

may be catalyzed for example, by KARI;

-2,3-dihydroxy-3-methylpentanoate to 3-methyl-2-oxo-pentanoate, which may be catalyzed for example, by DHAD;

-3-methyl-2-oxo-pentanoate to isoleucine, which may be catalyzed, for example, by branched chain aminotransferase (ilvE (BAT); which may be classified as EC 2.6.1.42).

In another embodiment, the pathway comprising a substrate to product conversion catalyzed by KARI is a leucine biosynthetic pathway comprising the following substrate to product conversions:

-pyruvate to acetolactate, which may be catalyzed, for example, by acetolactate synthase;

– acetolactate to 2,3-dihydroxyisovalerate, which may be catalyzed, for example, by ketol-acid reductoisomerase (KARI);

– 2,3-dihydroxyisovalerate to α -ketoisovalerate, which may be catalyzed, for example, by dihydroxyacid dehydratase (DHAD);

- α -ketoisovalerate to 2-isopropylmalate, which may be catalyzed, for example, by 2-isopropylmalate synthase (leuA, which may be classified as EC 2.3.3.13);

-2-isopropylmalate to 2-isopropylmaleate, which may be catalyzed, for example, by 3-isopropylmalate dehydratase (leu1; which may be classified as EC 4.2.1.33);

-2-isopropylmaleate to 3-isopropylmalate, which may be catalyzed, for example, by 3-isopropylmalate dehydratase (leu1; which may be classified as EC 4.2.1.33);

-3-isopropylmalate to 2-isopropyl-3-oxosuccinate, which may be catalyzed, for example by 3-isopropylmalate dehydrogenase (leuB; which may be classified as EC 1.1.1.85);

-2-isopropyl-3-oxosuccinate to 4-methyl-2-oxopentanoate (spontaneous reaction); and

-4-methyl-2-oxopentanoate to leucine, which may be catalyzed, for example, by branched chain aminotransferase (ilvE (BAT); which may be classified as EC 2.6.1.42)

In another embodiment, the pathway comprising a substrate to

product conversion catalyzed by KARI is a 3,3-dimethylmalate biosynthetic pathway comprising the following substrate to product conversions:

-pyruvate to acetolactate, which may be catalyzed, for example, by acetolactate synthase;

5 -acetolactate to 2,3-dihydroxyisovalerate, which may be catalyzed, for example, by ketol-acid reductoisomerase (KARI);

-2,3-dihydroxyisovalerate to α -ketoisovalerate, which may be catalyzed, for example, by dihydroxyacid dehydratase (DHAD);

10 - α -ketoisovalerate to (R)-3,3 dimethylmalate, which may be catalyzed for example, by dimethylmalatedehydrogenase (DMMD; which may be classified as 1.1.1.84).

Genes and polypeptides that can be used for certain of the substrate to product conversions described above as well as those for additional isobutanol pathways, are available in the art. For example, 15 described in U.S. Patent Appl. Pub. No. 2007/0092957 and PCT Pub. No. WO 2011/019894, both incorporated by reference in their entireties herein. US Appl. Pub. Nos. 2011/019894, 2007/0092957, 2010/0081154, which are herein incorporated by reference in their entireties, describe dihydroxyacid dehydratases including those from *Lactococcus lactis* and 20 *Streptococcus mutans*. Ketoisovalerate decarboxylases include those derived from *Lactococcus lactis*, *Macrococcus caseolyticus* (SEQ ID NO: 171) and *Listeria grayi* (SEQ ID NO: 170). U.S. Patent Appl. Publ. No. 2009/0269823 and U.S. Appl. Publ. No. 2011/0269199, incorporated by reference in their entireties, describe alcohol dehydrogenases, including 25 those that utilize NADH as a cofactor. Alcohol dehydrogenases include SadB from *Achromobacter xylosoxidans*. Additional alcohol dehydrogenases include horse liver ADH and *Beijerinckia indica* ADH. Alcohol dehydrogenases include those that utilize NADH as a cofactor. In one embodiment an isobutanol biosynthetic pathway comprises a) a ketol- 30 acid reductoisomerase that has a K_M for NADH less than about 300 μ M, less than about 100 μ M, less than about 50 μ M, less than about 20 μ M or less than about 10 μ M; b) an alcohol dehydrogenase that utilizes NADH as a cofactor; or c) both a) and b).

WO 2011/019894 and U.S. Appl. Pub. Nos. 2011/019894, 2007/0092957, 2010/0081154, which are herein incorporated by reference in their entireties, describe suitable dihydroxyacid dehydratases. Methods of increasing DHAD activity are described, for example, in U.S. Appl. Pub. Nos. 2010/0081173 and 2012/0064561A1, which are herein incorporated
5 by reference in their entireties.

Additional genes that can be used can be identified by one skilled in the art through bioinformatics or using methods well-known in the art.

Additionally described in U.S. Appl. Pub. No. US 2007/0092957 A1, which is incorporated by reference herein in its entirety, are construction of
10 chimeric genes and genetic engineering of bacteria and yeast for isobutanol production using the disclosed isobutanol biosynthetic pathways. Such construction and engineering methods could be readily employed by those of ordinary skill in the art to construct other pathways disclosed herein and/or known in the art which include a substrate to
15 product conversion catalyzed by KARI activity.

Suitable ketol-acid reductoisomerase (KARI) enzymes are described elsewhere herein. In some embodiments, the KARI enzyme has a specific activity of at least about 0.1 micromoles/min/mg, at least
20 about 0.2 micromoles/min/mg, at least about 0.3 micromoles/min/mg, at least about 0.4 micromoles/min/mg, at least about 0.5 micromoles/min/mg, at least about 0.6 micromoles/min/mg, at least about 0.7 micromoles/min/mg, at least about 0.8 micromoles/min/mg, at least about 0.9 micromoles/min/mg, at least about 1.0 micromoles/min/mg, or at least
25 about 1.1 micromoles/min/mg. Suitable polypeptides to catalyze the substrate to product conversion acetolactate to 2,3-dihydroxyisovalerate include those that have a K_M for NADH less than about 300 μM , less than about 100 μM , less than about 50 μM , less than about 25 μM or less than about 10 μM .

30

Modifications

Functional deletion of the pyruvate decarboxylase gene has been used to increase the availability of pyruvate for utilization in biosynthetic product pathways. For example, U.S. Application Publication No. US

2007/0031950 A1, which is herein incorporated by reference in its entirety, discloses a yeast strain with a disruption of one or more pyruvate decarboxylase genes and expression of a D-lactate dehydrogenase gene, which is used for production of D-lactic acid. U.S. Appl. Pub. No. U.S. 5 2005/0059136 A1, which is herein incorporated by reference in its entirety, discloses glucose tolerant two carbon source independent (GCSI) yeast strains with no pyruvate decarboxylase activity, which can have an exogenous lactate dehydrogenase gene. Nevoigt and Stahl (Yeast 12:1331-1337 (1996)) describe the impact of reduced pyruvate 10 decarboxylase and increased NAD-dependent glycerol-3-phosphate dehydrogenase in *Saccharomyces cerevisiae* on glycerol yield. U.S. Appl. Pub. No. 2009/0305363, which is herein incorporated by reference in its entirety, discloses increased conversion of pyruvate to acetolactate by engineering yeast for expression of a cytosol-localized acetolactate 15 synthase and substantial elimination of pyruvate decarboxylase activity.

In embodiments of the invention, a recombinant host cell disclosed herein can comprise a modification in an endogenous polynucleotide encoding a polypeptide having pyruvate decarboxylase (PDC) activity or a modification in an endogenous polypeptide having PDC activity. In 20 embodiments, a recombinant host cell disclosed herein can have a modification or disruption of a polynucleotide, gene and/or polypeptide encoding PDC. In embodiments, a recombinant host cell comprises a deletion, mutation, and/or substitution in an endogenous polynucleotide or gene encoding a polypeptide having PDC activity, or in an endogenous 25 polypeptides having PDC activity. Such modifications, disruptions, deletions, mutations, and/or substitutions can result in PDC activity that is reduced or eliminated, resulting, for example, in a PDC knock-out (PDC-KO) phenotype.

In embodiments of the invention, an endogenous pyruvate 30 decarboxylase activity of a recombinant host cell disclosed herein converts pyruvate to acetaldehyde, which can then be converted to ethanol or to acetyl-CoA via acetate. In other embodiments, a recombinant host cell is *Kluyveromyces lactis* containing one gene encoding pyruvate decarboxylase, *Candida glabrata* containing one gene encoding pyruvate

decarboxylase, or *Schizosaccharomyces pombe* containing one gene encoding pyruvate decarboxylase.

In other embodiments, a recombinant host cell is *Saccharomyces cerevisiae* containing three isozymes of pyruvate decarboxylase encoded by the PDC1, PDC5, and PDC6 genes, as well as a pyruvate decarboxylase regulatory gene, PDC2. In a non-limiting example in *S. cerevisiae*, the PDC1 and PDC5 genes, or the PDC1, PDC5, and PDC6 genes, are disrupted. In another non-limiting example in *S. cerevisiae*, pyruvate decarboxylase activity can be reduced by disrupting the PDC2 regulatory gene. In another non-limiting example in *S. cerevisiae*, polynucleotides or genes encoding pyruvate decarboxylase proteins such as those having about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, about 96%, about 97%, about 98%, or about 99% sequence identity to PDC1, PDC2, PDC5 and/or PDC6 can be disrupted.

In embodiments, a polypeptide having PDC activity or a polynucleotide or gene encoding a polypeptide having PDC activity corresponds to Enzyme Commission Number EC 4.1.1.1. In other embodiments, a PDC gene of a recombinant host cell disclosed herein is not active under the fermentation conditions used, and therefore such a gene would not need to be modified or inactivated.

Examples of recombinant host cells with reduced pyruvate decarboxylase activity due to disruption of pyruvate decarboxylase encoding genes have been reported, such as for *Saccharomyces* in Flikweert et al. (Yeast (1996) 12:247-257), for *Kluyveromyces* in Bianchi et al. (Mol. Microbiol. (1996) 19(1):27-36), and disruption of the regulatory gene in Hohmann (Mol. Gen. Genet. (1993) 241:657-666). *Saccharomyces* strains having no pyruvate decarboxylase activity are available from the ATCC with Accession #200027 and #200028.

Examples of PDC polynucleotides, genes and/or polypeptides that can be targeted for modification or inactivation in the recombinant host cells disclosed herein include, but are not limited to, those of the following Table 6.

Table 6. Pyruvate decarboxylase target gene coding regions and proteins.

Description	SEQ ID NO: Nucleic acid	SEQ ID NO: Amino acid
<i>PDC1</i> pyruvate decarboxylase from <i>Saccharomyces cerevisiae</i>	234	235
<i>PDC5</i> pyruvate decarboxylase from <i>Saccharomyces cerevisiae</i>	236	237
<i>PDC6</i> pyruvate decarboxylase from <i>Saccharomyces cerevisiae</i>	238	239
pyruvate decarboxylase from <i>Candida glabrata</i>	240	241
<i>PDC1</i> pyruvate decarboxylase from <i>Pichia stipitis</i>	242	243
<i>PDC2</i> pyruvate decarboxylase from <i>Pichia stipitis</i>	244	245
pyruvate decarboxylase from <i>Kluyveromyces lactis</i>	246	247
pyruvate decarboxylase from <i>Yarrowia lipolytica</i>	248	249
pyruvate decarboxylase from <i>Schizosaccharomyces pombe</i>	250	251
pyruvate decarboxylase from <i>Zygosaccharomyces rouxii</i>	252	253

Other examples of PDC polynucleotides, genes and polypeptides that can be targeted for modification or inactivation in a recombinant host cell disclosed herein include, but are not limited to, PDC polynucleotides, genes and/or polypeptides having at least about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, about 96%, about 97%, about 98%, or about 99% sequence identity to any one of the sequences of Table 6, wherein such a polynucleotide or gene encodes, or such a polypeptide has, PDC activity. Still other examples of PDC polynucleotides, genes and polypeptides that can be targeted for modification or inactivation in a recombinant host cell disclosed herein include, but are not limited to an active variant, fragment or derivative of any one of the sequences of Table 6, wherein such a polynucleotide or gene encodes, or such a polypeptide has, PDC activity.

In embodiments, a polynucleotide, gene and/or polypeptide encoding a PDC sequence disclosed herein or known in the art can be modified, as disclosed above for aldehyde dehydrogenase. In other

embodiments, a polynucleotide, gene and/or polypeptide encoding PDC can be used to identify another PDC polynucleotide, gene and/or polypeptide sequence or to identify a PDC homolog in other cells, as disclosed above for acetolactate dehydrogenase. Such a PDC encoding
5 sequence can be identified, for example, in the literature and/or in bioinformatics databases well known to the skilled person. For example, the identification of a PDC encoding sequence in other cell types using bioinformatics can be accomplished through BLAST (as described above) searching of publicly available databases with a known PDC encoding
10 DNA and polypeptide sequence, such as those provided herein. Identities are based on the Clustal W method of alignment using the default parameters of GAP PENALTY=10, GAP LENGTH PENALTY=0.1, and Gonnet 250 series of protein weight matrix.

The modification of PDC in a recombinant host cell disclosed herein
15 to reduce or eliminate PDC activity can be confirmed using methods known in the art. For example, disruption of a particular pyruvate decarboxylase could be confirmed with PCR screening using primers external to the gene sequence, or by Southern blot using a probe designed to the pyruvate decarboxylase gene sequence. Alternatively,
20 one could utilize analytical methods such as gas chromatography or HPLC to screen strains for decreased or eliminated production of acetaldehyde and/or ethanol.

Functional deletion of the hexokinase 2 gene has been used to reduce glucose repression and to increase the availability of pyruvate for
25 utilization in biosynthetic pathways. For example, International Publication No. WO 2000/061722 A1, which is incorporated herein by reference in its entirety discloses the production of yeast biomass by aerobically growing yeast having one or more functionally deleted hexokinase 2 genes or analogs. In addition, Rossell et al. (Yeast Research 8:155-164 (2008))
30 found that *Saccharomyces cerevisiae* with a deletion of the hexokinase 2 gene showed 75% reduction in fermentative capacity, defined as the specific rate of carbon dioxide production under sugar-excess and anaerobic conditions. After starvation, the fermentation capacity was similar to that of a strain without the hexokinase 2 gene deletion. Diderich

et al. (Applied and Environmental Microbiology 67:1587-1593 (2001)) found that *S. cerevisiae* with a deletion of the hexokinase 2 gene had lower pyruvate decarboxylase activity.

In embodiments, a recombinant host cell disclosed herein can
5 comprise a modification in an endogenous polynucleotide encoding a polypeptide having hexokinase 2 activity and/or a modification in a polypeptide having hexokinase 2 activity. In embodiments, a recombinant host cell disclosed herein can have a modification or disruption of a polynucleotide, gene or polypeptide encoding hexokinase 2. In
10 embodiments, a recombinant host cell comprises a deletion, mutation, and/or substitution in an endogenous polynucleotide or gene encoding a polypeptide having hexokinase 2 activity, or an endogenous polypeptide having hexokinase 2 activity. Such modifications, disruptions, deletions, mutations, and/or substitutions can result in hexokinase 2 activity that is
15 reduced or eliminated, resulting, for example, in a hexokinase 2 knockout (HXK2-KO) phenotype. In embodiments, the host cell comprises a modification as described in U.S. Appn. Pub. Nos. 2011/0124060 A1 or 2012/0015416 A1, which are incorporated herein by reference in their entireties.

20 In embodiments, a polypeptide having hexokinase 2 activity can catalyze the conversion of hexose to hexose-6-phosphate, and/or can catalyze the conversion of D-glucose to D-glucose 6-phosphate, D-fructose to D-fructose 6-phosphate, and/or D-mannose to D-mannose 6-phosphate. In other embodiments, a polynucleotide, gene or polypeptide
25 having hexokinase 2 activity can correspond to Enzyme Commission Number EC 2.7.1.1.

In embodiments of the invention, a recombinant host cell can be *S. cerevisiae* and a polynucleotide, gene or polypeptide having hexokinase 2 activity can be HXK2. In other embodiments, a recombinant host cell can
30 be *K. lactis* and a polynucleotide, gene or polypeptide having hexokinase 2 activity can be RAG5. In other embodiments, a recombinant host cell can be *H. polymorpha* and a polynucleotide, gene or polypeptide having hexokinase 2 activity can be HPGLK1. In other embodiments, a recombinant host cell can be *S. pombe* and a polynucleotide, gene or

polypeptide having hexokinase 2 activity can be HXK2.

Examples of hexokinase 2 polynucleotides, genes and polypeptides that can be targeted for modification or inactivation in a recombinant host cell disclosed herein include, but are not limited to, those of the following

5 Table 7.

Table 7. Hexokinase 2 target gene coding regions and proteins.

<i>HXK2</i> from <i>S. cerevisiae</i>	Nucleic acid (SEQ ID NO: 254)
	Amino acid (SEQ ID NO: 255)
<i>RAG5</i> from <i>K. lactis</i>	Nucleic acid (SEQ ID NO: 256)
	Amino acid (SEQ ID NO: 257)
<i>HPGLK1</i> from <i>H. polymorpha</i>	Nucleic acid (SEQ ID NO: 258)
	Amino acid (SEQ ID NO: 259)
<i>HXK2</i> from <i>S. pombe</i>	Nucleic acid (SEQ ID NO: 260)
	Amino acid (SEQ ID NO: 261)

Other examples of hexokinase 2 polynucleotides, genes and polypeptides that can be targeted for modification or inactivation in a recombinant host cell disclosed herein include, but are not limited to, hexokinase 2 polynucleotides, genes and/or polypeptides having at least about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, about 96%, about 97%, about 98%, or about 99% sequence identity to any one of the sequences of Table 9, wherein such a polynucleotide or gene encodes, or such a polypeptide has, hexokinase 2 activity. Still other examples of hexokinase 2 polynucleotides, genes and polypeptides that can be targeted for modification or inactivation in a recombinant host cell disclosed herein include, but are not limited to an active variant, fragment or derivative of any one of the sequences of Table 7, wherein such a polynucleotide or gene encodes, or such a polypeptide has, hexokinase 2 activity.

In embodiments, a polynucleotide, gene and/or polypeptide encoding a hexokinase 2 sequence disclosed herein or known in the art can be modified or disrupted, as disclosed above for aldehyde dehydrogenase. In other embodiments, a polynucleotide, gene and/or

polypeptide encoding hexokinase 2 can be used to identify another hexokinase 2 polynucleotide, gene and/or polypeptide sequence or to identify a hexokinase 2 homolog in other cells, as disclosed above for aldehyde dehydrogenase. Such a hexokinase 2 encoding sequence can
5 be identified, for example, in the literature and/or in bioinformatics databases well known to the skilled person. For example, the identification of a hexokinase 2 encoding sequence in other cell types using bioinformatics can be accomplished through BLAST (as described above) searching of publicly available databases with a known hexokinase
10 2 encoding DNA and polypeptide sequence, such as those provided herein. Identities are based on the Clustal W method of alignment using the default parameters of GAP PENALTY=10, GAP LENGTH PENALTY=0.1, and Gonnet 250 series of protein weight matrix.

The modification of hexokinase 2 in a recombinant host cell
15 disclosed herein to reduce or eliminate hexokinase 2 activity can be confirmed using methods known in the art. For example, disruption of hexokinase 2 could be confirmed with PCR screening using primers external to the hexokinase 2 gene, or by Southern blot using a probe designed to the hexokinase 2 gene sequence. Alternatively, one could
20 examine putative hexokinase 2 knockout strains for increased biomass yield on glucose-containing media.

Examples of additional modifications that can be useful in cells provided herein include modifications to reduce glycerol-3-phosphate dehydrogenase activity and/or disruption in at least one gene encoding a
25 polypeptide having pyruvate decarboxylase activity or a disruption in at least one gene encoding a regulatory element controlling pyruvate decarboxylase gene expression as described in U.S. Patent Appl. Pub. No. 2009/0305363 (incorporated herein by reference in its entirety), modifications to a host cell that provide for increased carbon flux through
30 an Entner-Doudoroff Pathway or reducing equivalents balance as described in U.S. Patent Appl. Pub. No. 2010/0120105 (incorporated herein by reference in its entirety). Other modifications include integration of at least one polynucleotide encoding a polypeptide that catalyzes a step in a pyruvate-utilizing biosynthetic pathway described in PCT Appn. Pub.

No. WO 2012/033832, which is herein incorporated by reference in its entirety. A genetic modification which has the effect of reducing glucose repression wherein the yeast production host cell is *pdc-* is described in U.S. Appl. Publ. No. US 2011/0124060, which is herein incorporated by
5 reference in its entirety.

U.S. Appl. Publ. No. 20120064561A1, which is herein incorporated by reference in its entirety, discloses recombinant host cells comprising (a) at least one heterologous polynucleotide encoding a polypeptide having dihydroxy-acid dehydratase activity; and (b)(i) at least one deletion,
10 mutation, and/or substitution in an endogenous gene encoding a polypeptide affecting Fe-S cluster biosynthesis; and/or (ii) at least one heterologous polynucleotide encoding a polypeptide affecting Fe-S cluster biosynthesis. In embodiments, the polypeptide affecting Fe-S cluster biosynthesis is encoded by AFT1, AFT2, FRA2, GRX3, or CCC1. In
15 embodiments, the polypeptide affecting Fe-S cluster biosynthesis is constitutive mutant AFT1 L99A, AFT1 L102A, AFT1 C291F, or AFT1 C293F.

Additionally, host cells can comprise heterologous polynucleotides encoding a polypeptides with phosphoketolase activity and/or a
20 heterologous polynucleotide encoding a polypeptide with phosphotransacetylase activity such as, for example, those encoded by SEQ ID NOs: 262 and 263, and as described in PCT Appn. Pub. No. WO 2011/159853 and U.S. Appl. Publ. No. 20120156735A1, which are herein incorporated by reference in their entireties.

25

Microbial Hosts for Isobutanol Production

Microbial hosts for isobutanol production can be selected from bacteria, cyanobacteria, filamentous fungi and yeasts. The microbial host used for butanol production should be tolerant to isobutanol so that the
30 yield is not limited by butanol toxicity. Although butanol-tolerant mutants have been isolated from solventogenic *Clostridia*, little information is available concerning the butanol tolerance of other potentially useful bacterial strains. Most of the studies on the comparison of alcohol tolerance in bacteria suggest that butanol is more toxic than ethanol (de

Cavalho, et al., Microsc. Res. Tech., 64: 215-22, 2004) and (Kabelitz, et al., FEMS Microbiol. Lett., 220: 223-227, 2003, Tomas, et al., J. Bacteriol., 186: 2006-2018, 2004) report that the yield of 1-butanol during fermentation in *Clostridium acetobutylicum* can be limited by 1-butanol toxicity. The primary effect of 1-butanol on *Clostridium acetobutylicum* is
5 disruption of membrane functions (Hermann et al., Appl. Environ. Microbiol., 50: 1238-1243, 1985).

The microbial hosts selected for the production of isobutanol should be tolerant to isobutanol and should be able to convert carbohydrates to isobutanol. The criteria for selection of suitable microbial hosts include
10 the following: intrinsic tolerance to isobutanol, high rate of glucose utilization, availability of genetic tools for gene manipulation, and the ability to generate stable chromosomal alterations.

Suitable host strains with a tolerance for isobutanol can be identified by screening based on the intrinsic tolerance of the strain. The
15 intrinsic tolerance of microbes to isobutanol can be measured by determining the concentration of isobutanol that is responsible for 50% inhibition of the growth rate (IC₅₀) when grown in a minimal medium. The IC₅₀ values can be determined using methods known in the art. For
20 example, the microbes of interest can be grown in the presence of various amounts of isobutanol and the growth rate monitored by measuring the optical density at 600 nanometers. The doubling time can be calculated from the logarithmic part of the growth curve and used as a measure of the growth rate. The concentration of isobutanol that produces 50%
25 inhibition of growth can be determined from a graph of the percent inhibition of growth versus the isobutanol concentration. In one embodiment, the host strain has an IC₅₀ for isobutanol of greater than about 0.5%.

The microbial host for isobutanol production should also utilize
30 glucose at a high rate. Most microbes are capable of metabolizing carbohydrates. However, certain environmental microbes cannot metabolize carbohydrates to high efficiency, and therefore would not be suitable hosts.

The ability to genetically modify the host is essential for the production of any recombinant microorganism. The mode of gene transfer technology can be by electroporation, conjugation, transduction or natural transformation. A broad range of host conjugative plasmids and drug resistance markers are available. The cloning vectors are tailored to the host microorganisms based on the nature of antibiotic resistance markers that can function in that host.

The microbial host also has to be manipulated in order to inactivate competing pathways for carbon flow by deleting various genes. This requires the availability of either transposons to direct inactivation or chromosomal integration vectors. Additionally, the production host should be amenable to chemical mutagenesis so that mutations to improve intrinsic isobutanol tolerance can be obtained.

Based on the criteria described above, suitable microbial hosts for the production of isobutanol include, but are not limited to, members of the genera *Clostridium*, *Zymomonas*, *Escherichia*, *Salmonella*, *Rhodococcus*, *Pseudomonas*, *Bacillus*, *Vibrio*, *Lactobacillus*, *Enterococcus*, *Alcaligenes*, *Klebsiella*, *Paenibacillus*, *Arthrobacter*, *Corynebacterium*, *Brevibacterium*, *Pichia*, *Candida*, *Issatchenkia*, *Hansenula*, *Kluyveromyces*, and *Saccharomyces*. Suitable hosts include: *Escherichia coli*, *Alcaligenes eutrophus*, *Bacillus licheniformis*, *Paenibacillus macerans*, *Rhodococcus erythropolis*, *Pseudomonas putida*, *Lactobacillus plantarum*, *Enterococcus faecium*, *Enterococcus gallinarum*, *Enterococcus faecalis*, *Bacillus subtilis* and *Saccharomyces cerevisiae*. In some embodiments, the host cell is *Saccharomyces cerevisiae*. *S. cerevisiae* yeast are known in the art and are available from a variety of sources, including, but not limited to, American Type Culture Collection (Rockville, MD), Centraalbureau voor Schimmelcultures (CBS) Fungal Biodiversity Centre, LeSaffre, Gert Strand AB, Ferm Solutions, North American Bioproducts, Martrex, and Lallemand. *S. cerevisiae* include, but are not limited to, BY4741, CEN.PK 113-7D, Ethanol Red® yeast, Ferm Pro™ yeast, Bio-Ferm® XR yeast, Gert Strand Prestige Batch Turbo alcohol yeast, Gert Strand Pot Distillers yeast, Gert Strand Distillers Turbo

yeast, FerMax™ Green yeast, FerMax™ Gold yeast, Thermosacc® yeast, BG-1, PE-2, CAT-1, CBS7959, CBS7960, and CBS7961.

Construction of Production Host

5 Recombinant microorganisms containing the necessary genes that will encode the enzymatic pathway for the conversion of a fermentable carbon substrate to butanol can be constructed using techniques well known in the art. In the present invention, genes encoding the enzymes of one of the isobutanol biosynthetic pathways of the invention, for example, 10 acetolactate synthase, acetohydroxy acid isomeroreductase, acetohydroxy acid dehydratase, branched-chain α -keto acid decarboxylase, and branched-chain alcohol dehydrogenase, can be isolated from various sources, as described above.

 Methods of obtaining desired genes from a genome are common and well known in the art of molecular biology. For example, if the 15 sequence of the gene is known, suitable genomic libraries can be created by restriction endonuclease digestion and can be screened with probes complementary to the desired gene sequence. Once the sequence is isolated, the DNA can be amplified using standard primer-directed 20 amplification methods such as polymerase chain reaction (U.S. 4,683,202) to obtain amounts of DNA suitable for transformation using appropriate vectors. Tools for codon optimization for expression in a heterologous host are readily available. Some tools for codon optimization are available based on the GC content of the host microorganism.

25 Once the relevant pathway genes are identified and isolated they can be transformed into suitable expression hosts by means well known in the art. Vectors or cassettes useful for the transformation of a variety of host cells are common and commercially available from companies such as EPICENTRE® (Madison, WI), Invitrogen Corp. (Carlsbad, CA), 30 Stratagene (La Jolla, CA), and New England Biolabs, Inc. (Beverly, MA). Typically the vector or cassette contains sequences directing transcription and translation of the relevant gene, a selectable marker, and sequences allowing autonomous replication or chromosomal integration. Suitable vectors comprise a region 5' of the gene which harbors transcriptional

initiation controls and a region 3' of the DNA fragment which controls transcriptional termination. Both control regions can be derived from genes homologous to the transformed host cell, although it is to be understood that such control regions can also be derived from genes that
 5 are not native to the specific species chosen as a production host.

Initiation control regions or promoters, which are useful to drive expression of the relevant pathway coding regions in the desired host cell are numerous and familiar to those skilled in the art. Virtually any promoter capable of driving these genetic elements, including those used
 10 in the Examples, is suitable for the present invention including, but not limited to, *CYC1*, *HIS3*, *GAL1*, *GAL10*, *ADH1*, *PGK*, *PHO5*, *GAPDH*, *ADC1*, *TRP1*, *URA3*, *LEU2*, *ENO*, *TPI* (useful for expression in *Saccharomyces*); *AOX1* (useful for expression in *Pichia*); and *lac*, *ara*, *tet*, *trp*, *IP_L*, *IP_R*, *T7*, *tac*, and *trc* (useful for expression in *Escherichia coli*,
 15 *Alcaligenes*, and *Pseudomonas*) as well as the *amy*, *apr*, *npr* promoters and various phage promoters useful for expression in *Bacillus subtilis*, *Bacillus licheniformis*, and *Paenibacillus macerans*. For yeast recombinant host cells, a number of promoters can be used in constructing expression cassettes for genes, including, but not limited to,
 20 the following constitutive promoters suitable for use in yeast: *FBA1*, *TDH3* (*GPD*), *ADH1*, *ILV5*, and *GPM1*; and the following inducible promoters suitable for use in yeast: *GAL1*, *GAL10*, *OLE1*, and *CUP1*. Other yeast promoters include hybrid promoters *UAS(PGK1)-FBA1p* (SEQ ID NO: 264), *UAS(PGK1)-ENO2p* (SEQ ID NO: 265), *UAS(FBA1)-PDC1p* (SEQ
 25 ID NO: 266), *UAS(PGK1)-PDC1p* (SEQ ID NO: 267), and *UAS(PGK)-OLE1p* (SEQ ID NO: 268).

Promoters, transcriptional terminators, and coding regions can be cloned into a yeast 2 micron plasmid and transformed into yeast cells (Ludwig, et al. *Gene*, 132: 33-40, 1993; US Appl. Pub. No.
 30 20080261861A1).

Adjusting the amount of gene expression in a given host may be achieved by varying the level of transcription, such as through selection of native or artificial promoters. In addition, techniques such as the use of

promoter libraries to achieve desired levels of gene transcription are well known in the art. Such libraries can be generated using techniques known in the art, for example, by cloning of random cDNA fragments in front of gene cassettes (Goh *et al.* (2002) *AEM* 99, 17025), by modulating
5 regulatory sequences present within promoters (Ligr *et al.* (2006) *Genetics* 172, 2113), or by mutagenesis of known promoter sequences (Alper *et al.* (2005) *PNAS*, 12678; Nevoigt *et al.* (2006) *AEM* 72, 5266).

Termination control regions can also be derived from various genes native to the hosts. Optionally, a termination site can be unnecessary or
10 can be included.

Certain vectors are capable of replicating in a broad range of host bacteria and can be transferred by conjugation. The complete and annotated sequence of pRK404 and three related vectors-pRK437, pRK442, and pRK442(H) are available. These derivatives have proven to
15 be valuable tools for genetic manipulation in Gram-negative bacteria (Scott *et al.*, *Plasmid*, 50: 74-79, 2003). Several plasmid derivatives of broad-host-range Inc P4 plasmid RSF1010 are also available with promoters that can function in a range of Gram-negative bacteria. Plasmid pAYC36 and pAYC37, have active promoters along with multiple
20 cloning sites to allow for the heterologous gene expression in Gram-negative bacteria.

Chromosomal gene replacement tools are also widely available. For example, a thermosensitive variant of the broad-host-range replicon pWV101 has been modified to construct a plasmid pVE6002 which can be
25 used to effect gene replacement in a range of Gram-positive bacteria (Maguin *et al.*, *J. Bacteriol.*, 174: 5633-5638, 1992). Additionally, *in vitro* transposomes are available to create random mutations in a variety of genomes from commercial sources such as EPICENTRE®.

The expression of a butanol biosynthetic pathway in various
30 microbial hosts is described in more detail below.

Expression of a butanol biosynthetic pathway in *E. coli*

Vectors or cassettes useful for the transformation of *E. coli* are common and commercially available from the companies listed above. For example, the genes of an isobutanol biosynthetic pathway can be

isolated from various sources, cloned into a modified pUC19 vector and transformed into *E. coli* NM522.

Expression of a butanol biosynthetic pathway in *Rhodococcus erythropolis*

A series of *E. coli*-*Rhodococcus* shuttle vectors are available for
 5 expression in *R. erythropolis*, including, but not limited to, pRhBR17 and
 pDA71 (Kostichka et al., Appl. Microbiol. Biotechnol., 62: 61-68, 2003).
 Additionally, a series of promoters are available for heterologous gene
 expression in *R. erythropolis* (Nakashima et al., Appl. Environ. Microbiol.,
 70: 5557-5568, 2004 and Tao et al., Appl. Microbiol. Biotechnol., 68: 346-
 10 354, 2005). Targeted gene disruption of chromosomal genes in *R.*
erythropolis can be created using the method described by Tao et al.,
supra, and Brans et al. (Appl. Environ. Microbiol., 66: 2029-2036, 2000).

The heterologous genes required for the production of isobutanol,
 as described above, can be cloned initially in pDA71 or pRhBR71 and
 15 transformed into *E. coli*. The vectors can then be transformed into *R.*
erythropolis by electroporation, as described by Kostichka et al., *supra*.
 The recombinants can be grown in synthetic medium containing glucose
 and the production of isobutanol can be followed using methods known in
 the art.

Expression of a butanol biosynthetic pathway in *B. subtilis*

Methods for gene expression and creation of mutations in *B. subtilis*
 are also well known in the art. For example, the genes of an isobutanol
 biosynthetic pathway can be isolated from various sources, cloned into a
 modified pUC19 vector and transformed into *Bacillus subtilis* BE1010.
 25 Additionally, the five genes of an isobutanol biosynthetic pathway can be
 split into two operons for expression. The three genes of the pathway
 (*bubB*, *ilvD*, and *kivD*) can be integrated into the chromosome of *Bacillus*
subtilis BE1010 (Payne, et al., J. Bacteriol., 173, 2278-2282, 1991). The
 remaining two genes (*ilvC* and *bdhB*) can be cloned into an expression
 30 vector and transformed into the *Bacillus* strain carrying the integrated
 isobutanol genes

Expression of a butanol biosynthetic pathway in *B. licheniformis*

Most of the plasmids and shuttle vectors that replicate in *B. subtilis*
 can be used to transform *B. licheniformis* by either protoplast

transformation or electroporation. The genes required for the production of isobutanol can be cloned in plasmids pBE20 or pBE60 derivatives (Nagarajan et al., Gene, 114: 121-126, 1992). Methods to transform *B. licheniformis* are known in the art (Fleming et al. Appl. Environ. Microbiol., 5 61: 3775-3780, 1995). The plasmids constructed for expression in *B. subtilis* can be transformed into *B. licheniformis* to produce a recombinant microbial host that produces isobutanol.

Expression of a butanol biosynthetic pathway in *Paenibacillus macerans*

Plasmids can be constructed as described above for expression in 10 *B. subtilis* and used to transform *Paenibacillus macerans* by protoplast transformation to produce a recombinant microbial host that produces isobutanol.

Expression of the butanol biosynthetic pathway in *Alcaligenes (Ralstonia) eutrophus*

15 Methods for gene expression and creation of mutations in *Alcaligenes eutrophus* are known in the art (Taghavi et al., Appl. Environ. Microbiol., 60: 3585-3591, 1994). The genes for an isobutanol biosynthetic pathway can be cloned in any of the broad host range vectors described above, and electroporated to generate recombinants that 20 produce isobutanol. The poly(hydroxybutyrate) pathway in *Alcaligenes* has been described in detail, a variety of genetic techniques to modify the *Alcaligenes eutrophus* genome is known, and those tools can be applied for engineering an isobutanol biosynthetic pathway.

25 Expression of a butanol biosynthetic pathway in *Pseudomonas putida*

Methods for gene expression in *Pseudomonas putida* are known in the art (see for example Ben-Bassat et al., U.S. Patent No. 6,586,229, which is incorporated herein by reference). The butanol pathway genes can be inserted into pPCU18 and this ligated DNA can be electroporated 30 into electrocompetent *Pseudomonas putida* DOT-T1 C5aAR1 cells to generate recombinants that produce isobutanol.

Expression of a butanol biosynthetic pathway in *Saccharomyces cerevisiae*

Methods for gene expression in *Saccharomyces cerevisiae* are known in the art (e.g., Methods in Enzymology, Volume 194, Guide to Yeast Genetics and Molecular and Cell Biology, Part A, 2004, Christine Guthrie and Gerald R. Fink, eds., Elsevier Academic Press, San Diego, CA). Expression of genes in yeast typically requires a promoter, followed by the gene of interest, and a transcriptional terminator. A number of yeast promoters, including those used in the Examples herein, can be used in constructing expression cassettes for genes encoding an isobutanol biosynthetic pathway, including, but not limited to constitutive promoters FBA, GPD, ADH1, and GPM, and the inducible promoters GAL1, GAL10, and CUP1. Suitable transcriptional terminators include, but are not limited to FBA_t, GPD_t, GPM_t, ERG10_t, GAL1_t, CYC1, and ADH1. For example, suitable promoters, transcriptional terminators, and the genes of an isobutanol biosynthetic pathway can be cloned into *E. coli*-yeast shuttle vectors and transformed into yeast cells as described in U.S. App. Pub. No. 20100129886. These vectors allow strain propagation in both *E. coli* and yeast strains. Typically the vector contains a selectable marker and sequences allowing autonomous replication or chromosomal integration in the desired host. Typically used plasmids in yeast are shuttle vectors pRS423, pRS424, pRS425, and pRS426 (American Type Culture Collection, Rockville, MD), which contain an *E. coli* replication origin (e.g., pMB1), a yeast 2 μ origin of replication, and a marker for nutritional selection. The selection markers for these four vectors are His3 (vector pRS423), Trp1 (vector pRS424), Leu2 (vector pRS425) and Ura3 (vector pRS426). Construction of expression vectors with genes encoding polypeptides of interest can be performed by either standard molecular cloning techniques in *E. coli* or by the gap repair recombination method in yeast.

The gap repair cloning approach takes advantage of the highly efficient homologous recombination in yeast. Typically, a yeast vector DNA is digested (e.g., in its multiple cloning site) to create a "gap" in its sequence. A number of insert DNAs of interest are generated that contain a ≥ 21 bp sequence at both the 5' and the 3' ends that sequentially overlap

with each other, and with the 5' and 3' terminus of the vector DNA. For example, to construct a yeast expression vector for "Gene X", a yeast promoter and a yeast terminator are selected for the expression cassette. The promoter and terminator are amplified from the yeast genomic DNA, and Gene X is either PCR amplified from its source organism or obtained from a cloning vector comprising Gene X sequence. There is at least a 21 bp overlapping sequence between the 5' end of the linearized vector and the promoter sequence, between the promoter and Gene X, between Gene X and the terminator sequence, and between the terminator and the 3' end of the linearized vector. The "gapped" vector and the insert DNAs are then co-transformed into a yeast strain and plated on the medium containing the appropriate compound mixtures that allow complementation of the nutritional selection markers on the plasmids. The presence of correct insert combinations can be confirmed by PCR mapping using plasmid DNA prepared from the selected cells. The plasmid DNA isolated from yeast (usually low in concentration) can then be transformed into an *E. coli* strain, e.g. *TOP10*, followed by mini preps and restriction mapping to further verify the plasmid construct. Finally the construct can be verified by sequence analysis.

Like the gap repair technique, integration into the yeast genome also takes advantage of the homologous recombination system in yeast. Typically, a cassette containing a coding region plus control elements (promoter and terminator) and auxotrophic marker is PCR-amplified with a high-fidelity DNA polymerase using primers that hybridize to the cassette and contain 40-70 base pairs of sequence homology to the regions 5' and 3' of the genomic area where insertion is desired. The PCR product is then transformed into yeast and plated on medium containing the appropriate compound mixtures that allow selection for the integrated auxotrophic marker. For example, to integrate "Gene X" into chromosomal location "Y", the promoter-coding regionX-terminator construct is PCR amplified from a plasmid DNA construct and joined to an autotrophic marker (such as *URA3*) by either SOE PCR or by common restriction digests and cloning. The full cassette, containing the promoter-coding regionX-terminator-*URA3* region, is PCR amplified with primer

sequences that contain 40-70 bp of homology to the regions 5' and 3' of location "Y" on the yeast chromosome. The PCR product is transformed into yeast and selected on growth media lacking uracil. Transformants can be verified either by colony PCR or by direct sequencing of chromosomal DNA.

Expression of a butanol biosynthetic pathway in *Lactobacillus plantarum*

The *Lactobacillus* genus belongs to the *Lactobacillales* family and many plasmids and vectors used in the transformation of *Bacillus subtilis* and *Streptococcus* can be used for *Lactobacillus*. Non-limiting examples of suitable vectors include pAM β 1 and derivatives thereof (Renault et al., Gene 183:175-182, 1996); and (O'Sullivan et al., Gene, 137: 227-231, 1993); pMBB1 and pHW800, a derivative of pMBB1 (Wyckoff et al., Appl. Environ. Microbiol., 62: 1481-1486, 1996); pMG1, a conjugative plasmid (Tanimoto et al., J. Bacteriol., 184: 5800-5804, 2002); pNZ9520 (Kleerebezem et al., Appl. Environ. Microbiol., 63: 4581-4584, 1997); pAM401 (Fujimoto et al., Appl. Environ. Microbiol., 67: 1262-1267, 2001); and pAT392 (Arthur et al., Antimicrob. Agents Chemother., 38: 1899-1903, 1994). Several plasmids from *Lactobacillus plantarum* have also been reported (van Kranenburg R, et al. Appl. Environ. Microbiol., 71: 1223-1230, 2005).

Expression of a butanol biosynthetic pathway in various *Enterococcus* species (*E. faecium*, *E. gallinarum*, and *E. faecalis*)

The *Enterococcus* genus belongs to the *Lactobacillales* family and many plasmids and vectors used in the transformation of *Lactobacilli*, *Bacilli* and *Streptococci* species can be used for *Enterococcus* species. Non-limiting examples of suitable vectors include pAM β 1 and derivatives thereof (Renault et al., Gene, 183: 175-182, 1996); and (O'Sullivan et al., Gene, 137: 227-231, 1993); pMBB1 and pHW800, a derivative of pMBB1 (Wyckoff et al. Appl. Environ. Microbiol., 62: 1481-1486, 1996); pMG1, a conjugative plasmid (Tanimoto et al., J. Bacteriol., 184: 5800-5804, 2002); pNZ9520 (Kleerebezem et al., Appl. Environ. Microbiol., 63: 4581-4584,

1997); pAM401 (Fujimoto et al., Appl. Environ. Microbiol., 67: 1262-1267, 2001); and pAT392 (Arthur et al., Antimicrob. Agents Chemother., 38: 1899-1903, 1994). Expression vectors for *E. faecalis* using the *nisA* gene from *Lactococcus* can also be used (Eichenbaum et al., Appl. Environ. Microbiol., 64: 2763-2769, 1998). Additionally, vectors for gene replacement in the *E. faecium* chromosome can be used (Nallaapareddy et al., Appl. Environ. Microbiol., 72: 334-345, 2006).

Fermentation Media

10 Fermentation media in the present invention must contain suitable carbon substrates. Suitable substrates can include but are not limited to monosaccharides such as glucose and fructose, oligosaccharides such as lactose, maltose, galactose, sucrose, polysaccharides such as starch or cellulose or mixtures thereof and unpurified mixtures from renewable
15 feedstocks such as cheese whey permeate, cornsteep liquor, sugar beet molasses, and barley malt. Additionally the carbon substrate can also be one-carbon substrates such as carbon dioxide, or methanol for which metabolic conversion into key biochemical intermediates has been demonstrated. In addition to one and two carbon substrates
20 methylotrophic microorganisms are also known to utilize a number of other carbon containing compounds such as methylamine, glucosamine and a variety of amino acids for metabolic activity. For example, methylotrophic yeast are known to utilize the carbon from methylamine to form trehalose or glycerol (Bellion et al., Microb. Growth C1 Compd., [Int. Symp.], 7th
25 (1993), 415-32. (eds): Murrell, J. Collin; Kelly, Don P. Publisher: Intercept, Andover, UK). Similarly, various species of *Candida* will metabolize alanine or oleic acid (Sulter et al., Arch. Microbiol., 153: 485-489, 1990). Hence it is contemplated that the source of carbon utilized in the present invention can encompass a wide variety of carbon
30 containing substrates and will only be limited by the choice of microorganism.

Although it is contemplated that all of the above mentioned carbon substrates and mixtures thereof are suitable in the present invention, in some embodiments, the carbon substrates are glucose, fructose, and

sucrose, or mixtures of these with C5 sugars such as xylose and/or arabinose for yeasts cells modified to use C5 sugars. Sucrose can be derived from renewable sugar sources such as sugar cane, sugar beets, cassava, sweet sorghum, and mixtures thereof. Glucose and dextrose
5 can be derived from renewable grain sources through saccharification of starch based feedstocks including grains such as corn, wheat, rye, barley, oats, and mixtures thereof. In addition, fermentable sugars can be derived from renewable cellulosic or lignocellulosic biomass through processes of pretreatment and saccharification, as described, for example, in U.S.
10 Patent Appl. Pub. No. 2007/0031918 A1, which is herein incorporated by reference in its entirety. Biomass refers to any cellulosic or lignocellulosic material and includes materials comprising cellulose, and optionally further comprising hemicellulose, lignin, starch, oligosaccharides and/or monosaccharides. Biomass can also comprise additional components,
15 such as protein and/or lipid. Biomass can be derived from a single source, or biomass can comprise a mixture derived from more than one source; for example, biomass can comprise a mixture of corn cobs and corn stover, or a mixture of grass and leaves. Biomass includes, but is not limited to, bioenergy crops, agricultural residues, municipal solid waste,
20 industrial solid waste, sludge from paper manufacture, yard waste, wood and forestry waste. Examples of biomass include, but are not limited to, corn grain, corn cobs, crop residues such as corn husks, corn stover, grasses, wheat, wheat straw, barley, barley straw, hay, rice straw, switchgrass, waste paper, sugar cane bagasse, sorghum, soy,
25 components obtained from milling of grains, trees, branches, roots, leaves, wood chips, sawdust, shrubs and bushes, vegetables, fruits, flowers, animal manure, and mixtures thereof.

In addition to an appropriate carbon source, fermentation media must contain suitable minerals, salts, cofactors, buffers and other
30 components, known to those skilled in the art, suitable for growth of the cultures and promotion of the enzymatic pathway necessary for butanol production described herein.

Culture Conditions

Typically cells are grown at a temperature in the range of about 20 °C to about 40 °C in an appropriate medium. Suitable growth media in the present invention are common commercially prepared media such as Luria Bertani (LB) broth, Sabouraud Dextrose (SD) broth or Yeast Medium (YM) broth or broth that includes yeast nitrogen base, ammonium sulfate, and dextrose (as the carbon/energy source) or YPD Medium, a blend of peptone, yeast extract, and dextrose in optimal proportions for growing most *Saccharomyces cerevisiae* strains. Other defined or synthetic growth media can also be used, and the appropriate medium for growth of the particular microorganism will be known by one skilled in the art of microbiology or fermentation science. The use of agents known to modulate catabolite repression directly or indirectly, e.g., cyclic adenosine 2',3'-monophosphate (cAMP), can also be incorporated into the fermentation medium.

Suitable pH ranges for the fermentation are between pH 5.0 to pH 9.0, where pH 6.0 to pH 8.0 is preferred for the initial condition. Suitable pH ranges for the fermentation of yeast are typically between about pH 3.0 to about pH 9.0. In one embodiment, about pH 5.0 to about pH 8.0 is used for the initial condition. Suitable pH ranges for the fermentation of other microorganisms are between about pH 3.0 to about pH 7.5. In one embodiment, about pH 4.5 to about pH 6.5 is used for the initial condition.

Fermentations can be performed under aerobic or anaerobic conditions. In one embodiment, anaerobic or microaerobic conditions are used for fermentation.

Industrial Batch and Continuous Fermentations

The present processes may employ a batch method of fermentation. A classical batch fermentation is a closed system where the composition of the medium is set at the beginning of the fermentation and not subject to artificial alterations during the fermentation. Thus, at the beginning of the fermentation the medium is inoculated with the desired microorganism or microorganisms, and fermentation is permitted to occur without adding anything to the system. Typically, however, a "batch"

fermentation is batch with respect to the addition of carbon source and attempts are often made at controlling factors such as pH and oxygen concentration. In batch systems the metabolite and biomass compositions of the system change constantly up to the time the fermentation is stopped. Within batch cultures cells moderate through a static lag phase to a high growth log phase and finally to a stationary phase where growth rate is diminished or halted. If untreated, cells in the stationary phase will eventually die. Cells in log phase generally are responsible for the bulk of production of end product or intermediate.

A variation on the standard batch system is the Fed-Batch system. Fed-Batch fermentation processes are also suitable in the present invention and comprise a typical batch system with the exception that the substrate is added in increments as the fermentation progresses. Fed-Batch systems are useful when catabolite repression is apt to inhibit the metabolism of the cells and where it is desirable to have limited amounts of substrate in the medium. Measurement of the actual substrate concentration in Fed-Batch systems is difficult and is therefore estimated on the basis of the changes of measurable factors such as pH, dissolved oxygen and the partial pressure of waste gases such as CO₂. Batch and Fed-Batch fermentations are common and well known in the art and examples can be found in Thomas D. Brock in Biotechnology: A Textbook of Industrial Microbiology, Second Edition (1989) Sinauer Associates, Inc., Sunderland, MA, or Deshpande, Mukund (Appl. Biochem. Biotechnol., 36: 227, 1992), herein incorporated by reference.

Although the present invention is performed in batch mode it is contemplated that the method would be adaptable to continuous fermentation methods. Continuous fermentation is an open system where a defined fermentation medium is added continuously to a bioreactor and an equal amount of conditioned medium is removed simultaneously for processing. Continuous fermentation generally maintains the cultures at a constant high density where cells are primarily in log phase growth.

Continuous fermentation allows for modulation of one factor or any number of factors that affect cell growth or end product concentration. For

example, one method will maintain a limiting nutrient such as the carbon source or nitrogen level at a fixed rate and allow all other parameters to moderate. In other systems a number of factors affecting growth can be altered continuously while the cell concentration, measured by medium
5 turbidity, is kept constant. Continuous systems strive to maintain steady state growth conditions and thus the cell loss due to the medium being drawn off must be balanced against the cell growth rate in the fermentation. Methods of modulating nutrients and growth factors for continuous fermentation processes as well as techniques for maximizing
10 the rate of product formation are well known in the art of industrial microbiology and a variety of methods are detailed by Brock, *supra*.

It is contemplated that the present invention can be practiced using either batch, fed-batch or continuous processes and that any known mode of fermentation would be suitable. Additionally, it is contemplated that
15 cells can be immobilized on a substrate as whole cell catalysts and subjected to fermentation conditions for isobutanol production.

Methods for Butanol Isolation from the Fermentation Medium

Bioproducted butanol can be isolated from the fermentation medium
20 using methods known in the art for ABE fermentations (see, e.g., Durre, *Appl. Microbiol. Biotechnol.* 49:639-648 (1998), Groot *et al.*, *Process. Biochem.* 27:61-75 (1992), and references therein). For example, solids can be removed from the fermentation medium by centrifugation, filtration, decantation, or the like. Then, the butanol can be isolated from the
25 fermentation medium using methods such as distillation, azeotropic distillation, liquid-liquid extraction, adsorption, gas stripping, membrane evaporation, or pervaporation.

Because butanol forms a low boiling point, azeotropic mixture with water, distillation can be used to separate the mixture up to its azeotropic
30 composition. Distillation can be used in combination with another separation method to obtain separation around the azeotrope. Methods that can be used in combination with distillation to isolate and purify butanol include, but are not limited to, decantation, liquid-liquid extraction, adsorption, and membrane-based techniques. Additionally, butanol can

be isolated using azeotropic distillation using an entrainer (see, e.g., Doherty and Malone, *Conceptual Design of Distillation Systems*, McGraw Hill, New York, 2001).

The butanol-water mixture forms a heterogeneous azeotrope so that distillation can be used in combination with decantation to isolate and purify the butanol. In this method, the butanol containing fermentation broth is distilled to near the azeotropic composition. Then, the azeotropic mixture is condensed, and the butanol is separated from the fermentation medium by decantation. The decanted aqueous phase can be returned to the first distillation column as reflux. The butanol-rich decanted organic phase can be further purified by distillation in a second distillation column.

The butanol can also be isolated from the fermentation medium using liquid-liquid extraction in combination with distillation. In this method, the butanol is extracted from the fermentation broth using liquid-liquid extraction with a suitable solvent. The butanol-containing organic phase is then distilled to separate the butanol from the solvent.

Distillation in combination with adsorption can also be used to isolate butanol from the fermentation medium. In this method, the fermentation broth containing the butanol is distilled to near the azeotropic composition and then the remaining water is removed by use of an adsorbent, such as molecular sieves (Aden *et al.*, *Lignocellulosic Biomass to Ethanol Process Design and Economics Utilizing Co-Current Dilute Acid Prehydrolysis and Enzymatic Hydrolysis for Corn Stover*, Report NREL/TP-510-32438, National Renewable Energy Laboratory, June 2002).

Additionally, distillation in combination with pervaporation can be used to isolate and purify the butanol from the fermentation medium. In this method, the fermentation broth containing the butanol is distilled to near the azeotropic composition, and then the remaining water is removed by pervaporation through a hydrophilic membrane (Guo *et al.*, *J. Membr. Sci.* 245, 199-210 (2004)).

In situ product removal (ISPR) (also referred to as extractive fermentation) can be used to remove butanol (or other fermentative alcohol) from the fermentation vessel as it is produced, thereby allowing

the microorganism to produce butanol at high yields. One method for ISPR for removing fermentative alcohol that has been described in the art is liquid-liquid extraction. In general, with regard to butanol fermentation, for example, the fermentation medium, which includes the microorganism, is contacted with an organic extractant at a time before the butanol concentration reaches a toxic level. The organic extractant and the fermentation medium form a biphasic mixture. The butanol partitions into the organic extractant phase, decreasing the concentration in the aqueous phase containing the microorganism, thereby limiting the exposure of the microorganism to the inhibitory butanol.

Liquid-liquid extraction can be performed, for example, according to the processes described in U.S. Patent Appl. Pub. No. 2009/0305370, the disclosure of which is hereby incorporated in its entirety. U.S. Patent Appl. Pub. No. 2009/0305370 describes methods for producing and recovering butanol from a fermentation broth using liquid-liquid extraction, the methods comprising the step of contacting the fermentation broth with a water immiscible extractant to form a two-phase mixture comprising an aqueous phase and an organic phase. Typically, the extractant can be an organic extractant selected from the group consisting of saturated, mono-unsaturated, poly-unsaturated (and mixtures thereof) C₁₂ to C₂₂ fatty alcohols, C₁₂ to C₂₂ fatty acids, esters of C₁₂ to C₂₂ fatty acids, C₁₂ to C₂₂ fatty aldehydes, and mixtures thereof. The extractant(s) for ISPR can be non-alcohol extractants. The ISPR extractant can be an exogenous organic extractant such as oleyl alcohol, behenyl alcohol, cetyl alcohol, lauryl alcohol, myristyl alcohol, stearyl alcohol, 1-undecanol, oleic acid, lauric acid, myristic acid, stearic acid, methyl myristate, methyl oleate, undecanal, lauric aldehyde, 20-methylundecanal, and mixtures thereof.

In some embodiments, the ester can be formed by contacting the alcohol in a fermentation medium with a carboxylic acid (e.g., fatty acids) and a catalyst capable of esterifying the alcohol with the carboxylic acid, as described in PCT Appn. Pub. No. WO/2011/159998 and U.S. Appl. Pub. No. 20120156738, which are herein incorporated by reference in their entireties. In such embodiments, the carboxylic acid can serve as an ISPR extractant into which the alcohol esters partition. The carboxylic

acid can be supplied to the fermentation vessel and/or derived from the biomass supplying fermentable carbon fed to the fermentation vessel. Lipids present in the feedstock can be catalytically hydrolyzed to carboxylic acid, and the same catalyst (e.g., enzymes) can esterify the carboxylic acid with the alcohol. The catalyst can be supplied to the feedstock prior to fermentation, or can be supplied to the fermentation vessel before or contemporaneously with the supplying of the feedstock. When the catalyst is supplied to the fermentation vessel, alcohol esters can be obtained by hydrolysis of the lipids into carboxylic acid and substantially simultaneous esterification of the carboxylic acid with butanol present in the fermentation vessel. Carboxylic acid and/or native oil not derived from the feedstock can also be fed to the fermentation vessel, with the native oil being hydrolyzed into carboxylic acid. Any carboxylic acid not esterified with the alcohol can serve as part of the ISPR extractant. The extractant containing alcohol esters can be separated from the fermentation medium, and the alcohol can be recovered from the extractant. The extractant can be recycled to the fermentation vessel. Thus, in the case of butanol production, for example, the conversion of the butanol to an ester may reduce the free butanol concentration in the fermentation medium, shielding the microorganism from the toxic effect of increasing butanol concentration. In addition, unfractionated grain can be used as feedstock without separation of lipids therein, since the lipids can be catalytically hydrolyzed to carboxylic acid, thereby decreasing the rate of build-up of lipids in the ISPR extractant.

In situ product removal can be carried out in a batch mode or a continuous mode. In a continuous mode of *in situ* product removal, product is continually removed from the reactor. In a batchwise mode of *in situ* product removal, a volume of organic extractant is added to the fermentation vessel and the extractant is not removed during the process. For *in situ* product removal, the organic extractant can contact the fermentation medium at the start of the fermentation forming a biphasic fermentation medium. Alternatively, the organic extractant can contact the fermentation medium after the microorganism has achieved a desired amount of growth, which can be determined by measuring the optical

density of the culture. Further, the organic extractant can contact the fermentation medium at a time at which the product alcohol level in the fermentation medium reaches a preselected level. In the case of butanol production according to some embodiments of the present invention, the carboxylic acid extractant can contact the fermentation medium at a time before the butanol concentration reaches a toxic level, so as to esterify the butanol with the carboxylic acid to produce butanol esters and consequently reduce the concentration of butanol in the fermentation vessel. The ester-containing organic phase can then be removed from the fermentation vessel (and separated from the fermentation broth which constitutes the aqueous phase) after a desired effective titer of the butanol esters is achieved. In some embodiments, the ester-containing organic phase is separated from the aqueous phase after fermentation of the available fermentable sugar in the fermentation vessel is substantially complete.

EXAMPLES

Construction of Strains

Table 8. Strains referenced in the Examples

Strain name	Genotype	Description
PNY2204	MATa ura3Δ::loxP his3Δ pdc6Δ pdc1Δ::P[PDC1]-DHAD ilvD_Sm- PDC1t-pUC19-loxP-kanMX-loxP- P[FBA1]-ALS alsS_Bs-CYC1t pdc5Δ::P[PDC5]-ADH sadB_Ax- PDC5t gpd2Δ::loxP fra2Δ adh1Δ::UAS(PGK1)P[FBA1]- kivD_LI(y)-ADH1t	PCT Publication No. WO2012033832, and U.S. Appl. Pub. No. US 20120237988A1, incorporated herein by reference in their entireties
PNY2211	MATa ura3Δ::loxP his3Δ pdc6Δ pdc1Δ::P[PDC1]-DHAD ilvD_Sm- PDC1t-P[FBA1]-ALS alsS_Bs-CYC1t pdc5Δ::P[PDC5]-ADH sadB_Ax- PDC5t gpd2Δ::loxP fra2Δ adh1Δ::UAS(PGK1)P[FBA1]- kivD_LI(y)-ADH1t	PCT Publication No. WO2012033832, and U.S. Appl. Pub. No. US 20120237988A1, incorporated herein by reference in their entireties
PNY2238	MATa ura3Δ::loxP his3Δ pdc6Δ pdc1Δ::P[PDC1]-DHAD ilvD_Sm-	herein

	PDC1t-P[FBA1]-ALS alsS_Bs-CYC1t pdc5Δ::P[PDC5]-ADH sadB_Ax- PDC5t gpd2Δ::loxP fra2Δ::P[PDC1]- ADH adh_Hl-ADH1t adh1Δ::UAS(PGK1)P[FBA1]- kivD_Ll(y)-ADH1t yprcΔ15Δ::P[PDC5]-ADH adh_Hl- ADH1t ymr226cΔ ald6Δ::loxP	
PNY2259	MATa ura3Δ::loxP his3Δ pdc6Δ pdc1Δ::P[PDC1]-DHAD ilvD_Sm- PDC1t-P[FBA1]-ALS alsS_Bs-CYC1t pdc5Δ::P[PDC5]-ADH sadB_Ax- PDC5t gpd2Δ::loxP fra2Δ::P[PDC1]- ADH adh_Hl-ADH1t adh1Δ::UAS(PGK1)P[FBA1]- kivD_Lg(y)-ADH1t yprcΔ15Δ::P[PDC5]-ADH adh_Hl- ADH1t ymr226cΔ ald6Δ::loxP	herein
PNY1556	MATa ura3Δ::loxP his3Δ pdc6Δ pdc1Δ::P[PDC1]-DHAD ilvD_Sm- PDC1t-P[FBA1]-ALS alsS_Bs-CYC1t pdc5Δ::P[PDC5]-ADH sadB_Ax- PDC5t gpd2Δ::loxP fra2Δ::P[PDC1]- ADH adh_Hl-ADH1t adh1Δ::UAS(PGK1)P[FBA1]- kivD_Lg(y)-ADH1t yprcΔ15Δ::P[PDC5]-ADH adh_Hl- ADH1t	herein

Construction of PNY1528 (hADH integrations in PNY2211)

Deletions/integrations were created by homologous recombination with PCR products containing regions of homology upstream and downstream of the target region and the *URA3* gene for selection of transformants. The *URA3* gene was removed by homologous recombination to create a scarless deletion/integration.

YPRCΔ15 deletion and horse liver adh integration

The YPRCΔ15 locus was deleted and replaced with the horse liver adh gene, codon optimized for expression in *Saccharomyces cerevisiae*, along with the PDC5 promoter region (538 bp) from *Saccharomyces cerevisiae* and the ADH1 terminator region (316 bp) from *Saccharomyces cerevisiae*. The scarless cassette for the YPRCΔ15 deletion- P[PDC5]-adh_HL(y)-ADH1t integration was first cloned into plasmid pUC19-URA3MCS.

Fragments A-B-U-C were amplified using Phusion High Fidelity PCR Master Mix (New England BioLabs; Ipswich, MA) and CEN.PK 113-7D genomic DNA as template, prepared with a Gentra Puregene

Yeast/Bact kit (Qiagen; Valencia, CA). YPRCΔ15 Fragment A was amplified from genomic DNA with primer oBP622 (SEQ ID NO: 269), containing a KpnI restriction site, and primer oBP623 (SEQ ID NO: 270), containing a 5' tail with homology to the 5' end of YPRCΔ15 Fragment B.

5 YPRCΔ15 Fragment B was amplified from genomic DNA with primer oBP624 (SEQ ID NO: 271), containing a 5' tail with homology to the 3' end of YPRCΔ15 Fragment A, and primer oBP625 (SEQ ID NO: 272), containing a FseI restriction site. PCR products were purified with a PCR Purification kit (Qiagen). YPRCΔ15 Fragment A - YPRCΔ15 Fragment B

10 was created by overlapping PCR by mixing the YPRCΔ15 Fragment A and YPRCΔ15 Fragment B PCR products and amplifying with primers oBP622 (SEQ ID NO: 269) and oBP625 (SEQ ID NO: 272). The resulting PCR product was digested with KpnI and FseI and ligated with T4 DNA ligase into the corresponding sites of pUC19-URA3MCS after digestion with the

15 appropriate enzymes. YPRCΔ15 Fragment C was amplified from genomic DNA with primer oBP626 (SEQ ID NO: 273), containing a NotI restriction site, and primer oBP627 (SEQ ID NO: 274), containing a PaeI restriction site. The YPRCΔ15 Fragment C PCR product was digested with NotI and PaeI and ligated with T4 DNA ligase into the corresponding sites of the

20 plasmid containing YPRCΔ15 Fragments AB. The PDC5 promoter region was amplified from CEN.PK 113-7D genomic DNA with primer HY21 (SEQ ID NO: 275), containing an AscI restriction site, and primer HY24 (SEQ ID NO: 276), containing a 5' tail with homology to the 5' end of adh_{HL}(y). adh_{HL}(y)-ADH1t was amplified from pBP915 (SEQ ID NO: 279) with

25 primers HY25 (SEQ ID NO: 277), containing a 5' tail with homology to the 3' end of P[PDC5], and HY4 (SEQ ID NO: 278), containing a PmeI restriction site. PCR products were purified with a PCR Purification kit (Qiagen). P[PDC5]-adh_{HL}(y)-ADH1t was created by overlapping PCR by mixing the P[PDC5] and adh_{HL}(y)-ADH1t PCR products and amplifying

30 with primers HY21 (SEQ ID NO: 275) and HY4 (SEQ ID NO: 278). The resulting PCR product was digested with AscI and PmeI and ligated with T4 DNA ligase into the corresponding sites of the plasmid containing YPRCΔ15 Fragments ABC. The entire integration cassette was amplified

from the resulting plasmid with primers oBP622 (SEQ ID NO: 269) and oBP627 (SEQ ID NO: 274).

Competent cells of PNY2211 were made and transformed with the *YPRCΔ15* deletion- P[PDC5]-*adh_HL(y)*-ADH1t integration cassette PCR product using a Frozen-EZ Yeast Transformation II kit (Zymo Research; Orange, CA). Transformation mixtures were plated on synthetic complete media lacking uracil supplemented with 1% ethanol at 30 °C. Transformants were screened for by PCR with primers URA3-end F (SEQ ID NO: 280) and oBP637 (SEQ ID NO: 283). Correct transformants were grown in YPE (1% ethanol) and plated on synthetic complete medium supplemented with 1% EtOH and containing 5-fluoro-orotic acid (0.1%) at 30 °C to select for isolates that lost the *URA3* marker. The deletion of *YPRCΔ15* and integration of P[PDC5]-*adh_HL(y)*-ADH1t were confirmed by PCR with external primers oBP636 (SEQ ID NO: 281) and oBP637 (SEQ ID NO: 282) using genomic DNA prepared with a YeaStar Genomic DNA kit (Zymo Research). A correct isolate of the following genotype was selected for further modification: CEN.PK 113-7D MATa *ura3Δ::loxP* *his3Δ* *pdh6Δ* *pdh1Δ::P[PDC1]-DHAD|ilvD_Sm-PDC1t-P[FBA1]-ALS|alsS_Bs-CYC1t* *pdh5Δ::P[PDC5]-ADH|sadB_Ax-PDC5t* *gpd2Δ::loxP* *fra2Δ* *adh1Δ::UAS(PGK1)P[FBA1]-kivD_LI(y)-ADH1t* *yprcΔ15Δ::P[PDC5]-ADH|adh_HL-ADH1t*.

Horse liver *adh* integration at *fra2Δ*

The horse liver *adh* gene, codon optimized for expression in *Saccharomyces cerevisiae*, along with the *PDC1* promoter region (870 bp) from *Saccharomyces cerevisiae* and the *ADH1* terminator region (316 bp) from *Saccharomyces cerevisiae*, was integrated into the site of the *fra2* deletion. The scarless cassette for the *fra2Δ*- P[PDC1]-*adh_HL(y)*-ADH1t integration was first cloned into plasmid pUC19-URA3MCS.

Fragments A-B-U-C were amplified using Phusion High Fidelity PCR Master Mix (New England BioLabs; Ipswich, MA) and CEN.PK 113-7D genomic DNA as template, prepared with a Gentra Puregene Yeast/Bact kit (Qiagen; Valencia, CA). *fra2Δ* Fragment C was amplified from genomic DNA with primer oBP695 (SEQ ID NO: 287), containing a

NotI restriction site, and primer oBP696 (SEQ ID NO: 288), containing a PacI restriction site. The *fra2Δ* Fragment C PCR product was digested with NotI and PacI and ligated with T4 DNA ligase into the corresponding sites of pUC19-URA3MCS. *fra2Δ* Fragment B was amplified from genomic DNA with primer oBP693 (SEQ ID NO: 285), containing a PmeI restriction site, and primer oBP694 (SEQ ID NO: 286), containing a FseI restriction site. The resulting PCR product was digested with PmeI and FseI and ligated with T4 DNA ligase into the corresponding sites of the plasmid containing *fra2Δ* fragment C after digestion with the appropriate enzymes.

10 *fra2Δ* Fragment A was amplified from genomic DNA with primer oBP691 (SEQ ID NO: 283), containing BamHI and AsiSI restriction sites, and primer oBP692 (SEQ ID NO: 284), containing AscI and SmaI restriction sites. The *fra2Δ* fragment A PCR product was digested with BamHI and AscI and ligated with T4 DNA ligase into the corresponding sites of the

15 plasmid containing *fra2Δ* fragments BC after digestion with the appropriate enzymes. The *PDC1* promoter region was amplified from CEN.PK 113-7D genomic DNA with primer HY16 (SEQ ID NO: 289), containing an AscI restriction site, and primer HY19 (SEQ ID NO: 290), containing a 5' tail with homology to the 5' end of *adh_Hl(y)*. *adh_Hl(y)*-ADH1t was amplified

20 from pBP915 with primers HY20 (SEQ ID NO: 291), containing a 5' tail with homology to the 3' end of P[PDC1], and HY4 (SEQ ID NO: 278), containing a PmeI restriction site. PCR products were purified with a PCR Purification kit (Qiagen). P[PDC1]-*adh_Hl(y)*-ADH1t was created by overlapping PCR by mixing the P[PDC1] and *adh_Hl(y)*-ADH1t PCR

25 products and amplifying with primers HY16 (SEQ ID NO: 289) and HY4 (SEQ ID NO: 278). The resulting PCR product was digested with AscI and PmeI and ligated with T4 DNA ligase into the corresponding sites of the plasmid containing *fra2Δ* Fragments ABC. The entire integration cassette was amplified from the resulting plasmid with primers oBP691 (SEQ ID

30 NO: 283) and oBP696 (SEQ ID NO: 288).

Competent cells of the PNY2211 variant with *adh_Hl(y)* integrated at *YPRCΔ15* were made and transformed with the *fra2Δ*- P[PDC1]-*adh_Hl(y)*-ADH1t integration cassette PCR product using a Frozen-EZ Yeast Transformation II kit (Zymo Research). Transformation mixtures

were plated on synthetic complete media lacking uracil supplemented with 1% ethanol at 30 °C. Transformants were screened for by PCR with primers URA3-end F (SEQ ID NO: 280) and oBP731 (SEQ ID NO: 293). Correct transformants were grown in YPE (1% ethanol) and plated on synthetic complete medium supplemented with 1% EtOH and containing 5-fluoro-orotic acid (0.1%) at 30 °C to select for isolates that lost the *URA3* marker. The integration of P[PDC1]-adh_{HL}(y)-ADH1t was confirmed by colony PCR with internal primer HY31 (SEQ ID NO: 294) and external primer oBP731 (SEQ ID NO: 293) and PCR with external primers oBP730 (SEQ ID NO: 292) and oBP731 (SEQ ID NO: 293) using genomic DNA prepared with a YeaStar Genomic DNA kit (Zymo Research). A correct isolate of the following genotype was designated PNY1528: CEN.PK 113-7D MATa ura3Δ::loxP his3Δ pdc6Δ pdc1Δ::P[PDC1]-DHAD|ilvD_Sm-PDC1t-P[FBA1]-ALS|alsS_Bs-CYC1t pdc5Δ::P[PDC5]-ADH|sadB_Ax-PDC5t gpd2Δ::loxP fra2Δ::P[PDC1]-ADH|adh_{HL}-ADH1t adh1Δ::UAS(PGK1)P[FBA1]-kivD_LI(y)-ADH1t yprcΔ15Δ::P[PDC5]-ADH|adh_{HL}-ADH1t.

PNY2237 (scarless YMR226c deletion)

The gene YMR226c was deleted from *S. cerevisiae* strain PNY1528 by homologous recombination using a PCR amplified 2.0 kb linear scarless deletion cassette. The cassette was constructed from spliced PCR amplified fragments comprised of the URA3 gene, along with its native promoter and terminator as a selectable marker, upstream and downstream homology sequences flanking the YMR226c gene chromosomal locus to promote integration of the deletion cassette and removal of the native intervening sequence and a repeat sequence to promote recombination and removal of the URA3 marker. Forward and reverse PCR primers (N1251 and N1252, SEQ ID NOs: 295 and 296, respectively), amplified a 1,208 bp URA3 expression cassette originating from pLA33 (pUC19::loxP-URA3-loxP (SEQ ID NO: 303)). Forward and reverse primers (N1253 and N1254, SEQ ID NOs: 297 and 298, respectively), amplified a 250 bp downstream homology sequence with a 3' URA3 overlap sequence tag from a genomic DNA preparation of *S.*

cerevisiae strain PNY2211 (above). Forward and reverse PCR primers (N1255 and N1256, SEQ ID NOs: 299 and 300, respectively) amplified a 250 bp repeat sequence with a 5' URA3 overlap sequence tag from a genomic DNA preparation of *S. cerevisiae* strain PNY2211. Forward and
 5 reverse PCR primers (N1257 and N1258, SEQ ID NOs: 301 and 302, respectively) amplified a 250 bp upstream homology sequence with a 5' repeat overlap sequence tag from a genomic DNA preparation of *S. cerevisiae* strain PNY2211.

Approximately 1.5 µg of the PCR amplified cassette was
 10 transformed into strain PNY1528 (above) made competent using the ZYMO Research Frozen Yeast Transformation Kit and the transformation mix plated on SE 1.0% -uracil and incubated at 30°C for selection of cells with an integrated *ymr226cΔ::URA3* cassette. Transformants appearing after 72 to 96 hours are subsequently short-streaked on the same medium
 15 and incubated at 30°C for 24 to 48 hours. The short-streaks are screened for *ymr226cΔ::URA3* by PCR, with a 5' outward facing URA3 deletion cassette-specific internal primer (N1249, SEQ ID NO: 312) paired with a flanking inward facing chromosome-specific primer (N1239, SEQ ID NO: 310) and a 3' outward-facing URA3 deletion cassette-specific primer
 20 (N1250, SEQ ID NO: 313) paired with a flanking inward-facing chromosome-specific primer (N1242, SEQ ID NO: 311). A positive PNY1528 *ymr226cΔ::URA3* PCR screen resulted in 5' and 3' PCR products of 598 and 726 bp, respectively.

Three positive PNY1528 *ymr226cΔ::URA3* clones were picked and
 25 cultured overnight in a YPE 1% medium of which 100µL was plated on YPE 1% + 5-FOA for marker removal. Colonies appearing after 24 to 48 hours were PCR screened for marker loss with 5' and 3' chromosome-specific primers (N1239 and N1242). A positive PNY1528 *ymr226cΔ* markerless PCR screen resulted in a PCR product of 801 bp. Multiple
 30 clones were obtained and one was designated PNY2237.

PNY2238 and PNY2243 (ALD6 deletion strains)

A vector was designed to replace the *ALD6* coding sequence with a Cre-lox recyclable URA3 selection marker. Sequences 5' and 3' of *ALD6* were amplified by PCR (primer pairs N1179 and N1180 and N1181 and N1182, respectively; SEQ ID NOs: 304, 305, 306, and 307, respectively).
 5 After cloning these fragments into TOPO vectors (Invitrogen Cat. No. K2875-J10) and sequencing (M13 forward (SEQ ID NO:314) and reverse (SEQ ID NO:315) primers), the 5' and 3' flanks were cloned into pLA33 (pUC19::loxP::URA3::loxP) (SEQ ID NO:303) at the *EcoRI* and *SphI* sites, respectively. Each ligation reaction was transformed into *E. coli* Stbl3
 10 cells, which were incubated on LB Amp plates to select for transformants. Proper insertion of sequences was confirmed by PCR (primers M13 forward (SEQ ID NO: 314) and N1180 (SEQ ID NO:305) and M13 reverse (SEQ ID NO:315) and N1181 (SEQ ID NO:306, respectively).

The vector described above (pUC19::ald6Δ::loxP-URA3-loxP) was
 15 linearized with *AhdI* and transformed into PNY1528 and PNY2237 using the standard lithium acetate method (except that incubation of cells with DNA was extended to 2.5h). Transformants were obtained by plating on synthetic complete medium minus uracil that provided 1% ethanol as the carbon source. Patched transformants were screened by PCR to confirm
 20 the deletion/integration, using primers N1212 (SEQ ID NO: 308) and N1180 (5' end) (SEQ ID NO: 305) and N1181 (SEQ ID NO: 306) and N1213 (SEQ ID NO: 309) (3' end). A plasmid carrying Cre recombinase (pRS423::GAL1p-Cre = SEQ ID No. 324) was transformed into the strain using histidine marker selection. Transformants were passaged on YPE
 25 supplemented with 0.5% galactose. Colonies were screened for resistance to 5-FOA (loss of URA3 marker) and for histidine auxotrophy (loss of the Cre plasmid). Proper removal of the URA3 gene via the flanking loxP sites was confirmed by PCR (primers N1262 and N1263, SEQ ID NOs: 316 and 317, respectively). Additionally, primers internal to
 30 the *ALD6* gene (N1230 and N1231; SEQ ID NOs: 322 and 323, respectively) were used to insure that no merodiploids were present. Finally, *ald6Δ::loxP* clones were screened by PCR to confirm that a translocation between *ura3Δ::loxP* (N1228 and N1229, SEQ ID NOs: 320

and 321) and *gpd2Δ::loxP* (N1223 and N1225, SEQ ID NOs: 318 and 319) had not occurred. Two positive clones were identified from screening of transformants of PNY1528. Clone B has been designated PNY2243. Three positive clones were identified from screening transformants of PNY2237. Clones E and K were both assessed for isobutanol production at small scale (below). Although statistically identical in most parameters, Clone E was selected (PNY2238) for further development.

Construction of strain PNY2259

The purpose of this example is to describe the assembly of the constructs used to replace the chromosomal copy of *kivD_LI(y)* in PNY2238 at the *adh1Δ* locus with *kivD_Lg(y)*.

The deletion/integration was created by homologous recombination with PCR products containing regions of homology upstream and downstream of the target region and the *URA3* gene for selection of transformants. The *URA3* gene was removed by homologous recombination to create a scarless deletion/integration. The plasmid to integrate *kivD_Lg(y)* was derived from a plasmid constructed to integrate UAS(PGK1)P[FBA1]-*kivD_LI(y)* into the *ADH1* locus of *Saccharomyces cerevisiae*. Construction of the plasmid used to integrate UAS(PGK1)P[FBA1]-*kivD_LI(y)* into the *ADH1* locus is described below. The plasmids were constructed in pUC19-URA3MCS.

Construction of the *ADH1* deletion/UAS(PGK1)P[FBA1]-*kivD_LI(y)* integration plasmid

The *kivD* coding region from *Lactococcus lactis* codon optimized for expression in *Saccharomyces cerevisiae*, *kivD_LI(y)*, was amplified using pLH468 (SEQ ID NO: 335) as template with primer oBP562 (SEQ ID NO: 325), containing a PmeI restriction site, and primer oBP563 (SEQ ID NO: 326), containing a 5' tail with homology to the 5' end of *ADH1* Fragment B. *ADH1* Fragment B was amplified from *Saccharomyces cerevisiae* CEN.PK 113-7D genomic DNA with primer oBP564 (SEQ ID NO: 327), containing a 5' tail with homology to the 3' end of *kivD_LI(y)*, and primer oBP565 (SEQ ID NO: 328), containing a FseI restriction site. PCR products were purified

with a PCR Purification kit (Qiagen; Valencia, CA). *kivD_LI(y)*-ADH1 Fragment B was created by overlapping PCR by mixing the *kivD_LI(y)* and ADH1 Fragment B PCR products and amplifying with primers oBP562 (SEQ ID NO: 325) and oBP565 (SEQ ID NO: 328). The resulting PCR
5 product was digested with PmeI and FseI and ligated with T4 DNA ligase into the corresponding sites of pUC19-URA3MCS after digestion with the appropriate enzymes. ADH1 Fragment A was amplified from genomic DNA with primer oBP505 (SEQ ID NO: 329), containing a SacI restriction site, and primer oBP506 (SEQ ID NO: 330), containing an AscI restriction
10 site. The ADH1 Fragment A PCR product was digested with SacI and AscI and ligated with T4 DNA ligase into the corresponding sites of the plasmid containing *kivD_LI(y)*-ADH1 Fragment B. ADH1 Fragment C was amplified from genomic DNA with primer oBP507 (SEQ ID NO: 331), containing a PacI restriction site, and primer oBP508 (SEQ ID NO: 332), containing a
15 Sall restriction site. The ADH1 Fragment C PCR product was digested with PacI and Sall and ligated with T4 DNA ligase into the corresponding sites of the plasmid containing ADH1 Fragment A-*kivD_LI(y)*-ADH1 Fragment B. The hybrid promoter UAS(PGK1)-P_{FBA1} (SEQ ID NO: 264) was amplified from vector pRS316- UAS(PGK1)-P_{FBA1}-GUS with primer
20 oBP674 (SEQ ID NO: 333), containing an AscI restriction site, and primer oBP675 (SEQ ID NO: 334), containing a PmeI restriction site. The UAS(PGK1)-P_{FBA1} PCR product was digested with AscI and PmeI and ligated with T4 DNA ligase into the corresponding sites of the plasmid containing *kivD_LI(y)*-ADH1 Fragments ABC to generate pBP1181.

25

Construction of pBP1716 and pBP1719

kivD_LI(y) was removed from the ADH1 deletion/UAS(PGK1)P[FBA1]-*kivD_LI(y)* integration plasmid pBP1181. The plasmid was digested with PmeI and FseI and the large DNA fragment
30 was purified on an agarose gel followed by a gel extraction kit (Qiagen). ADH1 fragment B was amplified from pBP1181 with primer oBP821 (SEQ ID NO: 336), containing a PmeI restriction site, and primer oBP484 (SEQ ID NO: 337), containing a FseI restriction site. The ADH1 fragment B PCR product was digested with PmeI and FseI and ligated with T4 DNA ligase

into the corresponding sites of the gel purified large DNA fragment. A PCR fragment corresponding to the 3' 500bp of *kivD_LI(y)* was cloned into the resulting vector for the targeted deletion of *kivD_LI(y)* in PNY1528. The fragment was amplified from pBP1181 with primers oBP822 (SEQ ID NO: 338), containing a NotI restriction site, and oBP823 (SEQ ID NO: 339), containing a PacI restriction site. The fragment was digested with NotI and PacI and ligated with T4 DNA ligase into the corresponding sites downstream of URA3 in the above plasmid with the *kivD_LI(y)* deletion after digestion with the appropriate restriction enzymes. The resulting plasmid was designated pBP1716.

The *kivD* coding region from *Listeria grayi* codon optimized for expression in *Saccharomyces cerevisiae* (SEQ ID NO: 340), *kivD_Lg(y)*, was synthesized by DNA2.0 (Menlo Park, CA). *kivD_Lg(y)* was amplified with primers oBP828 (SEQ ID NO: 341), containing a PmeI restriction site, and oBP829 (SEQ ID NO: 342) containing a PmeI restriction site. The resulting PCR product was digested with PmeI and ligated with T4 DNA ligase into the corresponding site in pBP1716 after digestion with the appropriate enzyme. The orientation of the cloned gene was checked by PCR with primers FBAp-F (SEQ ID NO: 343) and oBP829 (SEQ ID NO: 342). An isolate with *kivD_Lg(y)* in the correct orientation was designated pBP1719.

Construction of strain PNY2259

The *kivD_LI(y)* deletion/*kivD_Lg(y)* integration cassette was amplified from pBP1719 with primers oBP505 (SEQ ID NO: 329) and oBP823 (SEQ ID NO: 339). Competent cells of the PNY2238 were made and transformed with the PCR product using a Frozen-EZ Yeast Transformation II kit (Zymo Research; Orange, CA). Transformation mixtures were plated on synthetic complete media lacking uracil supplemented with 1% ethanol at 30C. Transformant strains were screened by PCR (JumpStart(TM) REDTaq (c) ReadyMix(TM)) using primers Ura3-end F (SEQ ID NO: 280) and HY-50 (SEQ ID NO: 344). Transformants were grown in YPE (1% ethanol) and plated on synthetic complete medium supplemented with 1% EtOH and containing 5-fluoro-

orotic acid (0.1%) at 30 C to select for isolates that lost the *URA3* marker. The deletion of *kivD_LI(y)* and integration of *kivD_Lg(y)* was confirmed by PCR with primers HY-50 and oBP834 (SEQ ID NO: 345). One correct isolate contained *kivD_Lg(y)* at the same locus and expressed from the same promoter as *kivD_LI(y)* in PNY2238 was designated PNY2259.

Construction of strain PNY1556

Described here is the assembly of the constructs used to replace the chromosomal copy of *kivD_LI(y)* in PNY1528 at the *adh1Δ* locus with *kivD_Lg(y)* and construction of strain PNY1556 expressing the *kivD_Lg(y)* gene. Deletions/integrations were created by homologous recombination with PCR products containing regions of homology upstream and downstream of the target region and the *URA3* gene for selection of transformants as described in the previous section. The plasmid to integrate *kivD_Lg(y)* was derived from a plasmid constructed to integrate UAS(PGK1)P[FBA1]-*kivD_LI(y)* into the *ADH1* locus of *Saccharomyces cerevisiae*. Construction of the plasmid used to integrate UAS(PGK1)P[FBA1]-*kivD_LI(y)* into the *ADH1* locus is described below. The plasmids were constructed in pUC19-URA3MCS.

Construction of the *ADH1* deletion/UAS(PGK1)P[FBA1]-*kivD_LI(y)* integration plasmid

The *kivD* coding region from *Lactococcus lactis* codon optimized for expression in *Saccharomyces cerevisiae*, *kivD_LI(y)*, was amplified using pLH468 (SEQ ID NO: 129) as template with primer oBP562 (SEQ ID NO: 384), containing a PmeI restriction site, and primer oBP563 (SEQ ID NO: 385), containing a 5' tail with homology to the 5' end of *ADH1* Fragment B. *ADH1* Fragment B was amplified from *Saccharomyces cerevisiae* CEN.PK 113-7D genomic DNA with primer oBP564 (SEQ ID NO: 386), containing a 5' tail with homology to the 3' end of *kivD_LI(y)*, and primer oBP565 (SEQ ID NO: 387), containing a FseI restriction site. PCR products were purified with a PCR Purification kit (Qiagen; Valencia, CA). *kivD_LI(y)*-*ADH1* Fragment B was created by overlapping PCR by mixing the *kivD_LI(y)* and *ADH1* Fragment B PCR products and amplifying with primers oBP562 (SEQ ID NO: 384) and oBP565 (SEQ ID NO 387). The resulting PCR

product was digested with PmeI and FseI and ligated with T4 DNA ligase into the corresponding sites of pUC19-URA3MCS after digestion with the appropriate enzymes. ADH1 Fragment A was amplified from genomic DNA with primer oBP505 (SEQ ID NO: 329), containing a SacI restriction site, and primer oBP506 (SEQ ID NO: 330), containing an Ascl restriction site. The ADH1 Fragment A PCR product was digested with SacI and Ascl and ligated with T4 DNA ligase into the corresponding sites of the plasmid containing kivD_LI(y)-ADH1 Fragment B. ADH1 Fragment C was amplified from genomic DNA with primer oBP507 (SEQ ID NO: 331), containing a PacI restriction site, and primer oBP508 (SEQ ID NO: 332), containing a Sall restriction site. The ADH1 Fragment C PCR product was digested with PacI and Sall and ligated with T4 DNA ligase into the corresponding sites of the plasmid containing ADH1 Fragment A-kivD_LI(y)-ADH1 Fragment B. The hybrid promoter UAS(PGK1)-P_{FBA1} was amplified from vector pRS316- UAS(PGK1)-PFBA1-GUS (SEQ ID NO: 389) with primer oBP674 (SEQ ID NO: 333), containing an Ascl restriction site, and primer oBP675 (SEQ ID NO: 334), containing a PmeI restriction site. The UAS(PGK1)-P_{FBA1} PCR product was digested with Ascl and PmeI and ligated with T4 DNA ligase into the corresponding sites of the plasmid containing kivD_LI(y)-ADH1 Fragments ABC to generate pBP1181.

kivD_LI(y) was removed from the ADH1 deletion/UAS(PGK1)P[FBA1]-kivD_LI(y) integration plasmid pBP1181. The plasmid was digested with PmeI and FseI and the large DNA fragment was purified on an agarose gel followed by a gel extraction kit (Qiagen). ADH1 fragment B was amplified from pBP1181 with primer oBP821 (SEQ ID NO: 336), containing a PmeI restriction site, and primer oBP484 (SEQ ID NO: 337), containing a FseI restriction site. The ADH1 fragment B PCR product was digested with PmeI and FseI and ligated with T4 DNA ligase into the corresponding sites of the gel purified large DNA fragment. A PCR fragment corresponding to the 3' 500bp of kivD_LI(y) was cloned into the resulting vector for the targeted deletion of kivD_LI(y) in PNY1528. The fragment was amplified from pBP1181 with primers oBP822 (SEQ ID NO: 338), containing a NotI restriction site, and oBP823 (SEQ ID NO: 339), containing a PacI restriction site. The fragment was digested with NotI and

PacI and ligated with T4 DNA ligase into the corresponding sites downstream of URA3 in the above plasmid with the *kivD_LI(y)* deletion after digestion with the appropriate restriction enzymes. The resulting plasmid was designated pBP1716.

5 The *kivD* coding region from *Listeria grayi* codon optimized for expression in *Saccharomyces cerevisiae* (SEQ ID NO: 390), *kivD_Lg(y)*, was synthesized by DNA2.0 (Menlo Park, CA). *kivD_Lg(y)* was amplified with primers oBP828 (SEQ ID NO: 341), containing a PmeI restriction site, and oBP829 (SEQ ID NO: 342) containing a PmeI restriction site. The
10 resulting PCR product was digested with PmeI and ligated with T4 DNA ligase into the corresponding site in pBP1716 after digestion with the appropriate enzyme. The orientation of the cloned gene was checked by PCR with primers FBAp-F (SEQ ID NO: 343) and oBP829 (SEQ ID NO: 342). An isolate with *kivD_Lg(y)* in the correct orientation was designated
15 pBP1719.

The *kivD_LI(y)* deletion/*kivD_Lg(y)* integration cassette was amplified from pBP1719 with primers oBP505 (SEQ ID NO: 329) and oBP823 (SEQ ID NO: 339). Competent cells of the PNY1528 were made and transformed with the PCR product using a Frozen-EZ Yeast
20 Transformation II kit (Zymo Research; Orange, CA). Transformation mixtures were plated on synthetic complete media lacking uracil supplemented with 1% ethanol at 30C. Transformants were grown in YPE (1% ethanol) and plated on synthetic complete medium supplemented with 1% EtOH and containing 5-fluoro-orotic acid (0.1%) at 30 C to select
25 for isolates that lost the *URA3* marker. The deletion of *kivD_LI(y)* and integration of *kivD_Lg(y)* was confirmed by PCR with primers oBP674 (SEQ ID NO: 333) and oBP830 (SEQ ID NO: 391) using genomic DNA prepared with a YeaStar Genomic DNA kit (Zymo Research). A correct isolate contained *kivD_Lg(y)* at the same locus and expressed from the
30 same promoter as *kivD_LI(y)* in PNY1528 and was designated PNY1556.

GENERAL METHODS FOR EXAMPLES 1-4

Yeast Transformation with Plasmids:

35 Frozen aliquots of competent cells of yeast strains to be

transformed with KARI-containing plasmids were made as follows. For cases where the KARI and DHAD genes were on separate plasmids, competent cells were first made from cells harboring the DHAD-containing plasmid (e.g. pBP915). Those competent cells were then transformed with
5 the KARI-containing plasmids.

10 mL of growth medium (YPE for plasmid-free yeast, SE -His for yeast harboring a DHAD-containing plasmid such as pBP915) was inoculated with a loop of cells from a freshly patched plate. The culture was shaken overnight at 30 °C. The OD_{600 nm} of the overnight culture was
10 measured with a cuvette spectrophotometer and a calculated amount of cells was used to inoculate a subsequent 30 mL culture at an initial OD_{600 nm} of 0.2. The growth medium was YPE for plasmid-free yeast or SE -His for yeast harboring a DHAD-containing plasmid such as pBP915. The flask containing the 30 mL culture was shaken for approximately 8 hours
15 at 30 °C until the OD_{600 nm} reached approximately 0.7 to 1.0. 25 mL of the culture was centrifuged at 4000 rpm for 10 minutes in a swinging-bucket rotor. The supernatant was discarded and the pellet was resuspended in 10 mL of EZ 1 solution (from the Frozen-EZ Yeast Transformation II Kit, Catalog # T2001, Zymo Research, Orange, California). The cells were
20 recentrifuged as above and the supernatant was discarded. The pellet was resuspended in 1.75 mL EZ 2 solution (Zymo Research) and aliquoted into microfuge tubes for freezing. The aliquots of competent cells were placed inside two concentric styrofoam boxes to prolong the freezing process. The assembly was placed in a freezer at -80 °C. The aliquots were
25 transferred out of the concentric styrofoam boxes into standard freezer boxes after no less than 12 hours.

Yeast cells were transformed with plasmids as follows: For each plasmid to be transformed, 8 µL (300-400 ng) of plasmid DNA solution was dispensed into a 1.5 mL microfuge tube. Aliquots of frozen competent
30 yeast cells were thawed on ice. 20 µL of thawed competent yeast cells was added to each tube and mixed with the DNA by pipette. 200 µL of EZ 3 Solution (Zymo Research) was added to each tube and mixed by pipetting. The mixtures were incubated at 30 °C for approximately 2 hours

with intermittent vortex mixing every 30-45 minutes. 150 μ L of each transformation mixture was spread onto SE -Ura or SE -Ura -His plates (as appropriate to the plasmid(s) in the experiment). The plates were sealed in zip-top plastic bags and incubated at 30 °C until colonies
5 appeared.

Yeast Cultivation Conditions

Aerobic cultivation medium: SE -Ura medium (or SE -Ura -His for 2-plasmid system experiments) with 2 g/l ethanol.

10 Anaerobic cultivation medium: SEG -Ura (or SEG -Ura -His for 2-plasmid system experiments) with 30 g/l glucose and 1 g/l ethanol, supplemented with 10 mg/l ergosterol, 50 mM MES buffer (pH 5.5), 30 mg/l thiamine, and 30 mg/l nicotinic acid.

48-well plates: Axygen catalog # P-5ML-48-C-S, 5 ml/well total
15 volume, culture volume of 1.5 ml/well.

Plates were covered with a permeable adhesive film for aerobic cultivation. Plates were shaken at 225 rpm at 30 °C. For anaerobic cultivation, freshly inoculated plates covered with permeable film were purged of oxygen by equilibration in an anaerobic chamber for 2 hours.
20 The plate covers were then exchanged for adhesive aluminum covers and each plate was placed into an airtight plastic box along with a fresh oxygen scavenger pack. The entire assembly (plate(s) and oxygen scavenger pack inside a sealed airtight plastic box) was removed from the anaerobic chamber and shaken at 225 rpm at 30 °C.

25

Experimental Protocol

Single yeast colonies on SE -Ura or SE -Ura -His agar plates (as appropriate for the plasmid(s) in the strains used) were streaked onto fresh agar plates of the same type and incubated at 30 °C until dense
30 patches of cells had grown. Liquid precultures in 48-well plates were inoculated with loops of these cells for initial aerobic cultivation. After shaking overnight, the OD600 of each culture well was measured by transferring 0.15 ml of each well into a flat-bottom 96-well plate and measuring the absorbance of each well at 600 nm with a Molecular

Devices plate reader. A linear transformation based on an experimentally-determined calibration line was applied to these plate reader-measured optical densities to convert them into comparable absorbance values for a cuvette-based spectrophotometer.

5

A calculated portion of each aerobic preculture well was inoculated into the corresponding well of a fresh 48-well plate with 1.5 ml of the anaerobic cultivation medium, to achieve an initial OD600 (in cuvette spectrophotometer absorbance units) of 0.2. In the process of inoculating the fresh plate, the aerobic preculture plate was centrifuged, the supernatant was removed from each well, and the cells in each well were resuspended in fresh anaerobic cultivation medium, in order to minimize carryover of metabolites from one cultivation to the next. This anaerobic cultivation plate was shaken for 2-3 days, depending on the experiment. The isobutanol concentration in the culture supernatants was measured by HPLC (either with a mass spectrometric detector or a refractive-index detector).

A follow-up anaerobic cultivation ("Passaging Cycle #2") was initiated from the first anaerobic cultivation as follows: A calculated portion of each anaerobic culture well was inoculated into the corresponding well of a fresh 48-well plate with 1.5 ml of the anaerobic cultivation medium, to achieve an initial OD600 (in cuvette spectrophotometer units) of 0.2. In the process of inoculating the fresh plate, the growth plate was centrifuged, the supernatant was removed from each well, and the cells in each well were resuspended in fresh anaerobic cultivation medium, in order to minimize carryover of metabolites from one passaging cycle to the next. The follow-up (second-cycle) anaerobic cultivation plate was shaken for 2-3 days, depending on the experiment. The isobutanol concentration in the culture supernatants was measured by HPLC as above.

Strain and Growth Medium Details were as follows for Examples 1-5:

Example 1: PNY2204 transformed with two plasmids: 1) a KARI variant plasmid based on SEQ ID NO: 162 and 2) the plasmid given as

SEQ ID NO: 163 for expression of *S. mutans* DHAD and growth media lacking uracil and histidine.

Example 2: PNY2238 transformed with two plasmids (SEQ ID NO: 163 and a KARI-variant plasmid based on SEQ ID NO: 162), growth media lacking uracil and histidine.

Example 3: PNY2238 transformed with two plasmids (SEQ ID NO: 163 and a KARI-variant plasmid based on SEQ ID NO: 162 as in Example 1), growth media lacking uracil and histidine.

Example 4: PNY2259 transformed with a single plasmid, growth media lacking uracil.

Example 5: PNY1556 transformed with a single plasmid, growth media lacking uracil.

To generate the KARI-variant plasmid for strains transformed with two plasmids (above), coding sequences for KARI variants were generated by DNA 2.0 (Menlo Park, CA) and were subcloned into a modified vector based on SEQ ID NO: 162. An example resultant KARI-variant plasmid (containing the coding sequence for KARI variant 65139; Figure 7) is given as SEQ ID NO: 347. Such KARI variant plasmids were used in combination with the plasmid given as SEQ ID NO: 163 as described above.

To generate the single plasmid, coding sequences for KARI variants were generated by DNA 2.0 (Menlo Park, CA) and were subcloned into a modified "single-plasmid vector" (SEQ ID NO: 162, Figure 3; modified plasmid sequence given as SEQ ID NO: 348), replacing the K9D3 KARI coding region. An example of a resulting plasmid (for expression of KARI variant SEQ ID NO: 159, "76437" and also known as "R9E8") is given as SEQ ID NO: 349, Figure 8.

EXAMPLE 1

Variants generated and tested in an isobutanol production pathway

Table 9. KARI Variants

Amino Acid SEQ ID NO:	Nucleic Acid SEQ ID NO:	Variant Identifier	Amino Acid Substitutions (relative to JEA1)				
3	393	54654	P47F	S292A	S322A		
4	394	54655	I13L	Y286F	I291V		
5	395	54656	P47F	V76I	A336R		
6	396	54657	Y286F	I291V	A336R		
7	397	54658	P47F	I291V	A336G		
8	398	54659	L88V	Y286F	A336R		
9	399	54660	V76I	I152V	A336G		
10	400	54661	I13L	V53A	I291V		
11	401	54662	I152V	Y286F	S322A		
12	402	54663	V76I	A268E	S292A		
13	403	54664	A268E	Y286F	S322A	A336G	
14	404	54665	Y286F	I291V	S292A	S322A	
15	405	54666	I13L	S292A	S322A	A336R	
16	406	54667	V76I	I152V	I291V	A336R	
17	407	54668	I13L	I152V	I291V	A336R	
18	408	54669	V76I	S292A	S322A	A336R	
19	409	54670	P47F	V76I	I291V	A336R	
20	410	54671	V76I	Y286F	S322A	A336R	
21	411	54672	P47F	Y286F	I291V	A336R	
22	412	54673	V76I	L88V	S322A	A336R	
23	413	54674	V76I	L88V	S292A	S322A	A336G
24	414	54675	V76I	Y286F	I291V	S322A	A336R
25	415	54676	V53A	A268E	Y286F	I291V	A336R
26	416	54677	V76I	I152V	Y286F	S322A	A336G
27	417	54678	I13L	L88V	Y286F	I291V	S292A
28	418	54679	I13L	A268E	Y286F	I291V	A336G
29	419	54680	I13L	V76I	I152V	S292A	A336R
30	420	54681	I13L	P47F	V53A	V76I	I152V
31	421	54682	P47F	V76I	Y286F	I291V	A336G
32	422	54683	P47F	V53A	I152V	S322A	A336G
2	392	54684 (JEA1)	-	-	-	-	-

Table 10. Measured Isobutanol Titers (from PNY2204, anaerobic passage #2)

Variant identifier	Isobutanol Titer (mM)	Variant identifier	Isobutanol Titer (mM)
54654	5	54670	2
54654	1	54670	1

Variant identifier	Isobutanol Titer (mM)		Variant identifier	Isobutanol Titer (mM)
54654	7		54670	2
54655	50		54671	45
54655	52		54671	49
54655	57		54671	58
54656	1		54672	3
54656	2		54672	2
54656	4		54672	1
54657	51		54673	32
54657	51		54673	31
54657	55		54673	21
54658	2		54674	32
54658	3		54674	21
54658	1		54674	34
54659	59		54675	56
54659	58		54675	62
54659	56		54675	57
54660	33		54676	57
54660	43		54676	57
54660	44		54676	57
54661	32		54677	50
54661	45		54677	38
54661	28		54677	46
54662	57		54678	40
54662	58		54678	43
54662	58		54678	44
54663	37		54679	25
54663	33		54679	39
54663	33		54679	34
54664	43		54680	43
54664	48		54680	56
54664	48		54680	48
54665	55		54681	1
54665	51		54681	2
54665	59		54681	1
54666	51		54682	4
54666	56		54682	6
54666	54		54682	3

Variant identifier	Isobutanol Titer (mM)		Variant identifier	Isobutanol Titer (mM)
54667	42		54683	2
54667	46		54683	2
54667	42		54683	1
54668	53		54684	41
54668	54		54684	43
54668	55		54684	47
54669	54			
54669	38			
54669	48			

5

EXAMPLE 2
Variants generated and tested in an isobutanol production pathway

10

Table 11. KARI Variants

Amino Acid SEQ ID NO:	Nucleic Acid SEQ ID NO:	Variant Identifier	Amino Acid Substitutions (relative to JEA1)						
6	396	54657	Y286F	I291V	A336R				
11	401	54662	Y286F	S322A	I152V				
2	392	54684 (JEA1)							
33	423	65130	S322A	I291V	A336R				
34	424	65131	Y286F	S322A	A336R				
35	425	65132	Y286F	S322A	I291V				
36	426	65133	Y286F	S322A	I291V	A336R			
37	427	65134	S322A	I152V	A336R				
38	428	65135	I291V	I152V	A336R				
39	429	65136	S322A	I291V	I152V				
40	430	65137	S322A	I291V	I152V	A336R			
41	431	65138	Y286F	I152V	A336R				
42	432	65139	Y286F	S322A	I152V	A336R			
43	433	65140	Y286F	I291V	I152V				
44	434	65141	Y286F	I291V	I152V	A336R			
45	435	65142	Y286F	S322A	I291V	I152V			
46	436	65143	Y286F	S322A	I291V	I152V	A336R		
47	437	65144	Y286F	S322A	P47F	I291V	F50A	A336R	
48	438	65145	S322A	P47F	I291V	I152V	F50A	A336R	
49	439	65146	Y286F	S322A	P47F	I152V	F50A	A336R	
50	440	65147	Y286F	P47F	I291V	I152V	F50A	A336R	

Amino Acid SEQ ID NO:	Nucleic Acid SEQ ID NO:	Variant Identifier	Amino Acid Substitutions (relative to JEA1)							
51	441	65148	Y286F	S322A	P47F	I291V	I152V	F50A		
52	442	65149	Y286F	S322A	P47F	I291V	I152V	F50A	A336R	
53	443	65150	Y286F	V76I	S322A	I291V	I152V	A336R		
54	444	65151	Y286F	V76I	S322A	I291V	A68E	A336R		
55	445	65152	S322A	I291V	I152V	I13L	A336R			
56	446	65153	Y286F	V53A	S322A	I291V	A336R	A268E		
57	447	65154	Y286F	V76I	S322A	I291V	I152V	I13L	A336R	
58	448	65155	I80T	I291V	I152V	I13L	A68E	A336R		
59	449	65156	Y286F	V117I	S322A	I152V	I13L			
60	450	65157	Y286F	V76I	S322A	I291V	G72W	A71K	A336R	
61	451	65158	Y286F	S322A	I291V	I152V	I13L	A336R	A329E	
62	452	65159	Y286F	S86A	S322A	I80T	I152V	A68E		
63	453	65160	Y286F	S322A	I291V	I152V	I13L	F50N	A336R	
64	454	65161	Y286F	V76I	S322A	I291V	G72W	A71K	A336R	A268T

Table 12. Measured Isobutanol Titters (from PNY2238, anaerobic passage #2)

Variant Identifier	Isobutanol Titer (mM)	Seq ID	Isobutanol Titer (mM)	Seq ID	Isobutanol Titer (mM)
54657	53	65139	49	65150	86
54657	53	65139	103	65151	54
54657	69	65139	100	65151	49
54662	61	65140	40	65151	81
54662	63	65140	62	65151	91
54662	62	65140	75	65152	67
54662	80	65140	82	65152	45
54684	52	65141	59	65152	98
54684	33	65141	50	65152	100
65130	53	65141	58	65153	38
65130	61	65141	74	65153	53
65130	67	65142	53	65153	62
65130	85	65142	59	65153	77
65131	55	65142	62	65154	47
65131	49	65142	74	65154	66
65131	56	65143	51	65154	77
65131	100	65143	51	65154	60
65132	44	65143	49	65155	47
65132	54	65143	101	65155	49
65132	55	65144	41	65155	51
65132	85	65144	36	65155	85
65133	56	65144	47	65156	58
65133	63	65144	76	65156	58
65133	87	65145	47	65156	67
65133	84	65145	67	65156	85
65134	65	65145	94	65157	54
65134	58	65145	70	65157	47
65134	52	65146	55	65157	87

Variant Identifier	Isobutanol Titer (mM)	Seq ID	Isobutanol Titer (mM)	Seq ID	Isobutanol Titer (mM)
65134	106	65146	46	65157	82
65135	61	65146	48	65158	56
65135	51	65146	103	65158	44
65135	55	65147	57	65158	69
65135	81	65147	47	65158	69
65136	70	65147	49	65159	53
65136	50	65147	86	65159	61
65136	82	65148	55	65159	47
65136	87	65148	48	65159	65
65137	47	65148	69	65160	64
65137	40	65148	63	65160	30
65137	63	65149	45	65160	39
65137	111	65149	47	65160	77
65138	58	65149	55	65161	52
65138	50	65149	73	65161	50
65138	52	65150	44	65161	49
65138	86	65150	82	65161	91
65139	28	65150	92		

5 **EXAMPLE 3**

Variants generated and tested in an isobutanol production pathway

Table 13. KARI Variants

Amino Acid SEQ ID NO:	Nucleic Acid SEQ ID NO:	Variant Identifier	Substitutions Relative to JEA1 (SEQ ID NO: 2)							
2	392	54684 (JEA1)								
65	455	66824				I152V	Y286F	I291V	S322A	A336R
66	456	66825	R306K	N267T		I152V		I291V	S322A	A336R
67	457	66826	V76I	V171I	V156A	I152V	Y286F	I291V	S322A	A336R
68	458	66827	S292L	N114G	M238I	I152V	Y286F	I291V	S322A	A336R
69	459	66828	V76I	S292L	L88V	I152V	Y286F	I291V	S322A	A336R
70	460	66829	V156A	M238I	A329E	I152V	Y286F	I291V	S322A	A336R
71	461	66830	V156A	I127V	A68E	I152V	Y286F	I291V	S322A	A336R
72	462	66831	L88V	K99N	A277V	I152V	Y286F	I291V	S322A	A336R
73	463	66832	V156A	N114G	L33C	I152V	Y286F	I291V	S322A	A336R
74	464	66833	N267T	F61L	A68E	I152V	Y286F	I291V	S322A	A336R
75	465	66834	V171I		L33C		Y286F	I291V	S322A	A336R
76	466	66835	N114G	I127V	F61L	I152V	Y286F	I291V	S322A	A336R
77	467	66836	S292L	L88V	A329V	I152V	Y286F	I291V	S322A	A336R
78	468	66837	V171I	V156A	I127V	I152V	Y286F	I291V	S322A	A336R
79	469	66838	F61L		A68E	I152V		I291V	S322A	A336R

Amino Acid SEQ ID NO:	Nucleic Acid SEQ ID NO:	Variant Identifier	Substitutions Relative to JEA1 (SEQ ID NO: 2)							
80	470	66839	R275K	I127V	A329V	I152V	Y286F	I291V	S322A	A336R
81	471	66840	I127V	F61L	A277V	I152V	Y286F	I291V	S322A	A336R
82	472	66841	V76I		R306K		Y286F	I291V	S322A	A336R
83	473	66842	V171I	L33C		I152V	Y286F	I291V		A336R
84	474	66843		A68E		I152V		I291V		A336R
85	475	66844		R275K	A329E		Y286F	I291V	S322A	A336R
86	476	66845	F61L	A329V		I152V	Y286F	I291V		A336R
87	477	66846	V152I	N114G	L88V	I152V	Y286F	I291V	S322A	A336R
88	478	66847	V76I	V156A	A277V	I152V	Y286F	I291V	S322A	A336R
89	479	66848		R275K				I291V	S322A	A336R
90	480	66849	R275K	K99N		I152V	Y286F	I291V		A336R
91	481	66850	V76I	A329E	A277V	I152V	Y286F	I291V	S322A	A336R
92	482	66851	V171I	F61L		I152V	Y286F	I291V		A336R
93	483	66852	L33C		A68E	I152V		I291V	S322A	A336R
94	484	66853		N114G	A329E		Y286F	I291V	S322A	A336R
95	485	66854	R306K	K99N	A329V	I152V	Y286F	I291V	S322A	A336R
96	486	66855	N267T	M238I	L33C	I152V	Y286F	I291V	S322A	A336R
97	487	66856	S292L	L88V	A277V	I152V	Y286F	I291V	S322A	A336R
98	488	66857	S292L	R275K	L33C	I152V	Y286F	I291V	S322A	A336R

Table 14. Measured Isobutanol Titters (from PNY2238, anaerobic passage #2)

5

Variant Identifier	Isobutanol Titer (mM)	Variant identifier	Isobutanol Titer (mM)
54684	39	66840	16
54684	38	66841	41
54684	30	66841	39
66824	50	66841	30
66824	37	66842	37
66825	35	66842	22
66825	31	66842	22
66825	17	66843	36
66826	33	66843	31
66826	27	66844	36
66826	20	66844	35
66827	42	66844	27
66827	38	66845	32
66828	28	66845	25
66828	25	66845	4
66829	44	66846	37
66829	37	66846	29
66829	31	66847	31
66830	25	66847	18
66830	22	66847	16

Variant Identifier	Isobutanol Titer (mM)	Variant identifier	Isobutanol Titer (mM)
66830	18	66848	42
66831	30	66848	25
66831	23	66848	21
66831	12	66849	55
66832	6	66849	38
66832	5	66850	40
66832	4	66850	36
66833	9	66850	30
66833	8	66851	34
66834	24	66851	32
66834	18	66851	22
66834	15	66852	20
66835	24	66852	10
66835	15	66853	36
66836	31	66853	34
66836	30	66853	34
66836	26	66854	34
66837	33	66854	28
66837	27	66855	10
66837	26	66855	9
66838	31	66856	33
66838	27	66856	26
66838	21	66856	17
66839	38	66857	24
66839	28	66857	14
66840	17	66857	14
66840	16		

EXAMPLE 4

- 5 Variants generated and tested in an isobutanol production pathway

10

Table 15. KARI Variants

Amino Acid SEQ ID NO	Nucleic Acid SEQ ID NO	Variant Identifier	Substitutions Relative to Variant identifier 65138 (SEQ ID NO: 41)		
41	431	65138			
99	489	76377	A71K		
100	490	76378	G72W		
101	491	76379	N114G		
102	492	76380	M238I		
103	493	76381	R306K		
104	494	76382	A329E		
105	495	76383	A71K	G72W	
106	496	76384	A71K	N114G	

Amino Acid SEQ ID NO	Nucleic Acid SEQ ID NO:	Variant Identifier	Substitutions Relative to Variant Identifier 65136 (SEQ ID NO: 41)			
107	497	76385	A71K	M238I		
108	498	76386	A71K	R306K		
109	499	76387	A71K	A329E		
110	500	76388	G72W	N114G		
111	501	76389	G72W	M238I		
112	502	76390	G72W	R306K		
113	503	76391	G72W	A329E		
114	504	76392	N114G	M238I		
115	505	76393	N114G	R306K		
116	506	76394	N114G	A329E		
117	507	76395	M238I	R306K		
118	508	76396	M238I	A329E		
119	509	76397	R306K	A329E		
120	510	76398	Y113F	R280L		
121	511	76399	M238I	E264K	R280D	
122	512	76400	Y239H	F286W		
123	513	76401	Y239H	A329R		
124	514	76402	Y113F	A329E		
125	515	76403	R280H	F286W		
126	516	76404	A69K	A71K		
127	517	76405	F286W	A329E		
128	518	76406	R306K	S322A		
129	519	76407	Q272T	A329R		
130	520	76408	A69K	G72W		
131	521	76409	N114S	A295V		
132	522	76410	G72W	V152C		
133	523	76411	N114S	R280H		
134	524	76412	G72W	I291N		
135	525	76413	A69K	K335M		
136	526	76414	A71K	R280L		
137	527	76415	A69T	M301I		
138	528	76416	A69T	S322A		
139	529	76417	E264K	R280D	A295V	
140	530	76418	N114G	K335M		
141	531	76419	S157T	Y239H		
142	532	76420	Q272T	R306K		
143	533	76421	R280L	S322A		
144	534	76422	N114G	A329R		
145	535	76423	N114S	I291N		
146	536	76424	E264K	R280D	M301I	
147	537	76425	Y113F	M301I		
148	538	76426	R280H	A295V		
149	539	76427	V152C	S157T		
150	540	76428	S157T	I291N		
151	541	76429	A69T	N114G		
152	542	76430	Q272T	K335M		
153	543	76431	V152C	M238I		
154	544	76432	A69T	A71K	Y113F	

Amino Acid SEQ ID NO	Nucleic Acid SEQ ID NO	Variant Identifier	Substitutions Relative to Variant identifier 65138 (SEQ ID NO: 41)			
155	545	76433	E264K	R280D	A329R	K335M
156	546	76434	A69K	V152C	R280H	
157	547	76435	N114S	M301I	A329E	
158	548	76436	Q272T	F286W	A295V	
159	549	76437	G72W	N114G	Y239H	
160	550	76438	R280L	R306K	S322A	
161	551	76439	S157T	M238I	I291N	

Table 16. Measured Isobutanol Titters (from PNY2259)

Variant identifier	Cycle 1 Isobutanol Titer (mM)	Cycle 2 Isobutanol Titer (mM)	Variant identifier	Cycle 1 Isobutanol Titer (mM)	Cycle 2 Isobutanol Titer (mM)
65138	28	67	76408	4	5
65138	34	57	76408	2	4
65138	31	65	76408	2	2
76377	22	60	76409	36	57
76377	35	73	76409	50	62
76377	27	59	76409	32	64
76378	31	58	76410	16	49
76378	32	71	76410	31	55
76378	36	63	76410	25	55
76379	39	57	76411	18	56
76379	32	59	76411	25	65
76379	31	66	76411	17	46
76380	15	43	76412	9	41
76380	30	68	76412	15	37
76380	23	53	76412	15	41
76381	18	31	76413	2	3
76381	12	33	76413	1	3
76381	9	23	76413	3	5
76382	27	57	76414	24	47
76382	32	77	76414	37	58
76382	17	44	76414	10	43
76383	37	62	76415	47	83
76383	29	59	76415	40	70
76383	31	63	76415	44	61
76384	35	68	76416	30	65
76384	36	66	76416	34	66
76384	32	63	76416	26	68
76385	36	71	76417	31	61
76385	31	70	76417	32	62
76385	30	62	76417	20	52
76386	36	58	76418	36	60
76386	29	59	76418	65	71
76386	19	41	76418	30	57
76387	38	58	76419	33	63
76387	54	73	76419	29	57
76387	22	56	76419	32	65
76388	36	67	76420	15	40

Variant Identifier	Cycle 1 Isobutanol Titer (mM)	Cycle 2 Isobutanol Titer (mM)	Variant Identifier	Cycle 1 Isobutanol Titer (mM)	Cycle 2 Isobutanol Titer (mM)
76388	20	49	76420	18	35
76388	27	60	76420	18	45
76389	29	54	76421	39	64
76389	36	78	76421	21	60
76389	28	83	76421	47	65
76390	11	46	76422	33	63
76390	8	24	76422	37	62
76390	13	37	76422	20	56
76391	22	51	76423	1	2
76391	25	54	76423	4	5
76391	28	64	76423	2	3
76392	33	67	76424	49	62
76392	41	67	76424	39	62
76392	38	62	76424	33	65
76393	3	4	76425	48	72
76393	3	3	76425	42	62
76393	5	7	76425	23	62
76394	44	47	76426	24	62
76394	44	74	76426	13	51
76394	24	52	76426	21	50
76395	4	8	76427	18	51
76395	6	6	76427	19	52
76395	6	11	76427	25	52
76396	28	70	76428	9	36
76396	26	60	76428	16	34
76396	15	39	76428	15	32
76397	13	40	76429	31	66
76397	8	22	76429	36	56
76397	6	15	76429	31	65
76398	53	63	76430	30	50
76398	23	59	76430	26	66
76398	28	64	76430	35	69
76399	27	51	76431	25	55
76399	31	58	76431	21	46
76399	30	75	76431	22	57
76400	5	9	76432	54	52
76400	11	14	76432	40	75
76400	6	10	76432	41	68
76401	48	63	76433	47	55
76401	38	70	76433	38	52
76401	48	65	76433	31	62
76402	37	74	76434	3	4
76402	32	61	76434	0	3
76402	31	64	76434	4	7
76403	2	3	76435	46	61
76403	3	10	76435	45	60
76403	3	6	76435	35	56
76404	6	9	76436	3	4
76404	5	7	76436	5	5
76404	4	9	76436	2	3

Variant identifier	Cycle 1 Isobutanol Titer (mM)	Cycle 2 Isobutanol Titer (mM)	Variant identifier	Cycle 1 Isobutanol Titer (mM)	Cycle 2 Isobutanol Titer (mM)
76405	3	3	76437	53	62
76405	6	8	76437	45	78
76405	2	2	76437	40	68
76406	36	61	76438	17	48
76406	18	41	76438	10	39
76406	29	56	76438	14	46
76407	28	57	76439	21	48
76407	3	11	76439	17	45
76407	35	65	76439	17	38

EXAMPLE 5**Variants for isobutanol production**

- 5 Variants provided in Table 17 were generated and tested as described for Example 4, except the strain was PNY1556 (transformed with a single-plasmid as described above). Anaerobic cycles 1 and 2 were 3 days long, Cycle 3 was 2 days long. Results are given in Table 18.

10

Table 17. KARI Variants

Amino Acid SEQ ID NO:	Nucleic Acid SEQ ID NO:	Variant Number	Substitutions Relative to Variant Identifier 65139 (Seq ID NO: 42)			
42	432	65139				
123	513	76401	Y239H	A322S	A329R	
350	552	85023	Y239H			
351	553	85024	A69T			
352	554	85025	A71K			
353	555	85026	Y113F			
354	556	85027	A69T	Y239H		
355	557	85028	A71K	Y239H		
356	558	85029	Y113F	Y239H		
357	559	85030	A69T	A71K		
358	560	85031	A69T	Y113F		
359	561	85032	A71K	Y113F		
360	562	85033	A69T	A71K	Y113F	
361	563	85034	A71K	Y113F	Y239H	
362	564	85035	A69T	Y113F	Y239H	
363	565	85036	A69T	A71K	Y239H	
364	566	85037	A69T	A71K	Y113F	Y239H
365	567	85038	A69T	M238I	Y239H	
366	568	85039	A71K	M238I	Y239H	

Amino Acid SEQ ID NO:	Nucleic Acid SEQ ID NO:	Variant Number	Substitutions Relative to Variant Identifier 65139 (Seq ID NO: 42)			
367	569	85040	Y113F	M238I	Y239H	
368	570	85041	A69T	A71K	M238I	
369	571	85042	A69T	Y113F	M238I	
370	572	85043	A71K	Y113F	M238I	
371	573	85044	A69T	Y239H	M301I	
372	574	85045	A71K	Y239H	M301I	
373	575	85046	Y113F	Y239H	M301I	
374	576	85047	A69T	A71K	M301I	
375	577	85048	A69T	Y113F	M301I	
376	578	85049	A71K	Y113F	M301I	
377	579	85050	A69T	Y239H	A322S	
378	580	85051	A71K	Y239H	A322S	
379	581	85052	Y113F	Y239H	A322S	
380	582	85053	A69T	A71K	A322S	
381	583	85054	A69T	Y113F	A322S	
382	584	85055	A71K	Y113F	A322S	

Table 18 . Measured Isobutanol Titers

Isobutanol Titer (mM)							
Variant Number	Cycle 1	Cycle 2	Cycle 3	Variant Number	Cycle 1	Cycle 2	Cycle 3
65139	12	51	17	85038	27	81	37
65139	5	49	30	85038	18	66	42
65139	2	12	27	85038	16	68	35
65139	2	13	34	85038	8	52	40
76401	27	84	36	85039	28	70	19
76401	12	70	48	85039	28	78	25
76401	5	54	54	85039	9	61	52
76401	2	9	18	85039	4	28	40
85023	21	67	19	85040	26	77	36
85023	13	59	32	85040	13	73	13
85023	12	44	43	85040	10	62	30
85023	6	59	52	85040	0	4	6
85024	10	55	9	85041	21	60	23
85024	5	32	22	85041	9	58	22
85024	4	35	40	85041	6	47	62
85024	2	9	4	85041	2	15	10
85025	5	49	24	85042	8	56	37
85025	4	27	18	85042	8	45	38
85025	4	27	32	85042	4	38	54
85025	1	3	2	85042	4	29	44
85026	12	47	30	85043	18	62	22
85026	3	9	5	85043	12	56	31
85026	2	6	9	85043	10	60	40
85026	2	12	31	85043	3	39	54
85027	18	83	29	85044	19	53	10

85027	16	62	38	85044	12	54	25
85027	13	53	44	85044	8	40	33
85027	2	20	18	85044	2	23	43
85028	25	60	3	85045	12	50	18
85028	22	62	23	85045	4	17	9
85028	9	64	18	85045	3	14	32
85028	7	52	39	85045	3	19	37
85029	12	48	33	85046	6	44	21
85029	6	55	43	85046	4	30	18
85029	5	44	45	85046	3	9	8
85029	3	49	58	85046	2	6	8
85030	11	48	20	85047	3	13	7
85030	10	51	23	85047	3	16	8
85030	4	30	19	85047	3	14	19
85030	4	16	41	85047	2	11	12
85031	12	49	17	85048	6	31	6
85031	4	25	25	85048	1	4	4
85031	4	29	40	85048	0	2	2
85031	3	17	16	85048	0	9	55
85032	9	50	11	85049	3	13	8
85032	5	29	21	85049	2	6	4
85032	3	16	17	85049	0	0	0
85032	1	8	15	85049	0	0	0
85033	9	53	13	85050	24	70	37
85033	5	34	37	85050	21	68	27
85033	4	20	8	85050	20	70	21
85033	3	17	43	85050	4	25	30
85034	18	65	22	85051	24	65	36
85034	9	54	13	85051	23	72	21
85034	6	51	34	85051	6	65	40
85034	6	48	29	85051	6	55	63
85035	15	65	22	85052	27	77	24
85035	13	55	27	85052	15	57	25
85035	5	39	45	85052	10	59	36
85035	2	44	58	85052	10	60	52
85036	20	58	17	85053	14	50	7
85036	10	80	23	85053	8	49	22
85036	6	48	54	85053	3	20	6
85036	6	51	37	85053	0	20	44
85037	20	56	13	85054	11	53	19
85037	6	52	53	85054	4	54	29
85037	3	31	70	85054	1	6	2
85037	3	13	11	85054	0	2	2
-	-	-	-	85055	4	10	1
-	-	-	-	85055	2	5	1
-	-	-	-	85055	1	4	2
-	-	-	-	85055	1	4	0

EXAMPLE 6

Identification of suitable substitutions by site-saturation for residues 152,

286, 336

5

All 20 amino acids at sites 152, 286, and 336 of parent variant R8-SOG1_y2 (amino acid SEQ ID NO: 346; nucleic acid SEQ ID NO: 383) were individually constructed and tested. This parent variant is JEA1 with substitutions
 5 A68E, I152V, Y286F, and A336R.

The General Methods are the same as in the application for Examples 1-4. The two-plasmid system was used, with KARI on a pLH556-based plasmid, and DHAD on pBP915. The yeast strain was PNY2259.

10 Site-Directed Mutagenesis and Subcloning into pLH556-based vector:

Position 152 was mutagenized by overlap-extension PCR with mutagenic primers. The KARI inserts were subcloned into pLH556 (with the KARI removed) by yeast gap-repair cloning. The sequence of the KARI portion and flanking regions of the resulting plasmids was confirmed by DNA sequencing (Sanger
 15 method, ABI Prism 3730xl DNA Analyzer).

Positions 286 and 336 were mutagenized using the QuikChangeII kit (Agilent); position 286 in a pCR2.1 vector (Invitrogen) and position 336 in a TOPO Blunt vector (Invitrogen). The KARI variants were sequenced in the invitrogen vectors, then subcloned by standard ligation into the PmeI and SfiI
 20 restriction sites of pLH556. The KARI inserts were confirmed by sequencing again in the pLH556 vector.

The resulting 60 variants are characterized in the table below as either functional (F, defined as supporting a mean yeast isobutanol production of at least 10% of the mean of the parent, or non-functional (NF, defined as not
 25 supporting a mean yeast isobutanol production of at least 10% of the mean of the parent).

Quantitative data (percentages of parental isobutanol titer) are provided in the second table. Data are based on the first anaerobic passaging cycle.

30 Table 19. Substitutions

Amino Acid	Position 152 (F/NF)	Position 286 (F/NF)	Position 336 (F/NF)
A, Ala	F	F	F
C, Cys	F	F	F
D, Asp	F	NF	F
E, Glu	F	NF	F
F, Phe	F	F	F
G, Gly	F	NF	F
H, His	F	F	F
I, Ile	F	F	F
K, Lys	F	NF	F
L, Leu	F	NF	F

Amino Acid	Position 152 (F/NF)	Position 286 (F/NF)	Position 336 (F/NF)
M, Met	F	F	F
N, Asn	F	NF	F
P, Pro	F	NF	F
Q, Gln	F	NF	F
R, Arg	F	NF	F
S, Ser	F	NF	F
T, Thr	F	NF	F
V, Val	F	NF	F
W, Trp	F	F	F
Y, Tyr	F	F	F

Table 20. Quantitative Data for the substitutions in Table 24 (expressed as a percentage of the parent's mean isobutanol titer) – First Anaerobic Cycle

Amino Acid	% of Parental Isobutanol Titer, Position 152	% of Parental Isobutanol Titer, Position 286	% of Parental Isobutanol Titer, Position 336
A,Ala	51%	16%	106%
C,Cys	128%	15%	98%
D,Asp	54%	1%	112%
E,Glu	77%	1%	89%
F,Phe	67%	100%	114%
G,Gly	25%	1%	95%
H,His	90%	38%	121%
I,Ile	46%	30%	89%
K,Lys	61%	2%	126%
L,Leu	52%	10%	103%
M,Met	53%	40%	94%
N,Asn	57%	1%	87%
P,Pro	34%	1%	76%
Q,Gln	82%	5%	131%
R,Arg	42%	3%	100%
S,Ser	86%	6%	115%
T,Thr	89%	3%	100%
V,Val	100%	9%	96%
W,Trp	82%	17%	100%
Y,Tyr	46%	51%	132%

CLAIMS

What is claimed is:

1. A polypeptide comprising

- a. the amino acid sequence of SEQ ID NO: 365, 366, 157, 159, 154, 377, 367, 123, 42, 41, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 20, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 35, 36, 37, 38, 39, 40, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 116, 118, 119, 120, 121, 124, 128, 129, 131, 132, 133, 134, 136, 137, 138, 139, 140, 141, 142, 143, 144, 146, 147, 148, 149, 150, 151, 152, 153, 155, 160, 161, 346, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 368, 369, 370, 371, 372, 373, 374, 375, 378, 379, 380, or 381,
- b. at least about 95% or at least about 99% identity to SEQ ID NO: 365, 366, 157, 159, 154, 377, 367, 123, 42, 41, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 20, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 35, 36, 37, 38, 39, 40, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 116, 118, 119, 120, 121, 124, 128, 129, 131, 132, 133, 134, 136, 137, 138, 139, 140, 141, 142, 143, 144, 146, 147, 148, 149, 150, 152, 154, 155, 160, 161, 346, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 368, 369, 370, 371, 372, 373, 374, 375, 378, 379, 380, or 381; or
- c. an active fragment of (a) or (b).

2. A polypeptide comprising at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99% identity to SEQ ID NO: 2, wherein the amino acid at position 52 is D or E, and wherein the polypeptide comprises at least one substitution in one of the following regions: in at least one of the inter-molecular dimer interface region, inter-domain interface region, N-domain surface helix region, hydrophobic bridge region, or the C-terminal tail region, wherein the at least one substitution is at position I13, V53, A68, A69, A71, G72, V76, S86, L88, K99, Y113, N114, V117, I127, I152, S157, V171, M238, Y239, E264, N267, A268, Q272, R275, A277, R280, Y286, I291, S292, A295, M301, R306, S322, A329, K335, or A336.
3. The polypeptide of claim 1, further comprising a substitution at at least one of position L33, P47, F50, F61, I80, or V156.
4. A polypeptide having ketol-acid reductoisomerase activity and comprising
at least about 85%, at least about 95%, or at least about 99% identity to SEQ ID NO: 2 and at least one of the following substitutions: Y286F, A336R, I152V, S322A, S292A, I291V, or a combination thereof;
or an active fragment of such polypeptide.
5. The polypeptide of claim 4 further comprising at least one of the following substitutions: I13L, P47Y, F50A, V53A, S86A, A268E, V76I, A336G, L88V, or a combination thereof.
6. The polypeptide of either Claim 4 or Claim 5 wherein the amino acid at the position corresponding to position 52 of SEQ ID NO: 2 is D or E.
7. The polypeptide of any one of the previous claims wherein

- a. the amino acid at the position corresponding to position 24 of SEQ ID NO: 2 is F;
 - b. the amino acid at the position corresponding to position 33 of SEQ ID NO: 2 is L;
 - c. the amino acid at the position corresponding to position 47 of SEQ ID NO: 2 is P;
 - d. the amino acid at the position corresponding to position 50 of SEQ ID NO: 2 is F;
 - e. the amino acid at the position corresponding to position 61 of SEQ ID NO: 2 is F;
 - f. the amino acid at the position corresponding to position 80 of SEQ ID NO: 2 is I; and
 - g. the amino acid at the position corresponding to position 156 of SEQ ID NO: 2 is V.
8. The polypeptide of any one claims 4-7 having at least about 95% or at least about 99% identity to SEQ ID NO: 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 20, 22, 23, 24, 25, 26, 27, 28, or 29.
9. A polypeptide having ketol-acid reductoisomerase activity and comprising at least about 85%, at least about 95%, or at least about 99% identity to SEQ ID NO: 2 and at least one of the following substitutions: Y286F, A71K, G72W, A336R, I152V, A268T, A329E, or a combination thereof; or an active fragment of such polypeptide.
10. The polypeptide of claim 9 wherein the amino acid at the position corresponding to position 52 of SEQ ID NO: 2 is D or E.
11. The polypeptide of claim 9 or 10 wherein
- a. the amino acid at the position corresponding to position 24 of SEQ ID NO: 2 is F;

- b. the amino acid at the position corresponding to position 33 of SEQ ID NO: 2 is L;
- c. the amino acid at the position corresponding to position 47 of SEQ ID NO: 2 is P;
- d. the amino acid at the position corresponding to position 50 of SEQ ID NO: 2 is F;
- e. the amino acid at the position corresponding to position 61 of SEQ ID NO: 2 is F;
- f. the amino acid at the position corresponding to position 80 of SEQ ID NO: 2 is I; and
- g. the amino acid at the position corresponding to position 156 of SEQ ID NO: 2 is V.

12. The polypeptide of any one of claims 9-11 having at least about 95% or at least about 99% identity to SEQ ID NO: 41, 42, 33, 34, 35, 36, 37, 38, 39, 40, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, or 64.

13. A polypeptide having ketol-acid reductoisomerase activity and comprising
at least about 85%, at least about 95%, or at least about 99% identity to SEQ ID NO: 41;
and at least one of the following substitutions M301I, Y239H, Y113F, S322A, A71K, N114G, A329R, A69T, N114S, G72W, A295V, E264K, R280D, A329E, S157T, M238I, Q272T, K335M, R280H, or a combination thereof;
or an active fragment of such polypeptide.

14. The polypeptide of claim 13 wherein the amino acid at the position corresponding to position 52 of SEQ ID NO: 2 is D or E.

15. The polypeptide of any one of claims 13-14 wherein

- a. the amino acid at the position corresponding to position 24 of SEQ ID NO: 2 is F;
- b. the amino acid at the position corresponding to position 33 of SEQ ID NO: 2 is L;
- c. the amino acid at the position corresponding to position 47 of SEQ ID NO: 2 is P;
- d. the amino acid at the position corresponding to position 50 of SEQ ID NO: 2 is F;
- e. the amino acid at the position corresponding to position 61 of SEQ ID NO: 2 is F;
- f. the amino acid at the position corresponding to position 80 of SEQ ID NO: 2 is I; and
- g. the amino acid at the position corresponding to position 156 of SEQ ID NO: 2 is V.

16. The polypeptide of any one of claims 13-15 having at least about 95% or at least about 99% identity to SEQ ID NO: 157, 159, 152, 123, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 116, 118, 119, 120, 121, 124, 128, 129, 131, 132, 133, 134, 136, 137, 138, 139, 140, 141, 142, 143, 144, 146, 147, 148, 149, 150, 151, 153, 154, 155, 160, or 161.

17. A polypeptide having ketol-acid reductoisomerase activity and comprising
at least about 85%, at least about 95%, or at least about 99% identity to SEQ ID NO: 346 and at least one of the following substitutions: A68E, I152V, Y286F, and A336R.

18. A polynucleotide encoding the polypeptide of any one of the previous claims.

19. A polypeptide comprising at least about 80% identity, at least about 85%, at least about 90%, at least about 95%, or at least about 99%

identity to SEQ ID NO: 2 and a substitution at at least one of the following positions: position I13, V53, A68, A69, A71, G72, V76, S86, L88, K99, Y113, N114, V117, I127, I152, S157, V171, M238, Y239, E264, N267, A268, Q272, R275, A277, R280, Y286, I291, S292, A295, M301, R306, S322, A329, K335, or A336.

20. A recombinant microbial host cell comprising the polypeptide of any one of claims 1-17 or 19.
21. The recombinant microbial host cell of claim 20 wherein said host cell further comprises reduced or eliminated acetolactate reductase activity.
22. The recombinant microbial host cell of claim 21 wherein said host cell further comprises at least one deletion, mutation, and/or substitution in *fra2*.
23. The recombinant microbial host cell of any one of claims 20-22 further comprising the substrate to product conversions:
 - a. pyruvate to acetolactate
 - b. 2,3-dihydroxyisovalerate to α -ketoisovalerate
 - c. α -ketoisovalerate to isobutyraldehyde; and
 - d. isobutyraldehyde to isobutanol.
24. The recombinant microbial host cell of claim 23 wherein the polypeptide having ketol-acid reductoisomerase activity is selected from the group consisting of SEQ ID Nos: 11, 41, and 42.
25. The recombinant microbial host cell of any one of claims 20-24 wherein said host cell is a yeast host cell.
26. The recombinant microbial host cell of claim 25 wherein said host cell is *Saccharomyces cerevisiae*.

27. A method for converting acetolactate to dihydroxyisovalerate comprising:

- a. providing a microbial host cell comprising a polypeptide of any one of claims 1-17 or 19;
- b. contacting the polypeptide with acetolactate wherein dihydroxyisovalerate is produced.

28. A method of producing a product selected from the group consisting of isobutanol, pantothenate, valine, leucine, isoleucine, 3, 3-dimethylmalate, and 2-methyl-1-butanol or combinations thereof comprising:

- a. providing the recombinant host cell of any one of claims 20-26 wherein the recombinant host cell comprises a product biosynthetic pathway; and
- b. contacting the microbial host cell with a carbon substrate under conditions whereby the product is produced.

29. The method of claim 28 wherein at least a portion of the contacting occurs under anaerobic conditions.

30. A composition comprising one or more product of claim 28.

31. The composition of claim 30, wherein the product is isobutanol or isobutanol and 2-methyl-1-butanol.

32. The composition of claim 30 or 31, wherein said composition is blended with a hydrocarbon fuel.

33. The composition of claim 30 or 31, wherein said composition is a chemical solvent or substrate for other chemical applications.

34. The polynucleotide of claim 18 wherein said polynucleotide comprises the sequence of 394, 396, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 410, 412, 413, 414, 415, 416, 417, 418, 419, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 506, 508, 510, 511, 513, 514, 518, 519, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 547, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 579, 580, 581, 582, or 583.

35. A polynucleotide comprising the sequence of SEQ ID NO: 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550,

551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, or 584.

36. A polynucleotide comprising the sequence of SEQ ID NO: 567, 568, 549, 544, 579, 569, 513, 432, or 431.

37. A recombinant host cell comprising the polynucleotide of any one of claims 34-36.

38. The recombinant host cell of claim 37, wherein said host cell produces isobutanol.

39. The recombinant host cell of claim 38, wherein said host cell is a yeast host cell.

40. The recombinant host cell of any one of claims 37-39 wherein said host cell further comprises reduced or eliminated acetolactate reductase activity.

41. The recombinant microbial host cell of claim 37-40 wherein said host cell further comprises at least one deletion, mutation, and/or substitution in *fra2*.

FIGURE 1




FIGURE 2

PF5 JEA1 amino acid alignment.apr

Section 1									
(1)	1	10	20	30	40	50	60	70	80
54684 (JEA1)	(1)	MKVFYDND	CDLSIQGK	KVAIIG	GSQGH	AQANL	KDS	GV	DTVGL
PF5 wildtype Translation	(1)	MKVFYDND	CDLSIQGK	KVAIIG	GSQGH	AQANL	KDS	GV	DTVGL
Consensus	(1)	MKVFYDND	CDLSIQGK	KVAIIG	GSQGH	AQANL	KDS	GV	DTVGL
Section 2									
(55)	55	60	70	80	90	100	110	120	130
54684 (JEA1)	(55)	KAEAHG	KVTDVA	AAVAG	ADLVMI	LP	DE	FQ	SQLYKNE
PF5 wildtype Translation	(55)	KAEAHG	KVTDVA	AAVAG	ADLVMI	LP	DE	FQ	SQLYKNE
Consensus	(55)	KAEAHG	KVTDVA	AAVAG	ADLVMI	LP	DE	FQ	SQLYKNE
Section 3									
(109)	109	120	130	140	150	160	170	180	190
54684 (JEA1)	(109)	FAIHYNQV	VRADLD	VIMIA	PNAP	SGH	TVR	SE	FVNSGGIP
PF5 wildtype Translation	(109)	FAIHYNQV	VRADLD	VIMIA	PNAP	SGH	TVR	SE	FVNSGGIP
Consensus	(109)	FAIHYNQV	VRADLD	VIMIA	PNAP	SGH	TVR	SE	FVNSGGIP
Section 4									
(163)	163	170	180	190	200	210	220	230	240
54684 (JEA1)	(163)	VALSYA	AGVGG	GR	TGI	I	ET	T	F
PF5 wildtype Translation	(163)	VALSYA	AGVGG	GR	TGI	I	ET	T	F
Consensus	(163)	VALSYA	AGVGG	GR	TGI	I	ET	T	F
Section 5									
(217)	217	230	240	250	260	270	280	290	300
54684 (JEA1)	(217)	GYAPE	MAY	F	E	C	L	H	E
PF5 wildtype Translation	(217)	GYAPE	MAY	F	E	C	L	H	E
Consensus	(217)	GYAPE	MAY	F	E	C	L	H	E
Section 6									
(271)	271	280	290	300	310	320	330	340	350
54684 (JEA1)	(271)	RCAMR	NAL	KRI	QD	GEY	AK	MEI	SE
PF5 wildtype Translation	(271)	RCAMR	NAL	KRI	QD	GEY	AK	MEI	SE
Consensus	(271)	RCAMR	NAL	KRI	QD	GEY	AK	MEI	SE
Section 7									
(325)	325	330	340	350	360	370	380	390	400
54684 (JEA1)	(325)	PWIG	ANK	I	V	D	K	A	K
PF5 wildtype Translation	(325)	PWIG	ANK	I	V	D	K	A	K
Consensus	(325)	PWIG	ANK	I	V	D	K	A	K




FIGURE 3




FIGURE 4

FIGURE 5





FIGURE 6






FIGURE 7




FIGURE 8




FIGURE 9




FIGURE 10B




FIGURE 10A




FIGURE 11A




FIGURE 11B




FIGURE 12